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Introduction: The human endometrium has a remarkable capacity for efficient 
cyclical repair following the inflammatory process of menstruation. Defective post-
menstrual repair may contribute to the common complaint of heavy menstrual 
bleeding (HMB). The mechanisms and factors involved in endometrial repair are still 
to be fully elucidated. Endometrial function is governed by the ovarian hormones and 
pre-menstrually progesterone levels decline as the corpus luteum regresses. 
Consequently, the synthesis of prostaglandins (PG) is increased, namely PGE2 and 
the potent vasoconstrictor PGF2α. Subsequent vasoconstriction of endometrial spiral 
arterioles is believed to result in a transient hypoxic episode in the upper endometrial 
layer.  
 
Therefore, the aims of this thesis were to determine (i) the endometrial expression of 
putative repair factors across the menstrual cycle (ii) the regulation of these factors 
by hypoxia, PGE2 and PGF2α (ii) the role of hypoxia inducible factor (HIF)-1α in 
endometrial repair and (iii) differences in endometrium from women with objectively 
measured HMB (>80ml) and normal controls (<80ml).  
 
Methods/Results: Putative repair factors, with known angiogenic, mitogenic and 
proliferative functions, were identified in human endometrial samples by quantitative 
reverse transcription PCR and immunohistochemistry. Interleulin-8 (IL-8), vascular 
endothelial growth factor (VEGF), adrenomedullin (AM), connective tissue growth 
factor (CTGF) and endothelin-1 (ET-1) were all maximally expressed during the 
menstrual and/or proliferative phases of the cycle, consistent with the onset of 
endometrial repair. Endometrial cells and tissue explants treated with 100nM 
PGE2/F2α and/or hypoxia (0.5% O2) revealed up-regulation of IL-8, VEGF, AM and 
CTGF. An in vitro progesterone antagonism model revealed that progesterone 
withdrawal, hypoxia and prostaglandins are all necessary for significant increases in 
repair factor expression in endometrial tissue. HIF-1α was detected in human 
endometrium but exclusively in the late-secretory and menstrual phases. Using short-
hairpin RNA against HIF-1α, it was determined that hypoxia up-regulated these 
factors via HIF-1α, whereas PGF2α acted in a HIF-1α independent manner to increase 
 iii
repair factor expression. Finally, whole genome array analysis was performed on 
menstrual endometrium from women with objectively measured heavy and normal 
menstrual bleeding to provide an unbiased comparison of gene expression. 259 
transcripts displayed significant changes between the two groups. Five candidate 
genes were validated using Q-RT-PCR. Bioinformatic analysis of the differentially 
expressed gene set identified bioprocesses that included positive regulation of 
biological and cellular processes, leukocyte differentiation, regulation of apoptosis 
and response to stress/hypoxia. The presence of HIF-1α protein was examined in 
menstrual endometrial tissue nuclear protein extracts by Western blot, revealing 
significantly decreased levels in women with HMB versus normal controls. 
Furthermore, the mRNA expression of known target genes of HIF-1α (VEGF, 
CXCR4) was also significantly decreased in these women. The functional impact of 
endometrial HIF-1α was assessed using an in vitro angiogenic assay. Silencing of 
HIF-1α in endometrial cells significantly reduced the angiogenic potential of culture 
supernatants when compared to untransfected cells or cells transfected with a 
scrambled sequence.  
 
Conclusions: Repair factors are significantly increased in the human endometrium 
following the onset of menstruation. Progesterone withdrawal, hypoxia via HIF-1α 
and prostaglandins appear necessary for the regulation of these factors at this time. 
Menstrual endometrium displays significant differences in gene expression and HIF-
1α protein levels between women with HMB and normal controls. The findings of 
this thesis contribute to the existing literature on both the physiological process of 
endometrial repair and the pathogenesis of HMB. Extension of this work may allow 
the identification of novel therapeutic targets for the treatment of this common, 
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1. Literature Review 
2 
1.1 The Human Endometrium and Menstrual Cycle 
The human endometrium displays a remarkable capacity for repair. Throughout the 
reproductive years of a woman’s life it is cyclically subjected to the inflammation 
and tissue destruction of menstruation. However, each cycle the endometrium can 
fully repair without loss of function or scarring. The mechanisms involved in this 
efficient endometrial repair have still to be fully defined. Aberrations may lead to 
common gynaecological pathologies, such as heavy menstrual bleeding and 
dysmenorrhoea (painful menstruation). This thesis focuses on the delineation of 
potential regulatory pathways involved in endometrial repair and their contribution to 
heavy menstrual bleeding (HMB). 
1.1.1 The ovarian cycle 
The cyclical shedding, repair and regeneration of the human endometrium is driven 
by the ovarian sex steroids (Johnson and Everitt, 2000) (Figure 1). Neurones in the 
hypothalamus secrete gonadotrophin releasing hormone in a pulsatile fashion. This 
causes the synthesis and release of lutenising hormone (LH) and follicle stimulating 
hormone (FSH) from the pituitary to regulate ovarian hormone production. During 
menstruation, increased FSH secretion stimulates a cohort of antral follicles to 
undergo preovulatory development.  
As the follicles grow they secrete increasing amounts of oestradiol, which negatively 
feeds back to the pituitary to lower FSH secretion. As smaller follicles require higher 
levels of FSH to survive than larger ones, a dominant follicle emerges and the 
smaller follicles undergo atresia. When the follicle is fully mature the high 
concentrations of oestradiol have a positive feedback effect at the hypothalamus and 
pituitary to induce an LH surge and ovulation. After ovulation, the remaining 
granulosa and theca cells form the corpus luteum. The corpus luteum produces the 
high levels of progesterone that dominate the secretory phase of the cycle, as well as 
producing oestradiol (E2) and inhibin A. These hormones maintain negative feedback 
on the pituitary. In the absence of pregnancy, the corpus luteum becomes less 
sensitive to LH, and luteolysis occurs. This results in a dramatic decrease in 





Figure 1.  The human menstrual cycle. Gonadotrophin release governs sex 
hormone production by the ovaries, leading to local endometrial changes across the 
menstrual cycle (FSH follicle stimulating hormone, LH lutenising hormone). 
4 
production reduces negative feedback on the pituitary, allowing the increase in FSH 
production required to stimulate the next cycle. 
1.1.2 Endometrial histology 
The fluctuations in ovarian E2 and progesterone production are reflected by well 
documented morphological changes in the endometrium (Noyes et al., 1950, Buckley 
and Fox, 1989). The human endometrium is composed of two distinct compartments; 
the basal layer and an upper functional layer (Figure 2). It is the functional layer that 
is shed during menstruation. Traditionally, regeneration of the endometrium was 
thought to occur from the remaining basal layer but recent investigation of laser 
capture microdissected basal and functional menstrual endometrium suggested the 
shed functional layer also contributes to this process (Gaide Chevronnay et al., 
2009). 
 
The human endometrium is a dynamic tissue consisting of various cell types, 
including the luminal and glandular epithelial cells and a stromal compartment. The 
stromal compartment contains fibroblast-like cells as well as the vascular and 
lymphatic systems. Endometrial vessels become heavily coiled in the second half of 
the menstrual cycle and consist of endothelial cells and surrounding pericytes. These 
specialised spiral arterioles differ from other arterioles by the absence of an internal 
elastic lamina (Robertson and Manning, 1974).  They arise from radial arteries at the 
endometrial/myometrial border and take a tortuous course towards the endometrial 
luminal surface. Endometrial lymphatic vessels are much less well described but are 
thought to be sparsely distributed in the functional layer, with larger lymphatic 










Figure 2. Endometrial histological changes across the menstrual cycle. (A) 
Proliferative, (B) Early secretory, (C) Mid Secretory and (D) Late Secretory phase 
endometrium. B: basal layer, F: functional layer, GE: glandular epithelial cells, SE: 
surface epithelial cells, St: stromal cell compartment. 
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1.1.3 Menstrual phase 
The menstrual phase of the cycle commences on day 1 following withdrawal of 
ovarian steroids and lasts until day 5-7. Detailed study of early endometrial growth in 
the human endometrium has been performed using scanning electron microscopy 
(Ludwig and Spornitz, 1991). After shedding of the functional layer at menstruation, 
the endometrium has a ragged and torn surface with gland openings and a lack of 
epithelial covering. Regrowth of the luminal epithelium occurs initially, prior to 
stromal expansion. This begins on day 2, during active bleeding, and full coverage of 
the lumen is usually achieved by day 6. A more recent hysteroscopic, histological 
and scanning electron microscopy study identified that the endometrium is shed in a 
piecemeal fashion (Garry et al., 2009). Furthermore, this study identified that the 
endometrial repair process commences in delineated areas while shedding occurs 
simultaneously in adjacent areas. Recent laser capture microdissection techniques 
have identified that both the stromal and epithelial cell compartments have an active 
role in this repair process (Gaide Chevronnay et al., 2010).  
1.1.4 Proliferative phase 
The proliferative phase of the menstrual cycle follows menstruation and lasts until 
ovulation (day 14 of a 28 day cycle). E2 is the dominant hormone of this phase and 
its production increases as the dominant follicle develops. The early proliferative 
phase lasts from approximately day 4 to 7 and is characterised by regeneration of the 
newly repaired endometrium after menstruation. During the mid and late 
proliferative phase (day 8 to 10 and day 11 to 13 respectively) there is continued 
growth and development of glands, stroma and vasculature. Histologically, 
proliferative glands are narrow and straight and the stromal compartment is compact 
(Noyes et al., 1950) (Figure 2A).  
1.1.5 Secretory phase 
Following ovulation, luteal production of progesterone dominates the endometrial 
endocrine environment and the secretory phase begins. During this phase emphasis 
switches from proliferation to differentiation and it is divided into three stages (i) 
early: day 14 to 18, (ii) mid: day 19 to 23 and (iii) late: day 24 to 28. The histological 
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appearance of the secretory endometrium has been described (Noyes et al., 1950, 
Buckley and Fox, 1989). After ovulation, sub-nuclear vacuoles appear in the 
glandular epithelium and the glands become tortuous (Figure 2B). By the mid 
secretory phase secretory activity of the glands is apparent, causing stromal oedema 
(Figure 2C). During this phase the endometrium is receptive to implantation should 
fertilisation occur. The late secretory phase is characterised by the maturation and 
differentiation of the spiral arterioles. The perivascular cell number increases with 
some cells undergoing decidualisation (Figure 2D). If pregnancy does not occur, 
glandular secretion declines and the endometrium becomes dehydrated, giving the 
glands a saw-toothed appearance. There is an influx of leukocytes during this phase 
(discussed in detail in section 1.2.1). The withdrawal of ovarian steroids during this 
phase results in tissue necrosis and menstruation. 
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1.2 Menstruation as an inflammatory process 
Menstruation displays many of the classic hallmarks of inflammation, including 
tissue oedema and influx of immune cells. Withdrawal of steroid hormones, 
progesterone in particular, during the late secretory phase triggers a cascade of 
molecular and cellular interactions, culminating in menstruation (Finn and Pope, 
1986). Breakdown of the extracellular matrix is mediated by key enzymes; the matrix 
metalloproteinases (MMPs) (Marbaix et al., 1996, Salamonsen and Woolley, 1999). 
These enzymes have the ability to degrade all components of the extracellular matrix 
(ECM) and are up-regulated at the time of menstruation as a result of progesterone 
withdrawal (Vassilev et al., 2005). However, MMPs in the perimenstrual phase are 
limited to the functional layer, suggesting a more local regulation. Leukocytes 
express MMPs and have the potential to stimulate MMP production from adjacent 
cells (Jabbour et al., 2006) making them potential candidates in the regulation of 
endometrial MMPs.  
1.2.1 Leukocytes 
Following progesterone withdrawal there is a dramatic rise in the endometrial 
leukocyte population. Neutrophil numbers are negligible throughout the cycle but 
increase perimenstrually to comprise 6-15% of the total cell number (Salamonsen 
and Lathbury, 2000). The most prevalent leukocyte is the uterine NK (uNK) cell 
(King, 2000), comprising 70% of endometrial leukocytes. These uNK cells are 
CD56bright, CD16-, CD3- and are phenotypically different from peripheral blood NK 
cells (Koopman et al., 2003). uNK cells increase in number during the mid-luteal 
phase and are located close to the endometrial glands and spiral arteries (Dosiou and 
Giudice, 2005). Their location suggests they have a role in vascular remodelling and 
the lack of spiral arteriole modification seen in mice deficient in uNK cells supports 
this hypothesis (Ashkar et al., 2003, Greenwood et al., 2000). uNK cells produce a 
wide range of regulatory cytokines, indicating a role in initiation of cellular and 
humoral responses.  Macrophages also increase in number throughout the secretory 
phase to reach maximal numbers perimenstrually (Bonatz et al., 1992, Critchley et 
al., 1999). These cells are involved in tissue remodelling and debris removal. The 
increase in leukocyte numbers during the perimenstrual phase implicates up-
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regulation due to progesterone withdrawal. However, the inability to identify the PR 
receptor on macrophages or uNK cells (King et al., 1996, Stewart et al., 1998, 
Henderson et al., 2003) suggests an indirect mechanism of hormonal regulation. 
Paracrine mediators are likely to control leukocyte regulation at the time of 
menstruation, with a range of chemokines emerging as potential candidates (Hannan 
and Salamonsen, 2007, Salamonsen and Lathbury, 2000). 
1.2.2 Chemokines 
Chemokines are chemotactic cytokines involved in leukocyte recruitment and 
activation. They have been implicated in numerous reproductive events, including 
menstruation and implantation (Dominguez et al., 2003). Chemokines are divided 
into four subclasses; C, CC, CXC and CX3C, depending on their amino-terminal 
cysteine motif. Progesterone withdrawal up-regulates a host of inflammatory 
mediators in vivo, including the chemokines CXCL8 (Interleukin-8) and CCL-2 
(monocyte chemoattractant protein-1) (Critchley et al., 1999). Gene microarray 
analysis of endometrial biopsies from women given the progesterone receptor 
antagonist mifepristone in the mid secretory phase revealed that 571 genes displayed 
significant changes when compared to untreated controls (Catalano et al., 2007). 
These included increases in CXCL5, 12 and CX3CL1 in biopsies taken six hours 
after mifepristone administration, signifying regulation of chemokine production by 
progesterone withdrawal. Endometrial chemokines appear to be tightly regulated 
through post-translational modification by MMPs and other proteases, which convert 
precursor forms into active chemokines (Hannan and Salamonsen, 2007). 
Immunohistochemical studies have localised endometrial chemokine production to 
the glandular cells and decidualised stromal cells (Jones et al., 2004). 
1.2.3 Prostaglandins 
The enzyme involved in prostaglandin synthesis, COX-2, is also up-regulated by 
progesterone withdrawal (Critchley et al., 1999) (Figure 3). Subsequent increased 
synthesis of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) in the 
endometrium has important implications for menstruation (Baird et al., 1996). There 
are significant numbers of prostaglandin receptors in the perivascular compartment 
of the endometrium (Milne and Jabbour, 2003, Milne et al., 2001) signifying a  
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Figure 3. Synthesis and signalling of prostaglandins (PG). Cyclo-oxygenase 
1/2  (COX-1/2), prostaglandin E receptors (EP), prostaglandin F2α receptors (FP), 
thromboxane (TXA), thromboxane receptor (TP), prostacyclin (PGI), prostacyclin 
receptor (IP), cyclic adenosine monophosphate (cAMP), Inositol trisphosphate (IP3). 
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functional role. PGE2 is a potent vasodilator, leading to increased oedema and may 
contribute to pain at the time of menstruation (Williams, 1979). Administration of 
PGE2 to healthy participants increased the diameter of cranial vessels and resulted in 
headache (Wienecke et al., 2009), demonstrating the pain inducing properties of this 
prostanoid. Interestingly, PGE2 has been shown to act synergistically with CXCL8 to 
increase plasma leakage and neutrophil accumulation in the skin (Colditz, 1990). 
PGF2α  is also vasoactive, inducing myometrial contractions and vasoconstriction 
(Lundstrom, 1977).  
1.2.4 Nuclear factor-κB  
Nuclear factor-κB (NF-κB) is an inducible transcription factor known to increase a 
variety of inflammatory molecules. It consists of different sub-units, including p50, 
p65, cRel and Rel B. NF-κB is held captive in the cytoplasm by its inhibitor IκB until 
stimulated by an extracellular signal, e.g. IL-1, TNF-α. This results in 
phosphorylation of IκB and its degradation via an ubiquitin-proteosome pathway. 
NF-κB is then translocated to the nucleus and activates the transcription of target 
genes. NF-κB increases the transcription of a wide variety of genes, including 
cytokines (IL-1, IL-6), chemokines (CXCL8, CCL-2) and adhesion molecules 
(ICAM, VCAM) (Kayisli et al., 2004). Human endometrial biopsies have been 
shown to express components of the NF-κB pathway and there is evidence for 
activation of NF-κB during the perimenstrual phase (King et al., 2001). Progesterone 
has inhibitory effects on NF-κB activity, mediated by increasing IκB production or 
by competing with NF-κB for recognition sites on relevant genes (Kelly et al., 2001). 
In this way the steroid hormones modulate the endometrial inflammatory 
environment by suppressing NF-κB activity until menstruation is required.  
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1.3 The processes involved in endometrial repair 
The human endometrium displays a remarkable capacity for repair following the 
florid inflammation associated with menstruation. This repair occurs with the 
absence of scarring and is so efficient that the endometrium regains full function in 
the subsequent cycle. The processes involved in endometrial repair have still to be 
fully delineated but are likely to be comparable to classic wound healing processes. 
These involve temporally overlapping phases of inflammation and its resolution, 
tissue formation, tissue remodelling and angiogenesis. The ability of the 
endometrium to regenerate in each menstrual cycle also raises the possibility of the 
presence of adult progenitor cells within the local endometrial environment (Gargett, 
2007). While acknowledging this important aspect of endometrial repair, study of 
these controversial cells is beyond the scope of this thesis. Therefore, this section 
focuses on the classic wound healing processes described above. The regulation of 
endometrial repair is discussed subsequently (Section 1.4). 
1.3.1 Inflammation 
Although endometrial inflammation results in tissue destruction and menstruation, it 
is also likely to form a fundamental component of the repair process. Withdrawal of 
the anti-inflammatory ovarian steroid progesterone during the late secretory phase 
increases endometrial chemokine production (Critchley et al., 2003, Salamonsen and 
Woolley, 1999). Chemokines promote leukocyte adhesion and extravasation, 
resulting in endometrial accumulation of these cells in the perimenstrual 
endometrium (Salamonsen and Lathbury, 2000, Le et al., 2004). Leukocytes have an 
active role in the endometrial repair process. In the mouse model of menstruation, 
neutrophil depletion using the antibody RB6-8C5 affected endometrial breakdown 
and markedly delayed endometrial repair (Kaitu'u-Lino et al., 2007b). Macrophage 
depletion has also been shown to result in defective repair, as demonstrated in a 
guinea pig model of adult skin wounds (Leibovich and Ross, 1975) and in 
myocardial injury in mice (van Amerongen et al., 2007). The timing, number and 
morphology of inflammatory cells appear to be critical for efficient tissue repair. 
Persistence of leucocytes at a site of injury leads to ineffective wound healing and 
excess fibrosis (Wynn, 2008). Investigation of endometrial macrophage morphology 
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during the late secretory phase revealed lower levels of activation and adhesion 
molecules (CD69 and CD54) when compared to macrophages found in peritoneal 
fluid and may serve to limit the inflammatory response at menstruation (Eidukaite 
and Tamosiunas, 2004).  
In addition to inflammatory cell influx, increased chemokine production in the 
perimenstrual endometrium may itself contribute to the endometrial repair process. 
Interleukin-8 (IL-8, CXCL8) is a CXC chemokine, best known for its role as a potent 
chemoattractant for neutrophils and T-cells (Larsen et al., 1989). In addition, it has 
been shown to induce mitogenesis of vascular smooth muscle cells (Yue et al., 1994) 
and to have a key role in angiogenesis in vivo (Koch et al., 1992). These processes 
are fundamental for endometrial shedding and repair. Previous studies have found 
IL-8 to be present in the human endometrium with an increase in IL-8 mRNA and 
protein during the late secretory phase (Arici et al., 1998, Milne et al., 1999).  IL-8 
interacts with two chemokine receptors CXCR1 and CXCR2; both have previously 
been shown to be expressed in the endometrium throughout the menstrual cycle 
(Mulayim et al., 2003). 
1.3.2 Resolution of Inflammation 
Similar processes may govern stimulation and resolution of inflammation, to induce 
a self-limiting inflammatory response at menstruation. The pro-inflammatory 
cytokine IL-1 has been shown to increase 11β hydroxysteroid dehydrogenase-1 
(11βHSD-1) (Rae et al., 2004). This enzyme converts cortisone to the anti-
inflammatory steroid cortisol. Endometrial 11βHSD-1 mRNA levels at menstruation 
have been demonstrated to be significantly increased, consistent with a role in 
resolution of endometrial inflammation (McDonald et al., 2006). Hence, local 
generation of glucocorticoids may prevent an excessive inflammatory response in the 
menstrual endometrium. Interestingly, women with heavy menstrual bleeding 
(HMB) were found to have significantly elevated levels of 11βHSD-2, which 
converts cortisol back to cortisone (Rae et al., 2009). Decreased cortisol levels and 




Another potentially important modulator of the inflammatory response in the 
endometrium is heme-oxygenase-1 (HO-1). As the rate limiting enzyme in the 
breakdown of heme, HO-1 has a protective role in times of tissue stress. In particular, 
HO-1 protects tissue from ischemia-reperfusion (I-R) injury, inflammation, hypoxia, 
haemorrhagic shock and heavy metal exposure (Farombi and Surh, 2006). In 
endothelial cells, HO-1 over-expression decreased levels of soluble Flt-1 and soluble 
endoglin (Cudmore et al., 2007). Both these mediators are increased in pre-eclampsia 
and their suppression by HO-1 suggests a protective role for HO-1 in pregnancy. 
Increased HO-1 also provides protection against liver damage induced by the 
chemical compounds acetaminophen and carbon tetrachloride (Farombi and Surh, 
2006). HO-1 is highly inducible, by haemin and a range of non-haem factors 
including ultraviolet, heavy metals, hypoxia and nitric oxide (Tyrrell et al., 1993, 
Motterlini et al., 2000, Keyse and Tyrrell, 1989).  Its induction results in the 
catabolism of haem to biliverdin (BV), carbon monoxide (CO) and free iron. These 
products mediate the cytoprotective effects of HO-1. BV is an endogenous 
antioxidant, as demonstrated in the rat liver model (Fondevila et al., 2004). When rat 
livers were subjected to I-R injury, adjuvant therapy with BV increased portal blood 
flow and decreased hepatocyte damage. After orthotopic liver transplantation, BV 
therapy increased animal survival from 50% to 90-100% (Fondevila et al., 2004). 
There was decreased infiltration of neutrophils and macrophages and a decrease in 
the number of anti-apoptotic molecules. CO production lead to vasodilation in the rat 
model via an increase in cyclic guanylate monophosphatase (cGMP) (Pannen et al., 
1998). This stimulated relaxation of smooth muscle in vessel walls leads to 
vasodilation and increased clearance of free heme, limiting its toxic effects. 
 
HO-1 has been identified in the human endometrium, localized to epithelial cells and 
macrophages (Yoshiki et al., 2001). Further studies are required to delineate the role 
of HO-1 in the endometrium as it has an attractive potential role in suppression of 
inflammation and initiation of endometrial repair. At the time of menstruation, tissue 
destruction and the associated bleeding results in high levels of haem in the uterine 
cavity. This hemorrhagic inflammation will theoretically stimulate HO-1 expression. 
Interestingly, administration of E2 to rats following trauma-haemorrhage increased 
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the expression of HO-1 in the liver (Hsu et al., 2007). If E2 has similar effects in the 
endometrium, it will provide a mechanism of endometrial protection following the 
hemorrhagic inflammation of menstruation. Effective resolution of inflammation 
post menstruation is crucial for endometrial repair. Intensive research into this aspect 
of endometrial function has potential transferable value for resolution of tissue injury 
elsewhere in the body. 
1.3.3 Tissue formation 
Detailed study of early endometrial growth using scanning electron microscopy of 
the human endometrium has been performed (Ludwig and Spornitz, 1991). After 
shedding of the functional layer at menstruation, the endometrium has a ragged and 
torn surface with gland openings and a lack of epithelial covering. Regrowth of the 
epithelium occurs first, prior to stromal expansion. Epithelial cells grow from the 
necks of the glands and spread to meet migrating cells from other glands, forming a 
new luminal surface. This begins on menstrual day 2 and full coverage of the lumen 
is achieved by day 6. The cellular and molecular mechanisms governing epithelial 
cell proliferation and migration after menstruation have not been fully elucidated. 
One hypothesis is the “free-edge” effect, where the absence of neighbouring cells at 
the wound margin acts as a growth signal (Heimark and Schwartz, 1985). 
Alternatively, examination of the mouse model of simulated menstruation has 
suggested that re-epithelialisation of the uterine surface arises from progenitor cells 
residing in the glandular epithelial cells (Kaitu'u-Lino et al., 2010). Examination of 
bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) 
immunofluorescence in this model revealed that glandular cells proliferated 
selectively during repair and BrdU labelling remained constant. In contrast, there was 
no significant difference in luminal cell proliferation before and after endometrial 
breakdown and rapid dilution of BrdU was observed. 
 
Growth factors released from stromal cells, epithelial cells, leukocytes and the ECM 
are likely to be important in endometrial repair. The ECM contains embedded 
cytokines and growth factors, (Mott and Werb, 2004) that may be released by MMP-
mediated breakdown at menstruation. In addition to the known high levels of MMPs 
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at menstruation, MMP-7 mRNA is highly expressed during the early proliferative 
phase and remains abundant throughout the secretory phase (Vassilev et al., 2005). 
The active form of MMP-7 specifically binds to endometrial epithelial cells and 
exhibits resistance against tissue inhibitor of metalloproteinase-2 (Berton et al., 
2007). MMP-7 null mice have demonstrated the importance of MMP-7 in re-
epithelialisation (Dunsmore et al., 1998). These studies suggest that, alongside their 
ability to initiate menstruation, MMPs may have an active role in repair and 
remodeling of the post-menstrual endometrium.  
 
The transforming growth factor-β superfamily is a group of pleiotropic growth 
factors with an important role in wound healing. TGF-β1 is a general regulator of cell 
proliferation, differentiation and extracellular matrix (ECM) repair. In human 
endometrial tissue, TGF-β1 mRNA and protein levels were reported to be maximal at 
menstruation (Gaide Chevronnay et al., 2008), suggesting a role in local repair 
mechanisms. There is evidence that MMP2 and 9 mobilise and activate TGF-β from 
bone matrix (Dallas et al., 2002) and a similar mechanism may be present in the 
perimenstrual endometrium. Culture of endometrial stromal cells with TGF-β1 in 
vitro resulted in significant suppression of progesterone receptor mRNA and 
attenuated protein levels, hence augmenting progesterone withdrawal. In addition, 
TGF-β1 significantly inhibited the expression of Dickkopf-1, a protein that inhibits 
Wnt signalling (Kane et al., 2008). The Wnt signalling cascade is thought to mediate 
uterine proliferation during the proliferative phase (Hou et al., 2004). Therefore, 
inhibition of a Wnt antagonist by TGF-β1 may increase endometrial repair.  
 
Connective tissue growth factor (CTGF) is a multifunctional growth factor that is a 
member of a family of cysteine-rich secreted proteins. In adult mammals, CTGF is 
expressed at high levels during wound repair and at sites of connective tissue 
formation (Igarashi et al., 1993). Biological effects of CTGF include chemotaxis, 
differentiation, ECM production, angiogenesis, tumour growth, wound healing and 
fibrosis (Ivkovic et al., 2003, Frazier et al., 1996, Hishikawa et al., 2000, Shimo et 
al., 2001, Igarashi et al., 1993, Oemar et al., 1997). CTGF is therefore an attractive 
candidate for endometrial repair. It has been shown to be transcriptionally activated 
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by TGF-β1 and hypoxia (Higgins et al., 2004, Harlow et al., 2002, Brunner et al., 
1991). CTGF has been detected in the human endometrium by 
immunohistochemistry and northern blot analysis (Uzumcu et al., 2000). 
Localisation revealed its presence in epithelial and endothelial cells in the 
proliferative and secretory phases, whereas stromal cells were only positively stained 
after decidualisation in the late secretory phase. No menstrual phase biopsies were 
included in this study but the presence of CTGF in the normal cycling endometrium 
suggests it may facilitate tissue repair and remodelling after menses. 
1.3.4 Tissue remodelling 
Following the rapid initial repair of the human endometrium, regrowth and 
regeneration takes place throughout the proliferative phase. Tissue recombination 
studies in the mouse model suggest that uterine epithelialisation is required for 
stromal responsiveness to ovarian steroids (Bigsby, 2002). This explains the 
sequence of re-epithelialisation preceding stromal expansion. Stromal cell mitoses 
first appear on day 5-6 of the human menstrual cycle, when E2 levels are rising and 
the epithelial layer is completely healed (Ferenczy et al., 1979). Macrophages, 
fibroblasts and blood vessels are required for endometrial regrowth. Macrophages 
provide essential growth factors, fibroblasts replenish the ECM, and blood vessels 
supply oxygen and nutrients necessary for cell metabolism. Synthesis and 
remodelling of the ECM by fibroblasts is essential for wound healing. Fibroblasts 
differentiate into contractile phenotypes during the last phases of wound healing and 
increase their smooth muscle actin (SMA) content. These fibroblasts, known as 
myofibroblasts, initiate wound contraction and secrete type I collagen, leading to scar 
formation (Hantash et al., 2008). Interestingly, normal human endometrial stromal 
cells (HESs) have significantly less α-SMA when compared to endometriotic stromal 
cells (Yuge et al., 2007). When collagen gel contractility was measured for both cell 
types, endometriotic cells showed a significantly higher contractility than normal 
HESs (Yuge et al., 2007). These results suggest there is less myofibroblastic 
differentiation in normal HESs, leading to reduced scar formation. Changes in 
fibroblast activity may alter repair mechanisms in the endometrium leading to 
pathology such as endometriosis and its associated adhesions and scarring. Control 
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of fibroblast activity could therefore lead to novel therapeutic targets for scar 
limitation and adhesion prevention in women with endometriosis. 
1.3.5 Angiogenesis 
1.3.5.1 Angiogenesis across the menstrual cycle 
Angiogenesis is the process of new blood vessel formation from pre-existing 
vasculature and is an essential component of the human menstrual cycle. There is 
general consensus that there are a minimum of three stages in the cycle when 
angiogenesis is likely to occur (Girling and Rogers, 2005). Firstly, at menstruation 
when there is rapid repair of injured blood vessels. This is usually completed by day 
5 of the cycle. Secondly, in the proliferative phase when there is rapid growth of the 
functional layer of endometrium. Thirdly, during the secretory phase when there is 
coiling and maturation of the spiral arterioles and growth of the subepithelial 
capillary plexus. However, it has been repeatedly demonstrated that levels of 
endothelial cell proliferation within the human endometrium do not show any 
consistent pattern across the menstrual cycle (Girling and Rogers, 2005). 
Interpretation of these results is challenging, as samples taken from women at the 
same stage of the menstrual cycle are extremely variable. This may be due to 
differences in hormone levels at the time of sampling or a variation in the region 
from which the biopsy was obtained. To overcome this variation, Nayak and Brenner  
conducted an elegant study in the ovariectomised primate model using sequential 
oestradiol and progesterone implants to simulate an artificial menstrual cycle (Nayak 
and Brenner, 2002). Using Ki67 or bromodeoxyuridine to identify proliferating 
endothelial cells, the authors demonstrated a 6-fold increase in proliferation during 
the mid-proliferative stage (day 8-10 after progesterone withdrawal). This peak was 
absent in the hormone-deprived animals, indicating endothelial cell proliferation at 
this stage in the cycle is oestradiol dependent. No significant changes in proliferation 
were observed at other stages of this artificial cycle.  
The finding that most vascular proliferation occurs during the mid-proliferative 
phase in the macaque concurs with stereological analysis of human endometrium 
(Gambino et al., 2002). However, examination of human endometrium suggests that 
there is a further peak in angiogenesis or remodelling during the secretory phase, 
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which is not observed in the macaque. This may be due to species variation or the 
constant E2 regimen used in the macaque studies, unlike a natural menstrual cycle. 
Alternatively it may be vessel maturation causing the vascular changes observed 
during the secretory phase of the cycle. Maturation involves proliferation of vascular 
mural cells rather than endothelial cells and would remain undetected in a system 
identifying only endothelial proliferation. In the mouse model, increases in mural cell 
proliferation and coverage were stimulated by progesterone but not E2, in keeping 
with its role in the secretory phase (Girling et al., 2007).  
1.3.5.2 Modes of endometrial angiogenesis 
Formation of new vessels from existing vasculature occurs by at least four methods 
(Figure 4). Sprouting involves breakdown of the basement membrane with 
endothelial proliferation and migration, leading to sprouting and lumen formation 
from existing vessels. Intussusception results from proliferation of endothelial cells 
inside a vessel causing internal division and formation of two discrete capillaries. 
Elongation is longitudinal growth of the vessel without formation of new vascular 
junctions. The fourth method involves incorporation of circulating endothelial cells 
into endometrial vessels (Asahara et al., 1997). Gambino et al. (Gambino et al., 
2002) used a computerized stereological program to determine if vessel elongation 
played a role in human endometrial angiogenesis. They analyzed full thickness 
endometrial sections from five phases of the menstrual cycle to determine blood 
vessel length density (Lv), branch point density (Nv) and mean vessel length per 
branch point (Lv/Nv). This allowed differentiation between determination of peaks of 
endothelial cell proliferation and measuring new vessel formation. This study 
revealed that vessel elongation was the major mechanism by which endometrial 
angiogenesis occurred between the early and the mid/late proliferative phases of the 
cycle. In the early-mid secretory phase intussusception was found to be the 
predominant method (Figure 3). There were no significant differences between 
different areas of the endometrium. These results suggest vessel elongation takes 
place in the proliferative phase, whereas vascular remodelling occurs during the 








Figure 4. Modes of angiogenesis. (A) Sprouting involves breakdown of the 
basement membrane leading to lumen formation from existing vessels. (B) 
Intussusception results from proliferation of endothelial cells within an existing 
vessel to form two discrete capillaries. (C) Elongation involves longitudinal growth 
of a vessel. (D) Incorporation of circulating endothelial cells into an existing vessel. 
Adapted from (Maybin and Critchley, 2009). 
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1.3.5.3 Endometrial angiogenic factors 
The constant angiogenic potential of the human endometrium is governed by the 
activity of a large number of pro- and anti-angiogenic growth factors. One of the 
most studied angiogenic factors is vascular endothelial growth factor (VEGF). A 
potent stimulator of endothelial cell proliferation, it also increases vascular 
permeability and has a key role in inflammation (Jabbour et al., 2006, Girling and 
Rogers, 2005, Ferrara, 2004, Smith, 2001). VEGF is a key factor in physiological 
and pathological angiogenesis (Ferrara, 2004, Carmeliet, 2005). Inactivation of a 
single VEGF allele results in embryonic lethality (Ferrara, 2004), indicating its 
fundamental role in development of the vascular system. The VEGF family is 
comprised of five members; VEGF-A, -B, -C, -D and placental growth factor. Of 
these, VEGF-A is considered the main contributor to endometrial angiogenesis and 
has five alternatively spliced isoforms (Girling and Rogers, 2005). VEGF-C induces 
endothelial cell proliferation and has been localised to uNK cells using in situ 
hybridisation (Li et al., 2001). VEGF-A is expressed in both the rodent and human 
endometrium, with localization to the stromal compartment, glandular epithelial cells 
and neutrophils (Ferrara, 2004, Charnock-Jones et al., 1993). VEGF-A acts via two 
tyrosine kinase receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), both of 
which are present in the human endometrium (Nayak et al., 2000, Punyadeera et al., 
2006).  
 
Early studies revealed conflicting evidence regarding changes in VEGF levels across 
the menstrual cycle. Some suggested an increase in protein levels during the 
secretory phase (Zhang et al., 1998), whereas other studies found no such difference 
(Li et al., 1994). Consideration of trends within different cell types and the 
interactions between these cells seems to have a more important influence on 
angiogenesis than total endometrial VEGF production. In the human endometrium, 
there appears to be no significant difference in stromal VEGF mRNA levels across 
the cycle (Gargett et al., 1999). However, neutrophils found in or around blood 
vessels did contain VEGF protein levels that correlated with surrounding endothelial 
cell proliferation (Gargett et al., 2001).  
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Adrenomedullin (AM) is another vasoactive peptide that belongs to the calcitonin 
gene peptide superfamily. It has a wide range of biological actions including 
vasodilation (Kitamura et al., 1993, Shindo et al., 2001, Wilkinson et al., 2001), 
tumour angiogenesis (Zhao et al., 1998, Oehler et al., 2002), cell growth (Nikitenko 
et al., 2000) and inhibition of apoptosis (Shichiri et al., 1999, Oehler et al., 2001) and 
is therefore a putative endometrial repair factor. AM knockout mice demonstrated 
embryologic lethality at approximately embryonic day 14 due to severe haemorrhage 
(Shindo et al., 2001). AM acts through a G protein coupled receptor, the calcitonin 
receptor like receptor (CLR). Receptor activity modifying proteins (RAMPs) 
associate with CLR to determine its ligand binding specificity (McLatchie et al., 
1998). RAMP2 and RAMP3 association promotes binding of AM to CRL, while 
RAMP1 and CLR association promotes binding of the calcitonin gene-related 
peptide. AM is known to be expressed in the human endometrium (Zhao et al., 1998, 
Laoag-Fernandez et al., 2000) but its regulation and differential expression across the 
menstrual cycle has still to be fully determined. 
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1.4 The regulation of endometrial repair 
1.4.1 Oestradiol 
As E2 is the dominant ovarian hormone in the proliferative phase, endometrial repair 
was traditionally thought to be an oestrogen dependent event. E2 acts via the 
oestrogen receptor (ER), which has two structurally related subtypes, ERα and ERβ. 
Both have been described in the human endometrium (Table 1) and are expressed in 
the nuclei of glandular epithelial and stromal cells (Lessey et al., 1988, Critchley et 
al., 2002), indicating E2 has a potential role in the regulation of repair. ERα has not 
been detected in endometrial vascular endothelial cells, hence E2 was previously not 
considered to have a direct impact on angiogenesis. However, ERβ was subsequently 
detected in these cells with both polyclonal and monoclonal antibodies (Critchley et 
al., 2001, Lecce et al., 2001) suggesting E2 may act directly on endometrial vessels. 
 
To explore the role of E2 in endometrial repair Kaitu’u-Lino et al utilised the murine 
model of simulated menstruation (Kaitu'u-Lino et al., 2007a). When progesterone 
support was withdrawn in ovariectomised mice, there was no significant difference 
in the rate of repair between mice with and without E2 replacement. The oestrogen 
deplete group were maintained on a soy-free diet and injected with an aromatase 
inhibitor to eliminate all oestrogenic influence, demonstrating that E2 is not essential 
for endometrial restoration in this model. Further evidence for oestrogen independent 
repair comes from observations in women following ovariectomy. Following this 
surgery, the endometrium has the ability to heal in the absence of ovarian hormones, 
providing further support for the importance of local regulation of the endometrial 
repair process. 
 
Hormonal control of endometrial repair factors was further investigated in the 
ovariectomised macaque model (Nayak and Brenner, 2002). The authors used VEGF 
as an example of an endometrial angiogenic repair factor. They found three peaks of 
VEGF mRNA expression; in the surface epithelium during the early proliferative 
phase, in the stroma during the mid proliferative phase and in the glands during the 







Table 1. Ovarian steroid receptors and prostaglandin receptors in the human endometrium 
across the cycle. ERα oestrogen receptor α, ERβ  oestrogen receptor β, PR-A progesterone receptor 
A, PR-B progesterone receptor B, FP prostaglandin F2α receptor, EP2 a prostaglandin E2 receptor, LS 
late secretory. (Critchley et al., 2001, Critchley et al., 2002, Lecce et al., 2001, Milne and Jabbour, 








Epithelial cell Stromal cell Receptor 
 






ERα present  ↓(LS) present ↓(LS) present absent 
ERβ present  present present ↓ (LS) present present 
PR-A present absent present present present absent 
PR-B present present present absent present absent 
FP present present absent absent present present 
EP2 present present present present present present 
IP present present present present present present 
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animals, the authors concluded that oestrogen is not essential for the early 
proliferative phase peak but is necessary for the increase in VEGF mRNA in stromal 
cells, seen during the mid-proliferative phase. They also reported a dramatic increase 
in VEGFR-1 and VEGFR-2 in the small blood vessels just below the newly formed 
surface epithelium during the early proliferative phase, which was independent of E2. 
The E2 dependent mid proliferative peak in VEGF expression in stromal cells 
correlated with a dramatic increase in endothelial cell proliferation. Of note, there 
was no correlation between vascular proliferation and VEGF expression in the glands 
or surface epithelium. The authors concluded that VEGF played a dual role in the 
endometrium. Firstly, a role in initial repair of damaged vessels following 
progesterone withdrawal in the early proliferative phase endometrium, which is 
oestrogen independent. Secondly, VEGF is involved in endometrial regeneration 
involving vascular proliferation during the mid-proliferative stage of the cycle. This 
latter role has an absolute requirement for oestrogen.  
 
E2 stimulation of VEGF expression in stromal cells has also been shown in the 
mouse model (Ma et al., 2001) and with in vitro experimentation (Huang et al., 
1998). Other groups have suggested that it is the endometrial epithelial cells that are 
regulated by E2 to increase VEGF expression (Albrecht et al., 2003). Human 
myometrial microvascular endothelial cells cultured with human recombinant VEGF 
were demonstrated to increase their tube formation by approximately 65% over 
formation in media only. This increase was replicated when the endothelial cells 
were cultured with endometrial epithelial cells. A further increase was seen when E2 
was added to the co-culture. No such increases in tube formation were seen when 
stromal cells were co-cultured with endometrial epithelial cells.  
 
Taken together, these results suggest that E2 has an important role in endometrial 
proliferation and remodelling but may not be essential for the initial repair of 
menstrual endometrium. Therefore, rather than increasing E2 levels, the initiation of 
endometrial repair may be due to progesterone withdrawal in the late secretory 
phase. 
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1.4.2 Progesterone and its withdrawal 
Progesterone is the dominant hormone of the secretory phase of the cycle. It has anti-
inflammatory properties and governs differentiation of the endometrium in 
preparation for implantation. In the absence of pregnancy, progesterone levels fall 
dramatically due to pre-menstrual luteolysis and at the time of endometrial repair 
progesterone levels are low. There are two progesterone receptor isoforms, PRA and 
PRB, which are differentially regulated in the human endometrium (Table 1) (Mote 
et al., 2001, Mulac-Jericevic et al., 2000). During the secretory phase PRB is down-
regulated in both glandular and stromal cells, whereas PRA persists in the stromal 
compartment (Brosens et al., 1999, Wang et al., 1998b, Mote et al., 2001).  
 
Rodent studies have revealed progesterone has a possible stimulatory role for repair 
factors (Ma et al., 2001, Hyder et al., 2000). After an injection of progesterone, a 
small but persistent rise in VEGF occurred in the stromal cell compartment. 
Therefore progesterone may maintain VEGF expression throughout the menstrual 
cycle.  
 
The withdrawal of progesterone in the late secretory phase, rather than its presence, 
is more likely to have a significant impact on endometrial repair factors. Proliferative 
human endometrial explants cultured in vitro with 17β-oestradiol and progesterone 
or in the absence of ovarian steroids were subjected to microarray analysis (Gaide 
Chevronnay et al., 2010). Functional analysis of differentially expressed genes 
revealed that in the absence of hormones “wound healing and inflammation” was a 
top scoring biological process. Studies in ovariectomised primates also demonstrate 
that progesterone withdrawal is a stimulus for VEGF expression (Nayak and 
Brenner, 2002). In addition, VEGF receptor (VEGFR-2) mRNA was dramatically 
up-regulated in human and macaque endometrium in stromal cells of the superficial 
endometrial zones during the premenstrual phase, i.e. the time of progesterone 
withdrawal (Nayak et al., 2000). Promatrix metalloproteinase-1 (MMP-1) was 
coordinately up regulated in the same stromal cell population, leading the authors to 
hypothesize that VEGF-VEGFR-2 interactions may influence MMPs in the upper 
27 
zones of the endometrium during the premenstrual phase, and that these interactions 
might play a role in induction of menstruation and/or endometrial repair.  
 
It remains to be determined whether progesterone withdrawal increases repair factors 
directly, due to removal of an inhibitory influence of progesterone, or as a result of 
its downstream effects. Progesterone withdrawal is known to up-regulate cyclo-
oxygenase-2 (COX-2), the enzyme that drives production of prostaglandin E2 and F2α 
(Hapangama et al., 2002, Critchley et al., 1999). Inhibition of COX-2 in COX-1 (-/-) 
null mice induced complete reproductive failure, suggesting a lack of alternative 
methods of prostaglandin production (Reese et al., 2001). Both PGE2 and PGF2α 
appear to be essential for normal endometrial function. Mice lacking prostaglandin 
receptors display significant reproductive defects. Loss of EP2, a PGE2 receptor, 
resulted in impaired ovulation and reduced litter size (Tilley et al., 1999, Kennedy et 
al., 1999). Gene ablation of the FP receptor, the receptor for PGF2α, resulted in loss 
of parturition (Sugimoto et al., 1997). In addition, there is mounting evidence that the 
eicosanoids contribute to the processes involved in endometrial repair.   
 
PGE2 has been shown to promote expression of pro-angiogenic factors such as 
VEGF in the mouse and in human endometrial cells (Seno et al., 2002, Sonoshita et 
al., 2001, Sales et al., 2004). In addition, PGE2 induced migration and tube formation 
of murine pulmonary microvascular endothelial cells in vitro and increased 
angiogenesis in vivo (Rao et al., 2007). PGE synthase and synthesis of PGE2 have 
been localised to glandular epithelial and endothelial cells throughout the human 
endometrium and to stromal cells in the functional layer (Milne et al., 2001). PGE2 
acts via the G-protein-coupled receptor EP, of which there are four subtypes, termed 
EP1, EP2, EP3 and EP4. EP2 and EP4 activate adenylate cyclase and the 
cAMP/protein kinase A pathway, whereas EP1 and EP3 activate phospholipase C 
and mobilise the inositol triphosphate pathway (Figure 3)(Coleman et al., 1994). EP2 
and EP4 have been detected in the human endometrium across the menstrual cycle 




PGF2α is highly expressed in the human myometrium, where its well characterised 
function is to induce myometrial contractility (Senior et al., 1992, Sugimoto et al., 
1997). In addition to its presence in the myometrium, PGF2α is also produced from 
human endometrial explants cultured in vitro (Abel et al., 1980, Leaver and 
Richmond, 1984). PGF2α is emerging as a potential key player in the initiation of 
endometrial repair factor expression. PGF2α has been demonstrated to induce a host 
of endometrial angiogenic factors, including VEGF, FGF-2 and IL-8 (Sales et al., 
2005, Sales et al., 2009, Keightley et al., 2010). Functionally, PGF2α increased 
endometrial epithelial cell proliferation in culture (Milne and Jabbour, 2003) and is 
known to induce vasoconstriction of endometrial spiral arterioles (Baird et al., 1996). 
This vasoconstriction may result in a transient, local hypoxic insult in the uppermost 
endometrial layer. Therefore, PGF2α may increase repair factors directly and may 
also indirectly up-regulate these factors as a result of induction of hypoxic 
conditions. 
 
Prostacyclin (PGI) is also produced by the human endometrium (Smith et al., 1981b). 
This prostanoid acts via a heptahelical G protein-coupled receptor (IP receptor) 
(Battersby et al., 2004). Knockout studies in mice have demonstrated a role for PGI 
in prevention of thrombosis and increased inflammation (Murata et al., 1997, Ueno et 
al., 2000). Therefore, this prostanoid may be involved in menstruation and 
endometrial repair. Endometrial expression of the IP receptor has been demonstrated 
at maximal levels during menstruation (Smith et al., 2006) and was localized to 
epithelial, stromal and perivascular cells. Furthermore, treatment of endometrial 
explants with a PGI analogue significantly increased expression of proangiogenic 
genes (Smith et al., 2006).  
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1.5 The role of hypoxia in repair 
1.5.1 Evidence for the presence of endometrial hypoxia 
It is postulated that a period of transient hypoxia occurs in the uppermost endometrial 
zones following progesterone withdrawal, due to constriction of the spiral arterioles. 
Evidence for vasoconstriction in the perimenstrual period comes from early studies 
by Markee in the rhesus monkey (Markee, 1940). Endometrial explants were 
transplanted into the anterior chamber of the eye and vascular changes observed 
following progesterone withdrawal. Early changes included shrinkage of the stroma, 
increased spiral arteriole coiling and vascular stasis. After 24 hours, there was 
intense vasoconstriction, tissue necrosis and menstruation. More recently, the use of 
pimonidazole (hydroxyprobe®) in the mouse model of simulated menstruation 
identified the presence of hypoxia during menstruation (Fan et al., 2008). 
Pimonidazole is a marker of oxygen partial pressures less than 10mmHg and was 
detected in the uppermost endometrial zones during the simulated menstrual phase. 
In contrast, negligible levels were observed by day five post progesterone 
withdrawal. There is evidence that this transient hypoxic episode is also likely to 
occur in human endometrial tissue. Markers of tissue hypoxia (CAIX and hypoxia 
inducible factor-1α) have been detected immunohistochemically in the human 
endometrium during menstruation, with a distinct reduction in staining of both 
markers after cycle day 5 (Critchley et al., 2006b, Punyadeera et al., 2006). 
 
Confirmation of human endometrial vasoconstriction in vivo is technically 
challenging. Using laser Doppler fluxmetry to measure the number of red blood cells 
transiting a monitored volume per unit time, Gannon et al failed to detect any 
episodes of ischaemia during menstruation (Gannon et al., 1997). This finding may 
be due to the limited spatial resolution of fluxmetry. Focal or prolonged ischaemia-
reperfusion episodes would not be detectable with this method, particularly if 
episodes last longer than the authors’ 10min sampling time. In addition, the study 
does not state exclusion of women with HMB. There is some evidence that women 
with HMB have reduced levels of endometrial vasoconstrictors in the perimenstrual 
phase, such as endothelin-1 (Marsh et al., 1997, Smith et al., 1981a). In addition, 
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women with HMB have been shown to have increased uterine blood flow, quantified 
using pulsatility index measurement (Hurskainen et al., 1999).  Therefore aberrant 
vasoconstriction in these women may skew results, preventing the accurate 
delineation of normal endometrial physiology and detection of a reduction in 
endometrial perfusion during menses.  
 
Early studies detecting vasoconstriction of spiral arterioles resulted in the hypothesis 
that endometrial hypoxia stimulates menstruation (Markee, 1940). As MMPs are 
responsible for the degradation of endometrial tissue at menstruation, it was 
subsequently proposed that hypoxia up-regulated MMP expression. However, recent 
evidence raises questions about this theory. Primary human endometrial stromal cells 
cultured in normoxic (21% O2) and hypoxic (2% O2) conditions for 24 and 48 hours 
revealed that hypoxia in fact decreased the secretion of membrane-type 1 MMP, 
active MMP-2, proMMP-1 and proMMP-3 (Zhang and Salamonsen, 2002). Similar 
decreases in MMPs were also observed in the culture supernatants from whole 
endometrial explants cultured in 0.1% O2 for 24 hours (Gaide Chevronnay et al., 
2010). These results suggest that hypoxia is not responsible for endometrial 
breakdown and support the “tissue inflammation and destruction” hypothesis for the 
initiation of menses. However, hypoxic conditions may have a fundamental role in 
the initiation of endometrial repair. 
1.5.2 Hypoxia inducible factor 
Hypoxia-inducible factor (HIF) is a transcription factor that controls the cellular 
adaptive response to hypoxia. It is composed of two subunits; the oxygen-
destructible α-subunit and the constitutively expressed β-subunit. Three isoforms of 
the α-subunit (HIF-1α, HIF-2α, and HIF-3α) have the ability to bind to HIF-1β to 
modulate the in vivo response to hypoxia. HIF-1α-HIF-1β  and HIF-2α-HIF-1β 
heterodimers have overlapping but distinct target gene specificities (Ratcliffe, 2007, 
Sowter et al., 2003). In contrast to HIF-1α, HIF-2α is not expressed in every cell 
type. HIF-3α is much less studied but appears to have an inhibitory action on HIF 
activity (Makino et al., 2001, Makino et al., 2007). HIF-1α and HIF-1β contain basic 
helix-loop-helix (bHLH) and Per-ARNT-Sim (PAS) domains that mediate 
heterodimerization and DNA binding (Figure 5). HIF-1α also contains two 
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transactivation domains (TAD) that interact with co-activators such as p300 and 
CREB binding protein (CBP) (Kallio et al., 1998, Jiang et al., 1997). When αβ 
dimerisation occurs, HIF translocates to the nucleus and initiates the transcription of 
genes with hypoxic response elements (Figure 6). Target genes of HIF include those 
involved in tissue remodelling, apoptosis, energy metabolism and angiogenesis (e.g. 
VEGF, CTGF, Ang-2, GAPDH, AM, CXCL8) (Semenza, 2000, Higgins et al., 2004, 
Cormier-Regard et al., 1998, Graven et al., 1999).  
1.5.2.1 Regulation of HIF by oxygen 
The activity of the oxygen destructible alpha subunit of HIF is regulated by post-
translational mechanisms (Figure 6). In the presence of oxygen, two prolyl residues 
are hydroxylated in its oxygen-dependent degradation domain. This targets HIF-1α 
for proteasomal degradation by promoting ubiquitylation and interaction with the 
von Hippel-Lindau protein (Jaakkola et al., 2001, Ivan et al., 2001). In addition, 
hydroxylation of an asparagine residue in the c-teminus of the alpha subunit inhibits 
the binding of coactivators (p300/CBP) (Dann et al., 2002). Oxygen is required as a 
co-substrate for the enzymes carrying out these hydroxylation reactions, the prolyl 
hydroxylases (PHD). The reaction also requires an Fe(II) ion cofactor and 2-
oxoglutarate but oxygen appears to be the rate limiting factor for enzymatic activity 
in physiological conditions (Semenza, 2004). In hypoxic conditions hydroxylation 
cannot take place, resulting in rapid HIF-1α accumulation. On re-oxygenation HIF-
1α is degraded with a half-life of less than 5min (Wang et al., 1995).  
1.5.2.2 Non hypoxic activation of HIF 
In addition to activation by hypoxia, many inflammatory and growth factors have 
been shown to influence HIF-1 activity, including TNFα, IL-1β, PGE2 and NFκB 
(Hellwig-Burgel et al., 1999, Critchley et al., 2006b, Haddad and Land, 2001, van 
Uden et al., 2008). Unlike hypoxic conditions, the main mechanism by which these 
factors induce HIF-1 activity is by increasing HIF-1α protein translation, rather than 
protein stabilisation (Frede et al., 2005, Page et al., 2002). An increase in HIF-1α 
mRNA transcription has also been demonstrated in the non-hypoxic induction of 
HIF-1α (Blouin et al., 2004, Rius et al., 2008). HIF-1α protein degradation appears to 











Figure 5. HIF-1α and HIF-1β protein structure. Both proteins contain 
transactivation domains (TAD) which regulate the transcription of HIF-1 target 
genes and also bind co-activators such as p300/CBP and Ref-1 to increase HIF 
transcription. Both HIF-1α and HIF-1β contain a basic helix-loop-helix (bHLH) 
domain essential for DNA binding. The bHLH domain is also responsible for subunit 
dimerisation. HIF-1α contains an oxygen dependent degradation domain (ODD) 
through which the degradation of HIF-1α in normoxia is triggered. (PAS Per-ARNT-












Figure 6.  Hypoxia inducible factor -1 (HIF-1) activity in normoxic and 
hypoxic conditions. In normoxia, hydroxylation of HIF-1α at two proline residues 
promotes its proteosomal degradation. Hydroxylation is mediated by prolyl 
hydroxylases (PDH), which require an iron ion cofactor (Fe2+), 2-oxoglutarate and 
oxygen. In hypoxic conditions these processes are suppressed, allowing HIF-1α to 
dimerise with HIF-1β, translocate to the nucleus and bind to hypoxic response 
elements (HRE) on target genes to induce transcription.  
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HIF-1α mRNA appears sufficient to increase HIF-1α protein levels by shifting the 
balance towards HIF-1α synthesis to surpass its degradation.   
1.5.2.3 HIF in the human endometrium 
HIF-1α has been identified in the human endometrium and has an attractive role in 
the co-ordination of angiogenic and mitogenic factors for endometrial repair. HIF-1α 
was demonstrated by immunohistochemistry to be present exclusively in the late 
secretory and menstrual phases (Critchley et al., 2006b). It was localised to the 
surface epithelial, glandular and stromal cells in the functional layer, with staining 
limited to the glandular cells in the basal layer. Interestingly, HIF-1α protein co-
localised with the EP2 receptor, suggesting up-regulation by PGE2. This was 
confirmed by HIF-1α protein detection in endometrial cells treated with 100nM 
PGE2 in normoxic conditions but not those treated with vehicle. This PGE2 induction 
of HIF-1α in normoxic conditions has been previously demonstrated in prostate 
cancer cells and colon cancer cells (Liu et al., 2002, Fukuda et al., 2003). In addition, 
HIF-1α has been shown to regulate the endometrial angiogenic factor cysteine rich 
protein 61 (CYR61) (Gashaw et al., 2008). This pro-angiogenic factor was up-
regulated at the mRNA and protein level during menstruation. Hypoxic conditions 
increased endometrial cell CYR61 mRNA expression and secreted protein levels. 
Silencing of HIF-1α in these cells using short interfering RNA (SiRNA) resulted in a 
significant reduction in hypoxia-induced CYR61 mRNA and protein when compared 
to cells transfected with control SiRNA.  
 
Cognisant of the contribution of HIF to the up-regulation of factors involved in 
metabolism, angiogenesis and extracellular matrix remodelling in other systems 
(Semenza, 2004), it has an attractive role as the master regulator of endometrial 
repair. Its endometrial induction may be classical, due to a transient hypoxic episode, 
or due to the inflammatory mediators present during menstruation. The contribution 
and presence of HIF-2α in the endometrium is similarly unknown and endometrial 
target genes of the HIF heterodimer are still to be elucidated. Not only has HIF-1 a 
potential role in the repair and remodelling of the normal human endometrium but its 
aberrant expression may contribute to defective repair and the common 
gynaecological complaint of heavy menstrual bleeding.   
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1.6 Heavy menstrual bleeding 
1.6.1 Definition of heavy menstrual bleeding (HMB)  
HMB is defined as excessive menstrual blood loss that interferes with a woman’s 
physical, emotional, social and/or material quality of life, (NICE, 2007). This 
subjective definition of HMB is useful clinically as it is the woman’s perception and 
ability to cope with her bleeding that determines the need for treatment, rather than 
the actual volume of menstrual blood loss (MBL) (Warner et al., 2004). In contrast, 
high individual variability in the subjective definition of HMB poses problems for 
clinical research into this disorder. Therefore, HMB can also be defined objectively 
as a monthly menstrual blood loss (MBL) of greater than 80ml (Hallberg et al., 
1966a). Menstrual fluid is composed of blood, endometrium and a serous 
endometrial transudate, but objective measurements are usually based on menstrual 
haemoglobin content alone. Early Scandinavian studies demonstrated that the mean 
MBL was 40ml and that regular loss greater than 63ml was associated with iron 
deficiency anaemia (Hallberg et al., 1966a, Hallberg et al., 1966b, Hallberg and 
Nilsson, 1964). The 90th centile for MBL in these studies was 80ml, and this has 
been adopted as the lower limit at which blood loss is traditionally defined as heavy.  
1.6.2 The significance of HMB 
HMB is a common condition in women of reproductive age. One in three women 
finds their menstrual loss excessive, with this figure rising to one in two as the 
menopause approaches (Prentice, 1999). Over 800 000 women seek treatment per 
year in the UK alone (NICE, 2007) and menstrual complaints constitute greater than 
20% of all secondary referrals to gynaecology outpatient clinics (Santer et al., 2005). 
Considering almost 70% of women between 16 and 59 in the UK are in employment 
(2000), this debilitating condition has a significant socio-economic impact. 
Assessment of the economic impact of menstrual complaints in the US demonstrated 
financial losses of greater than $2000 per patient per year due to absence from work 
and home management costs (Frick et al., 2009). Although medical treatment options 
are available for HMB, many women proceed to surgery due to medical treatment 
failure or side effects. Hysterectomy remains one of the most commonly performed 
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surgical procedures (NICE, 2007), with HMB a leading indication. The English rate 
of surgery for heavy menstrual bleeding is 140 women per 100 000 (Cromwell et al., 
2009). Annual treatment costs exceed £65 million and women are subjected to all the 
risks associated with surgical procedures (Weeks et al., 2000). It is essential to fully 
understand the pathogenesis of HMB to improve medical treatments and avoid the 
risks of surgery. Ideally treatments for HMB would be non-hormonal, to avoid 
troublesome side effects and exclusion of their use in women wishing to conceive. 
1.6.3 Pathogenesis of HMB 
A new classification system for abnormal uterine bleeding has recently been 
outlined, describing bleeding due to polyps, adenomyosis, leiomyoma, malignancy, 
coagulopathy, ovulatory dysfunction, endometrial, iatrogenic and not-yet classified 
(the PALM-COEIN system) (Munro et al., 2011). However, approximately 50% of 
cases of HMB occur in the absence of recognised pathology. In such circumstances 
HMB is likely to be a consequence of disturbance of local endometrial mechanisms 
leading to increased flow and/or prolonged bleeding. Observational studies have 
reported the typical normal duration of bleeding to be from three to eight days 
(Treloar et al., 1967, Harlow and Campbell, 1994). Prolonged menstrual bleeding 
(>eight days) may be due to excessive inflammation at menstruation, defective 
endometrial homeostatic mechanisms or delayed repair of endometrial vessels and 
tissue. Increased flow at menstruation is likely to be due to impaired vasoconstriction 
of the specialised endometrial spiral arterioles. 
1.6.3.1 Impaired vasoconstriction 
As the radius of a vessel is the major determinant of resistance to flow, decreased 
constriction of endometrial vessels at the time of menstruation will contribute 
significantly to increased blood loss (Figure 7). PGF2α and endothelin-1 (ET-1) are 
two endometrial factors with known vasoconstrictive properties (Baird et al., 1996, 
Marsh et al., 1997). Women with menstrual blood loss in excess of 90ml have been 
shown to have a significantly decreased PGF2α/PGE2 ratio (Smith et al., 1981a) and 
decreased FP receptor expression (Smith et al., 2007). Excessive PGE2 production at 
the expense of PGF2α may result in less constriction of the spiral arterioles prior to 
menstruation. In addition, women with HMB have decreased endometrial expression 
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of the potent vasoconstrictor ET-1 and increased levels of its metabolising enzyme, 
neural endopeptidase (Marsh et al., 1997). The authors suggest that increased 
metabolism of endothelin could explain its decreased endometrial expression and 
cause dilation of endometrial vessels at menstruation. Altered spiral arteriole 
maturation may also contribute to inefficient spiral arteriole vasoconstriction at 
menstruation. Vessel wall circumference and focal discontinuities were noted to be 
larger in the endometrium of women with HMB than normal controls (Mints et al., 
2007). Women with heavy bleeding had significantly reduced vascular smooth 
muscle cell proliferation in spiral arterioles during the mid-late secretory phase when 
compared to normal controls (Abberton et al., 1999b). In addition, smooth muscle 
myosin heavy chain, a contractile protein used as a marker of vascular smooth 
muscle cell maturation, was also significantly decreased in spiral arterioles of women 
with HMB (Abberton et al., 1999a). Taken together, the decreased levels of 
vasoconstrictive factors and immature vessels present in women with HMB will 
significantly increase MBL. Application of Poiseuille’s equation (Figure 7) reveals 
that a two fold increase in vessel radius leads to a sixteen fold decrease in resistance 
to flow, highlighting that even small changes in endometrial vasoconstriction will 
lead to a dramatic increase in menstrual loss. 
1.6.3.2 Defective homeostasis 
In other tissues, disruption of blood vessels after injury results in adherence of 
platelets to collagen on the injured basement membrane. Platelet aggregation 
stimulates the coagulation cascade and formation of a fibrin clot. In contrast, studies 
of the endometrium suggest that platelet involvement is relatively low and that 
vasoconstriction and the clotting cascade are more important in achieving 
homeostasis post-menstruation (Gelety and Chaudhuri, 1995). The coagulation 
cascade is activated by two pathways; extrinsic and intrinsic (Figure 8). Each 
culminates in the conversion of factor X to Xa, which catalyses the conversion of 
pro-thrombin to thrombin, ultimately leading to the formation of a fibrin clot. 
Disorders that interfere with systemic haemostasis have an impact on MBL. Von 
Willebrand disease is the most common of these disorders, with a prevalence of 13% 












Figure 7.  The influence of vessel radius on blood flow at menstruation. 
Progesterone levels decrease during the late secretory phase as the corpus luteum 
regresses. In women with normal menstrual bleeding (NMB), prostaglandin F2α 
(PGF2α) and endothelin-1 cause vasoconstriction of the spiral arterioles at 
menstruation to decrease blood flow. Women with heavy menstrual bleeding (HMB) 
have been shown to have lower levels of FP receptor (Smith et al., 2007), endothelin-
1 (Marsh et al., 1997), and spiral arteriole maturation (Abberton et al., 1999a). In 
addition, they have higher levels of the vasodilator, prostaglandin E2 (Smith et al., 
1981a). The resulting lack of vasoconstriction has a profound effect on blood loss, 









     
 





Figure 8. Haemostasis: the coagulation cascade and fibrinolytic system. 
Activation of coagulation occurs by two pathways, extrinsic and intrinsic. 
Conversion of fibrinogen to fibrin allows formation of a haemostatic clot. 
Breakdown of this clot is mediated by the fibrinolytic system. Some women with 
heavy menstrual bleeding have been shown to have increased endometrial levels of 
tissue plasminogen activator (tPA) (Gleeson et al., 1993), leading to high plasmin 
levels and increased breakdown of the haemostatic clot. 
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Fibrin deposits are essential for homeostasis but inadequate resolution of the deposit 
can result in scarring. Degradation of the fibrin clot is mediated by the fibrinolytic 
system (Figure 8). After peritoneal surgery there is defective endogenous 
fibrinolysis, which may explain the high level of adhesion formation observed post-
operatively (Hellebrekers et al., 2000). Fibrinolysis involves conversion of 
plasminogen to active plasmin, promoting the degradation of fibrin deposits. Tissue 
plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) drive the 
production of plasmin. In contrast, plasminogen activator inhibitor (PAI) inhibits 
fibrinolytic activity. The human endometrium contains t-PA and u-PA, as well as 
PAI and the uPA receptor (Gleeson et al., 1993, Nordengren et al., 2004). An active 
fibrinolytic system at menstruation may confer protection against scarring during 
endometrial repair. However, an overactive fibrinolytic system may interfere with 
haemostasis and contribute to HMB. Women suffering from heavy menstrual loss 
have raised levels of t-PA activity on the second day of bleeding when compared to 
those with normal loss (Gleeson et al., 1993). Further evidence for this over 
activation of the fibrinolytic system comes from the efficacy of tranexamic acid as a 
treatment for HMB. This antifibrinolytic reduces t-PA and PAI levels in women with 
HMB and results in a 58% reduction in blood loss (Gleeson et al., 1994). Of note, 
women taking tranexamic acid do not suffer from scarring or adhesion formation 
within the endometrium, suggesting that the balance between PA and PAI may be 
more important in scar prevention than absolute levels. 
1.6.3.3 Excessive menstrual inflammation 
The finding of increased levels of the pro-inflammatory cytokine TNFα in the 
menstrual effluent of women with HMB compared to normal controls lends support 
to the hypothesis that excessive inflammation can contribute to HMB (Malik et al., 
2006). The role of the prostaglandin synthesis pathway has also been examined in 
women with objective measurement of their menstrual blood loss. Analysis of gene 
expression in endometrial biopsies from the secretory phase revealed significant 
elevation of COX-2 mRNA expression in women with blood loss greater than 80ml 
(Smith et al., 2007). Increased levels of total prostaglandins have been found in the 
endometrium of women with HMB (Smith et al., 1981a, Smith et al., 1981b). 
Increased signalling of PGE2 through its EP2 and EP4 receptors has also been 
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suggested due to elevated production of cyclic AMP in endometrium from women 
with heavy versus normal bleeding. Furthermore, the enzyme involved in cAMP 
hydrolysis, phosphodiesterase E4, was decreased in women with HMB (Smith et al., 
2007). These findings suggest excessive prostaglandin production and signalling in 
the endometrium of women with HMB. The resulting exaggerated inflammation may 
lead to increased and prolonged tissue damage at the time of menstruation. Currently 
prostaglandin synthesis inhibitors are a useful medical treatment for reduction of 
menstrual blood loss (Cameron et al., 1990). However, although women treated with 
mefenamic acid had a significant decrease in menstrual loss, 52% maintained a blood 
loss greater than 80ml after two months of treatment (Cameron et al., 1990). 
1.6.3.4 Delayed endometrial repair 
Lack of vasoconstriction during menstruation may not only increase menstrual flow 
but also limit or prevent the perimenstrual hypoxic insult in the upper endometrial 
zones of women with HMB. This may impact on the initiation of endometrial repair. 
Decreased activation of HIF-1 may prolong menstrual bleeding if there is a 
subsequent decrease in the transcription of angiogenic repair factors. VEGF is an 
angiogenic factor that is a well established target gene of HIF-1 (Fukuda et al., 
2003). Women with blood losses in excess of 80ml have been shown to have 
significantly lower VEGF mRNA at menstruation than women with a loss less than 
80ml (Malik et al., 2006). VEGF promotes the migration and differentiation of 
vascular smooth muscle cells (Arkonac et al., 1998) and contributes to initiation of 
coagulation (Blum et al., 2001). Decreased VEGF expression at menstruation may 
delay repair of damaged vessels and increase menstrual loss. 
 
Evidence for the need for controlled perimenstrual inflammation, followed by well 
timed resolution and repair is mounting. Unrestrained inflammation or aberrant 
repair may both contribute to the onset of HMB (Figure 9). Treatment of women 
with resistant HMB may require maximisation of the repair process in addition to 
current treatments that focus on limitation of the inflammatory response. Further 
research into the pathways involved in endometrial repair, including the contribution 
of HIF-1 and NFκB, may identify potential targets for novel therapeutic intervention 









Figure 9.  Local endometrial inflammatory and repair factor expression 
during luteo-follicular transition (adapted from Critchely & Maybin. Semin 
Reprod Med. 2011). As the corpus luteum regresses during the late secretory phase, 
progesterone levels fall. This triggers a cascade of inflammatory mediators in the 
pre- and early-menstrual endometrium, including cyclo-oxygenase-2 (COX-2), 
interleukin-8 (IL-8) and prostaglandins (PG) E2 and F2α. Glucocorticoids and heme-
oxygenase (HO-1) may be involved in limitation of this inflammatory response. 
Vasoconstriction of the endometrial spiral arterioles occurs following P-withdrawal, 
due to increasing levels of endothelin-1 (ET-1) and PGF2α. This is thought to lead to 
a transient hypoxic episode in the uppermost endometrial zones, which may 
stimulate endometrial repair factor production. Vascular endothelial growth factor 
(VEGF), connective tissue growth factor (CTGF), adrenomedullin (AM), and 
fibronectin are factors with a putative role in endometrial repair and remodelling post 
menstruation. There is evidence that local endometrial factors are aberrant in women 
with HMB, red arrows (Smith et al., 1981a, Smith et al., 2007, Marsh et al., 1997, 
Rae et al., 2009, Malik et al., 2006).  
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1.7 Hypotheses  
The mechanisms involved in endometrial repair are still to be fully characterised. 
Likewise, the regulation of this tightly controlled, efficient process remains 
undefined. Delineation of the physiology of endometrial repair may lead to novel 
treatment strategies for the common gynaecological complaint of HMB.  
 
1. As endometrial repair is thought to commence on day two of the cycle, 
during active bleeding, factors involved in this process would be expected to 
be increased during the menstrual phase. It is clear that inflammation, its 
resolution, tissue formation/remodelling, vasoconstriction and angiogenesis 
are all key events in the repair process. Factors with putative roles in 
endometrial repair include IL-8 (inflammation/angiogenesis), AM and VEGF 
(angiogenesis), CTGF (tissue formation/remodelling) and ET-1 
(vasoconstriction).  
 
Hypothesis: Factors involved in endometrial repair (IL-8, VEGF, AM, CTGF, ET-1) 
are significantly up-regulated during menstruation.  
 
2. The predominant hormonal change in the pre-menstrual endometrium is the 
withdrawal of progesterone as the corpus luteum regresses. The subsequent 
increased synthesis of prostaglandins is well established (Baird et al., 1996). 
There is also evidence for a transient, local hypoxic episode in the upper 
endometrial zones (Critchley et al., 2006b, Fan et al., 2008). Any menstrual 
up-regulation of factors involved in endometrial repair is, therefore, 
potentially regulated by progesterone withdrawal, prostaglandins and/or 
hypoxia. 
 
Hypothesis: Progesterone withdrawal, Hypoxia, PGE2 and/or PGF2α up-regulate 
endometrial repair factors. 
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3. The transcription factor HIF is known to regulate the cellular response to 
hypoxia (Maxwell, 2005). NFκB is a transcription factor with a key role in 
the inflammatory response (Baldwin, 1996). Both factors have been identified 
in the human endometrium during the late-secretory/menstrual phase 
(Critchley et al., 2006b, King et al., 2001). Hence, prostaglandin and hypoxia 
induced up-regulation of endometrial repair genes may be due to increased 
activity of HIF and/or NFκB. 
 
Hypothesis: Prostaglandins and Hypoxia increase repair factor expression in the 
human endometrial cells via the initiation of transcription by HIF and/or NFκB. 
 
4. Defective endometrial repair may contribute to the common gynaecological 
complaint of HMB. Decreased vasoconstriction, excessive inflammation or 
delayed vascular repair can lead to heavy or prolonged bleeding. Examination 
of endometrium from women with objectively measured MBL may identify 
aberrant gene expression and potential therapeutic targets. 
 
Hypothesis: menstrual endometrium from women with HMB exhibits altered repair 






The specific aims of this PhD were to: 
 
1. determine the expression of putative repair factors in human endometrial 
biopsies from across the menstrual cycle. 
 
2. elucidate the role of hypoxia, prostaglandin E2 and prostaglandin F2α in the 
regulation of endometrial repair factors. 
 
3. assess the contribution of HIF and NFκB to the regulation of endometrial 
repair factors. 
 
4. examine differences in endometrial repair factor expression between women 















2. General Materials & Methods 
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2.1 Patient recruitment and endometrial tissue collection 
Written informed consent was obtained from 187 healthy women of reproductive age 
(Figure 10) (Appendix 1). Institutional ethical approval was obtained from the 
Lothian Research Ethics Committee (LREC/07/S1103/29) (Appendix 2). Participants 
were aged 22 to 50 years (median age 41; mean age 41). All reported regular 
menstrual cycles (cycle length 21 to 35 days) and had not taken any exogenous 
hormones or used an intrauterine device during the 3 months prior to tissue 
collection. Women with known uterine pathology such as large fibroids (>3cm) and 
endometriosis were excluded.  
 
Human endometrial biopsies were collected from 179 of the 187 women at the time 
of hysterectomy or investigation in the gynaecology out-patient setting for a 
subjective complaint of HMB (Figure 10, patient recruitment flow chart). 
Endometrial tissue was not obtained from eight women due to technical difficulties 
(n=3) or failure to attend for their appointment (n=5). A further 21 tissues were 
excluded from the study due to inconsistent dating (n=13) or due to the subsequent 
finding of uterine pathology (n=8). 
 
Endometrial biopsies were collected with an endometrial suction curette (Pipelle, 
Laboratorie CCD, Paris, France). Immediately after collection tissue was divided and 
placed in: 
 
(i) RNA later, an RNA stabilisation solution (Ambion (Europe) Ltd., 
Warrington, UK) and stored at -70ºC for RNA extraction 
(ii) neutral buffered formalin (NBF) to fix tissue prior to wax embedding 









Figure 10.  Recruitment figures, including details of exclusions. DNA: did not 
attend. 
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At hysterectomy, an additional full thickness section including the functional and 
basal endometrial layers and adjacent myometrium was taken from the uterine cavity 
and fixed in NBF for immunohistochemical studies. The biopsies were dated 
according to three criteria: 
 
(i) the histological appearance based on the criteria of Noyes et al. (Noyes 
et al., 1950), assessed by a consultant pathologist (Dr Alistair Williams) 
(ii) the participant’s reported last menstrual period (LMP) 
(iii) the circulating serum progesterone and oestradiol levels in serum 
samples collected from each woman at the time of endometrial biopsy 
(radioimmunoassay by Mr Ian Swanston).  
 
Consistency for all three parameters was necessary before inclusion in the study. 
Biopsies were classified as proliferative (P), early secretory (ES), mid secretory 
(MS), late secretory (LS) or menstrual (M) for analysis (Table 2).  
 
Table 2. Classification and clinical details of endometrial tissue samples examined in this thesis. 
*oestradiol values significantly decreased when compared to proliferative, early and mid-secretory 
values (M p<0.001, LS p<0.05). δprogesterone values significantly decreased compared to early and 
mid-secretory values (M p<0.001, P p<0.01, LS p<0.05). 
 
 

















































































































Of the 179 women who provided tissue samples, 21 consented to return for a repeat 
endometrial biopsy 3-6 months following insertion of a levonorgestrel-releasing 
intrauterine system (LNG-IUS) for treatment of their subjective complaint of HMB. 
This IUS has been shown to markedly down-regulate hormone receptors in all 
endometrial compartments (Critchley et al., 1998, Burton et al., 2003), resulting in a 
“progesterone-deprived” environment. Of the 21 women, 12 returned for a second 
endometrial sample collection (Figure 11). This tissue was divided and placed in 
RNA later and NBF as above. The repeat biopsies were paired with pre-insertion 
samples from the same women for analysis (see Chapter 4). Initial biopsies were 
dated as proliferative (P) (n=4), early secretory (ES) (n=5), mid secretory (MS) 
(n=1), late secretory (LS) (n=1) and menstrual (M) (n=1). 
2.2 Menstrual blood loss collection 
In addition to provision of endometrial tissue, a subset of women (n=81) consented 
to undergo objective measurement of their menstrual blood loss (MBL) over one 
menstruation. Of these women, 71 completed the collection and provided an 
endometrial biopsy (Figure 11). Four women did not complete the menstrual 
collection, three did not provide endometrial tissue due to unsuccessful sampling and 
three were excluded due to inconsistencies in endometrial dating. Women were given 
the same brand of tampon and/or pad (Tampax tampons and Always towels, Proctor 
and Gamble, UK), with verbal and written instruction on collection (Appendix 3). 
Measurement of MBL was based on a modified alkaline-haematin method as 
previously described (Hallberg and Nilsson, 1964, Warner et al., 2004). In brief, used 
sanitary products were added to a measured volume of 5% sodium hydroxide. The 
contents were left for 24h to allow conversion of haemoglobin to haematin. During 
the same time period, a 1 in 200 dilution of the patient’s venous blood in 5% sodium 
hydroxide was made and stored separately. After 24h, an aliquot of sodium 
hydroxide was removed from the volume soaking the sanitary products and filtered 
through hardened filter paper (Whartman No. 54, Maidstone, UK). The optical 
density (OD) of the menstrual blood solution and venous blood sample were then 










Figure 11.  Recruitment of women to levonorgestrel-releasing intrauterine 
system (LNG-IUS) group (Chapter 4) and the objectively measured menstrual 
blood loss (MBL) subset (Chapter 6). Pre and post LNG-IUS samples are used as 
an in vivo model of progesterone “deprivation”. DNA: did not attend.
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MBL was calculated as a quantity of the patient’s own venous blood using the 
following equation (van Eijkeren et al., 1986): 
 
  (OD of menstrual blood solution x total volume of added NaOH) 
MBL =    (OD of venous blood x 200)  
 
A MBL measurement of greater than 80ml was classified as heavy menstrual 
bleeding (HMB) and less than 80ml as normal (NMB). Full details of the 
endometrial tissue from women with an objective MBL measurement can be found 
in Chapter 6.2.1, Table 11. 
2.2.1  Validation of MBL measurement methodology 
Validation of this method was carried out using time expired whole blood measured 
and applied to the same sanitary products given to the participants. 50ml, 100ml and 
300ml of blood was placed onto sanitary products and subject to the same collection 
and processing procedure as above. The validations were carried out in triplicate for 
each blood volume. Results showed a consistent 8-9% decrease in MBL value 
compared to known amount of blood added. Known volume of 50ml = measured 
value of 46ml (SD 0), 100ml = 92ml (SD 1), 300ml = 273ml (SD 10.5). 
2.2.2 Menstrual Pictogram 
Thirty women collecting their menstrual loss were also given a menstrual pictogram 
(see Appendix 4) with verbal and written instructions on mode of completion. 
Participants were asked to complete the pictogram each time they changed their 
pad/tampon. The menstrual pictogram contains pictorial representations of graded 
staining from slight to severely stained sanitary pads and tampons. In addition to 
scoring the amount of staining, women were asked to specify if pads were normal or 
night-time and if tampons were regular, super or super-plus. Women were also asked 
to provide an estimation of extraneous blood loss in the form of clots or flooding. 
Finally, women indicated if the period they collected was representative of a normal 
period, or whether it was a lot lighter, slightly lighter, slightly heavier or a lot heavier 
than usual.  
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A scoring system for the feminine hygiene product pictogram was devised (see 
Appendix 5) based on previous studies (Higham et al., 1990, Wyatt et al., 2001, 
Wilkens et al., 2008). In addition, extraneous loss was scored separately. Small, 
medium and large clots that were documented were scored as 1, 3 and 5ml 
respectively and each episode of flooding was assigned 3ml. The scores from the 
menstrual pictogram icons for feminine hygiene products (without extraneous loss) 
were compared with objective blood loss measured by the alkaline-haematin 
technique (results described in Chapter 6.3.1). 
2.3 In vitro culture 
2.3.1 Endometrial explant culture 
Endometrial biopsies were divided into equal explants and incubated on raised 
platforms in 24 well plates, just covered with serum free RPMI 1640 medium plus 
penicillin (50 μg/ml, Sigma, Dorset, UK), streptomycin (50μg/ml, Sigma) and 
gentamycin (5μg/ml, Sigma). Experimental conditions and treatments are detailed 
within each results chapter (Chapter 4.2.3 and Chapter 6.2.10). 
2.3.2 Isolation and culture of primary human endometrial stromal 
(HES) cells 
Stromal cells were isolated from human endometrial tissue from the proliferative, 
early and mid secretory phases by enzymatic digestion previously described (Kane et 
al., 2008). Briefly, specimens were washed in Dulbecco’s PBS (Sigma) and finely 
dissected with a scalpel. The chopped tissue was digested in collagenase (10mg/ml, 
Sigma) and DNase (4mg/ml, Sigma) for 90 min at 37ºC. The tissue was resuspended 
in 2ml RPMI 1640 medium (Sigma) and repeat passage through a 19-gauge needle 
was used to aid tissue dispersion. Filtration through a 40μm nylon cell strainer 
(Falcon; BD Biosciences, Bedford MA, USA) was carried out prior to centrifugation 
(1700rpm, 3 min). The supernatant was discarded and the pellet resuspended in 10 
ml RPMI 1640 medium supplemented with 10% fetal calf serum (Mycoplex; PAA 
Laboratories, Kingston-Upon-Thames, UK), penicillin (50μg/ml, Sigma), 
streptomycin (50μg/ml, Sigma) and gentamycin (5μg/ml, Sigma). The cell 
suspension was then plated into a 162cm3 flask and grown to confluence. All 
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experiments were carried out at passage ≤4 in serum free RPMI at timepoints 
identified by timecourse experiments. 
2.3.3 Transfection and culture of endometrial epithelial cells 
Human Ishikawa endometrial adenocarcinoma cells (European collection of cell 
culture, Centre for Applied Microbiology, Wiltshire, UK) had been previously stably 
transfected as described in (Sales et al., 2004), with either the prostaglandin F-series 
prostanoid receptor (FPS) or the prostaglandin E-series prostanoid receptor 2, one of 
the G protein-coupled receptors shown to transduce prostaglandin E2 signalling in the 
human endometrium (EP2S cells). Cells were maintained in DMEM nutrient mixture 
F-12 with glutamax-1 and pyridoxine, supplemented with 10% fetal calf serum, 1% 
antibiotics (stock 500IU/ml penicillin and 500μg/ml streptomycin), and 200μg/ml 
G418 (Calbiochem, Nottingham, UK) at 37ºC. All experiments were carried out in 
serum free DMEM media and are described in further detail within each results 
chapter (Chapter 4.2.2, Chapter 5.2.2-4 and Chapter 6.2.11). 
2.4 RNA extraction and quantitative reverse transcription 
polymerase chain reaction  
2.4.1 RNA extraction 
Total RNA from cells and endometrial tissue was extracted using the commercially 
available product RNeasy Mini Kit (Qiagen Ltd, Sussex, UK) according to the 
manufacturer’s instructions. Samples were treated for DNA contamination by 
DNAase digestion during RNA purification. Following extraction, RNA was 
quantified using the Nanodrop 1000 spectrophotometer v3.7 (ThermoScientific, DE, 
USA) and stored at -80°C. Quality of the RNA was assessed using the Agilent 2100 
Bioanalyser system in combination with the RNA6000 nano chips (Agilent 
Technologies, Cheshire, UK), according to manufacturer’s instructions. Only RNA 
that displayed intact 18S and 28S peaks was reverse transcribed to cDNA for real-
time PCR analysis. In addition, the RNA Integrity Number (RIN) was determined by 
the 2100 Expert software (Agilent Technologies) for tissue samples sent for array 
analysis. A RIN number below 7.5 suggests degradation of the RNA; all array 
samples had a RIN above 9.5. 
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2.4.2 Reverse transcription 
RNA samples were reverse transcribed using MgCl2 (5.5mM), deoxy (d) nucleotide 
triphosphates (0.5mM each) random hexamers (2.5μM), ribonuclease inhibitor 
(0.4U/μl) and multiscribe reverse transcriptase (1.25U/ μl; all from PE Biosystems, 
Warrington, UK). The mix was aliquoted into individual tubes (8μl per tube), and 
200ng of RNA added (2μl per tube of 100ng/μl RNA). A tube with no reverse 
transcriptase and a further tube with water replacing RNA were included to control 
for DNA contamination. After mixing, samples were incubated for 20 min at 25ºC, 
60 min at 42ºC, and 5 min at 95ºC. Complementary DNA (cDNA) samples were 
subsequently stored at -20ºC.  
2.4.3 Quantitative polymerase chain reaction (Q-RT-PCR) 
Q-RT-PCR was used to measure the level of gene specific sequences in cDNA 
generated by reverse transcription. This method uses forward and reverse primers to 
the target sequence of cDNA, along with a probe that recognizes a sequence between 
the two primer annealing sites. The probe is labelled with two fluorescent dyes; a 5’ 
reporter label (FAM; 6-carboxyfluorescein) and a 3’ quencher label (TAMRA; 6-
carboxytetramethylrhodamine). When the probe is intact, the quencher suppresses 
the fluorescence of the reporter. During the amplification phase of the PCR process, 
the probe is cleaved by AmpliTaq Gold. This separates the two fluorescent labels, 
removing the inhibition of the reporter label. The resulting fluorescent signal is 
directly proportional to the amount of PCR product. Fluorescence is only detected if 
the target sequence for the probe is amplified during the reaction, preventing the 
detection of non-specific amplification. 18S ribosomal RNA detection was used as 
an internal control as levels remain constant relative to the amount of cDNA present. 
The reporter dye present on the 18S probe is VIC, which emits fluorescence at a 
different wavelength to the FAM reporter on the probe of the gene of interest.  
 
Primers and probes used in this study were designed using Primer Express Software 
(Applied Biosystems, Warrington, UK) or the Universal Probe Library Assay Design 
Centre (Roche Diagnostics Ltd, Burgess Hill, UK). BLAST (basic local alignment 
search tool) was used to determine the presence of sequences in the scientific 
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databases that are similar to those amplified by specific primers. In all cases, primer 
and probe sets for target genes of interest were found to be unlikely to amplify non-
specific templates.   
 
A reaction mix was prepared containing Taqman buffer (5.5mM MgCl2, 200μM 
dATP, 200μM dCTP, 200μM dGTP, 400μM deoxyuridine triphosphate), ribosomal 
18S primers and probe (Applied Biosystems, Warrington, UK) and specific forward 
primer, reverse primer and probe for the gene of interest (Table 3). After mixing, 
36μl aliquots were placed in separate tubes and 1.5μl cDNA added, including water 
negative and reverse transcriptase negative cDNA samples. Into one aliquot, 1.5μl 
water was added as a no template control. Triplicate 12μl samples were placed into a 
PCR plate. PCR was carried out using an ABI Prism 7900 (Applied Biosystems) 
using standard conditions. Data were analysed and processed using Sequence 
Detector version 2.3 (PE Biosystems).  
 
PCR data was analyzed using the ΔΔCT method as described by Applied Biosystems. 
This normalises the amount of target mRNA to RNA loading for each sample using 
18S ribosomal RNA, which is then related to an internal control. The linearity of the 
response of primers and probes to specific cDNA was determined by serial dilution. 
Primers and probes were diluted up to 64 times using a standard pool of RNA. The 
log of ng total RNA was plotted against ΔCT units and the gradient of the lines 
through these points determined. The absolute value of the slope was <0.1 for all 
primers and probes used herein.
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2.5 Western Blotting 
Western blotting identifies the presence of proteins by detection with specific 
antibodies after separation by electrophoresis and transfer to a polyvinylidene 
difluoride membrane. 
2.5.1 Nuclear protein extraction from cells 
Cytoplasmic proteins were extracted with a cytoplasmic protein lysis buffer [10mM 
HEPES  (pH 7.8), 10nM KCl, 2mM MgCl2, 1mM dithiothreitol, 0.1mM EDTA, 10% 
Nonident P-40] containing protease inhibitors (Complete mini protease inhibitor 
cocktail; Roche Diagnostics Ltd., Lewes, UK). The membrane fraction was pelleted 
by centrifugation at 13000rpm for 1 min at 4ºC. The cytoplasmic fraction supernatant 
was removed and stored at -80ºC. Thereafter, the nuclear fraction was extracted with 
a nuclear protein lysis buffer [50mM HEPES (pH 7.8), 50nM KCl, 300mM NaCl, 
0.1mM EDTA, 1mM dithiothreitol, 10% glycerol] containing protease inhibitors 
(Roche) followed by agitation for 20 min at 4ºC and centrifugation at 13000 rpm for 
5 min at 4ºC. The nuclear fraction supernatant was removed and stored at -80ºC. 
Protein content was determined using protein assay kits (Bio-Rad, Hemel 
Hempstead, UK). 
2.5.2 Nuclear protein extraction from endometrial tissue 
Endometrial tissue was incubated in RNA later solution (Ambion Ltd) for 24h and 
subsequently frozen at -80ºC. Nuclear protein was extracted from approximately 
20mg of this frozen tissue using a commercially available nuclear extract kit (Active 
Motif, Rixensart, Belgium) according to the manufacturer’s instructions. 
2.5.3 Electrophoresis 
For HIF-1α and β-actin, a total of 10μg of nuclear protein was resuspended in a 2:1 
ratio with Laemmli buffer [125mM Tris-HCl (pH 6.8), 4% SDS, 5% 2-
mercaptoethanol, 20% glycerol and 0.05% bromophenol blue] and denatured for 5 
min at 90ºC. Proteins were separated on 4-12% Bis-Tris Gels (NuPAGE Novex, 
Invitrogen, Carlsbad, CA) in NuPage MOPS SDS running buffer (Invitrogen), 
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alongside Precision Plus protein standards, all blue (Bio-Rad, Hemel Hempstead, 
UK). The electrophoresis tank was run at 150V, 50mA, 25W for 70min.  
2.5.4 Electrotransfer 
The protein was transferred onto polyvinylidene difluoride membranes (Millipore, 
Watford, UK), which had been pre-soaked in methanol. Transfer buffer: 12.2g tris 
(Sigma), 5.6g glycine (Sigma), 200ml methanol (Fisher Scientific), 1800ml distilled 
H2O. The gel and membrane were assembled in the electrotransfer apparatus and the 
transfer performed at 250mA, 300V, 50W for 2h. 
2.5.5 Western Blot 
Membranes were blocked overnight in 5% milk solution in Tris buffered saline with 
Tween (TBST; 50mM Tris-HCl, 150mM NaCl and 0.05% vol/vol Tween 20). After 
washing with TBST, the membranes were incubated with primary antibodies for 2h 
at room temperature; mouse monoclonal anti-HIF-1α antibody (BD Biosciences, 
Oxford, UK) diluted 1:250, rabbit polyclonal to β-actin (Abcam, Cambridge, UK) at 
1:5000. After washing, the membrane was incubated with horseradish peroxidase 
conjugated goat anti-mouse IgG (Dako) or horseradish peroxidase conjugated mouse 
anti-rabbit IgG (Sigma), both at 1:20000. The chemiluminescent horseradish 
perioxidase substrate (Immobilon Western, Millipore Corporation, MA, USA) was 
used for immunoreactive protein detection according to manufacturer’s instructions.  
2.6 Immunohistochemistry 
This technique utilises specific primary antibodies to localise an antigen within a 
section of tissue. Immunohistochemistry was performed to detect IL-8, VEGF, 
CTGF, AM, HIF-1α and HIF-1β proteins in endometrial tissue biopsies. With the 
exception of HIF-1α, all antigens were detected using a standard avidin-biotin 
horseradish peroxidase (ABC-HRP) method. A sequence of primary antibody, 
biotinylated secondary antibody and the pre-formed avidin-biotin-HRP enzyme 
complex is used in this method. Chain polymer-conjugated technology was 
employed for HIF-1α staining, using the EnVision system. Here the primary 
antibody is followed by incubation with an enzyme-labelled inert molecule of 
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dextran, meaning avidin and biotin blocking steps were not required. Both methods 
utilised 3,3-diaminobenzidine for detection. 
 
All protocols were optimised to determine appropriate conditions for maximal and 
specific immunostaining. Specific protocols are summarised in Table 4. All 
immunohistochemical staining was performed on paraffin sections (3μm). These 
were dewaxed for 10min in xylene before rehydration in descending grades of 
alcohol. Slides were washed in distilled water for 10min prior to antigen retrieval. 
2.6.1 Antigen retrieval 
Different antigen retrieval methods were employed depending on the antibody used 
(see Table 4).  
• A pressure cooker was filled with 2 litres of 0.01M sodium citrate buffer (pH 
6) and placed on a hot plate. When heated, slides were submerged and the lid 
sealed. Slides were heated for 5min at full pressure.  
• Microwave antigen retrieval was carried out in either pH 6 antigen retrieval 
buffer (Vector Laboratories, Peterborough, UK) or pH 9.0 Hiar buffer (10 
mM TRIS; 1 mM EDTA; and 0.05% Tween-20). Sections were heated in the 
appropriate buffer on full power for 15min. 
All slides were allowed to cool for 20min before washing in PBS for 10min. 
2.6.2 Blocking 
Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in distilled 
water for 10min at room temperature and washed twice in PBS. Slides were 
incubated sequentially with avidin and biotin (Vector Labs, Peterborough, UK) for 
10min at room temperature to block endogenous avidin-binding activity in all but 
HIF-1α staining. After washing in PBS, background staining was further prevented 
by incubation with a non-immune block to prevent non-specific binding of the 
secondary antibody. Serum from the species in which the secondary antibody was 
raised was diluted 1:5 in PBS with 5% BSA (Sigma-Aldrich Company Ltd, Dorset, 
UK). Alternatively, the commercially available protein block (DAKO, Cambridge, 
UK) was used.  
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2.6.3 Primary Antibodies and controls 
Tissue sections were incubated overnight at 4°C with 125μl of primary antibody at 
the appropriate concentration. Dilutions were carried out in the serum solution used 
for blocking or in commercially available antibody diluent (DAKO). Where possible, 
the primary antibody was pre-absorbed against a blocking peptide for use as a 
negative control. Alternatively, the primary antibody was substituted with an 
equimolar concentration of generic immunoglobulins from the same species in which 
the primary antibody was produced. Positive controls were tissue sections known to 
express high levels of the protein of interest. The next day, sections were washed 
between each stage with PBS containing 0.05% Tween-20.  
2.6.4  Secondary Antibodies 
Sections were incubated with the appropriate biotinylated secondary antibody, raised 
against the immunoglobulins of the species in which the primary antibody was 
produced. Antibodies were diluted (see Table 4) and 125μl applied to all sections for 
1h at room temperature. For HIF-1α immunohistochemical staining, EnVision 
polymer reagent was used in place of the secondary/tertiary antibody (Figure 13B).  
2.6.5  Amplification 
The ABC-Elite detection system (Vector) was used to amplify the signal from the 
biotinylated secondary antibody. Three drops of ABC-Elite were added per slide and 
incubated for 1h at room temperature. This step was not required when Envision was 
used (HIF-1α protocol). 
2.6.6 Detection 
Positive staining was visualised using the peroxidase substrate 3,3-diaminobenzidine 
(DAB; DAKO), which forms a brown precipitate on contact with the antigen-
antibody complex.  
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2.6.7 Dehydration and mounting 
All slides were washed in distilled water before counterstaining with Harris’ 
haematoxylin. Sections were then dehydrated in ascending grades of alcohol, 
incubated for 10min in xylene and mounted in Pertex.  
2.6.8 Semi-quantitative scoring 
Localisation and intensity of immunostaining was evaluated blindly by two 
independent observers using a semi-quantitative scoring system. The intensity of 
staining was graded with a three point scale (0 = no staining, 1 = mild staining, 2 = 
strong staining). This was applied to the glands and stromal cells in both the basal 
and functional layer of the endometrium (in full thickness sections), as well as the 
surface epithelium, perivascular and endothelial cells where visualised. The 
percentage of tissue in each intensity scale was recorded. A value was derived for 
each of the cellular compartments by using the sum of these percentages after 
multiplication by the intensity of staining. This histoscore system is a standard 
method used in previous studies (Aasmundstad et al., 1992, Wang et al., 1998a, 
Critchley et al., 2006b) and has previously been validated in a set of tissue sections 
where immunoreactivity was also measured with a computerised image analysis 
system (Wang et al., 1998b). There was a strong correlation between quantitative 
data derived from image analysis and subjective scores by trained observers.  
2.7 Enzyme linked immunosorbant assay (ELISA) 
This technique is used to determine the concentration of a given substance in a 
solution by comparison with a standard curve created from solutions of known 
concentration. There are two principle forms of ELISA: 
 
(i) Sandwich ELISA. Plates are pre-coated with an antibody (C), which 
binds to a specific epitope on the substance to be measured (S). Next a 
detection antibody (D) that is labelled with biotin, binds to a different 
epitope of S. Finally, streptavidin peroxidase binds to biotin and is 
detected by addition of substrate. This type of ELISA was used to 
measure IL-8, CTGF and VEGF secreted proteins. 
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(ii) Competition ELISA. Plates are pre-coated with the recombinant protein 
of interest (rP) and then blocked to remove non-specific binding. The 
solution containing the protein of interest (P) is then added in 
combination with a primary anti-serum. This antiserum recognises 
identical epitopes on rP and P and competitively binds. If the solution 
being measured contains a high concentration of P, then most of the 
antiserum will have become conjugated to it and will be washed off in 
subsequent wash cycles. In contrast, if the solution contains low 
concentrations of P, then the antibody will have become bound to rP on 
the ELISA plate. A secondary antibody is added and detected. Sample 
wells with low levels of P (high levels of antibody bound to rP) will have 
a high OD value and those with high levels of P (low amounts of antibody 
bound to rP) will have a low OD value. This form of ELISA was used to 
measure AM protein. 
2.7.1 IL-8 ELISA 
IL-8 protein concentrations in culture supernatants was quantified using a 
commercially available enzyme linked immunosorbent assay (ELISA) (R&D 
Systems, Oxford, UK) as described previously (Denison et al., 1998). Plates were 
coated overnight with 100μl/well of mouse monoclonal anti-human IL-8 capture 
antibody (500μg/ml diluted 1:360 with ELISA buffer) (R&D Systems). After 
washing, 100μl of standard or sample was added. A biotinylated polyclonal goat 
anti-human IL-8 detection antibody (50μg/ml diluted 1:1200) was used (R&D 
Systems). 100μl/well of strepavidin peroxidase (1:2000 dilution) was added and 
plates incubated for 30min at room temperature. After washing, 200μl Tetra Methyl 
Benzidine substrate was added to each well for 10min, followed by quenching with 
50μl/well of 2N sulphuric acid. Plates were read on a plate reader at 450nm. The 
intra- and interassay precisions were 9.1% and 22% respectively and the detection 
limit of the assay was 8 pg/ml. 
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2.7.2 CTGF ELISA 
CTGF secreted protein concentrations were measured using a human CTGF ELISA 
development kit (PeproTech, London, UK) according to manufacturer’s instructions. 
In brief, 96 well ELISA microplates were coated with 100μl of rabbit anti human 
CTGF capture antibody at 1μg/ml and incubated overnight. After washing, wells 
were blocked for 1h with 1% BSA in PBS. 100μl of sample or standard was added 
per well and incubated at room temperature for 2h. A biotinylated antigen-affinity 
purified rabbit anti human CTGF detection antibody was used at 100μg/ml. 
Incubation with avidin-horseradish peroxidase (HRP) conjugate at a dilution of 
1:2000 for 30min was followed by detection with ABTS liquid substrate solution 
(Sigma). Colour development was measured on an ELISA plate reader at 405nm. 
Minimum Detectable Concentration = 63 pg/ml. There no significant cross-reactivity 
for human BMP-4, CTGFL/WISP-2, CYR61, IGF-I, IGF-II, IGF-BP1, NOV, TGF-
β, WISP-1 or WISP-3. 
2.7.3 VEGF ELISA 
The human VEGF ELISA development kit (PeproTech, London, UK) was used 
according to manufacturer’s instructions to measure VEGF protein concentrations in 
culture supernatants. Each well of the ELISA plate was coated with 100μl of 
0.5μg/ml rabbit anti human VEGF capture antibody. The next day, the plate was 
washed, blocked for 1h and incubated with 100μl of sample or standard per well. 
After washing, 100μl of 0.25μl/ml of biotinylated rabbit anti human VEGF detection 
antibody was added to each well and incubated for 2h. Incubation with avidin-HRP 
conjugate at a dilution of 1:2000 for 30min was followed by detection with ABTS 
liquid substrate solution (Sigma). Colour development was measured on an ELISA 
plate reader at 405nm. Minimum Detectable Concentration = 63 pg/ml. There was 
100% cross-reactivity for human VEGF121 and murine VEGF but no significant 
cross-reactivity for human EG-VEGF, EGF, RANTES, FGF-16, GM-CSF, PDGF-
AA, PDGF-AB, PDGF-BB or SCF. 
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2.7.4 AM ELISA 
AM concentration in conditioned media was measured using a human AM (1-52) 
EIA kit from Phoenix Peptides (Karlsruhe, Germany) according to manufacturer’s 
instructions. 50µl of standards, samples and positive controls were added to each 
well with 25µl of anti-serum (rabbit anti-peptide IgG) and 25µl of biotinylated 
peptide. The plate was incubated at room temperature for 2h. After washing, 100µl 
of streptavidin-HRP solution was added per well and incubated for 1h. 100µl of 
3,3',5,5'-tetramethylbenzidine (TMB) substrate solution was added to each well after 
washing and incubated for 1h. Reactions were terminated with 2N HCl before 
absorbance optical densities were read at 450nm. Minimum Detectable 
Concentration = 0.13 ng/ml, interassay error <14%, intraassay error <5%. There was 
100% cross-reactivity for rat AM (1-50) and human AM (13-52) and mouse AM (1-
50) but no reported cross-reactivity for endothelin-1, amilin, CGRP, CGRP-2, αANP 
or BNP-32.  
2.8 Capillary tube formation assay 
A capillary tube formation assay was used to assess in vitro angiogenic potential, as 
endothelial proliferation and migration are integral components of angiogenesis. 
Methodology was previously established in our laboratory (Rae et al., 2009). 100μl 
Matrigel (BD Biosciences, Bedford, MA) was added per well in a 48 well plate and 
allowed to polymerise for 1h at 37ºC. Human umbilical vascular endothelial cells 
were seeded at a density of 2x104 in 200μl EBM-2 media (Lonza, MD, USA) 
supplemented with GA1000 and ascorbic acid SingleQuots®. 200µl of treated RPMI 
media or culture supernatants from endometrial cell or explants experiments were 
then added to the HUVEC cells (see Chapter 3.2.5 and Chapter 6.2.11). Each 
supernatant was assessed in triplicate in three separate experiments. Capillary tube 
formations were visualised after 8h. Images were captured in the same position in 
each well using an inverted microscope at x5 magnification. Branch points of the 
formed tubes were counted by an observer blinded to the sample origin and an 
average of the replicates was determined after unblinding.  
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2.9 RNA Interference 
This “loss of function” technique is used to elucidate the function of a gene. RNA 
interference (RNAi) occurs naturally in vivo, as part of a cell’s antiviral defence 
mechanism (Fire et al., 1998). Double stranded RNA is cleaved into short interfering 
RNAs (siRNA) by an enzyme known as Dicer. These siRNAs then become 
integrated into a protein complex named the RNA induced silencing complex 
(RISC). This guides the siRNA to its target RNA and becomes involved in the 
degradation of this complementary sequence to suppress gene expression. Production 
of synthetic siRNA sequences has allowed this method to be harnessed as a tool for 
assessing gene function (Figure 12).  
2.9.1 Small interfering RNA 
Double stranded, chemically synthesized RNA that was chemically labelled with 6-
FAM was used as a transfection indicator in EP2S cells (siGLO Green, Thermo 
Scientific Dharmacon®, Lafayette, CO). Approximately 1x105 EP2S cells were 
seeded per well of a 6 well plate in DMEM media containing 10% fetal calf serum. 
The next day, when cells were at 60% confluence, transfection mixes were prepared  
containing siGLO and HiPerfect transfection reagent (Qiagen, West Sussex, UK). 
This mix was swirled gently and incubated for 10 min before dropping onto the cells. 
SiGLO was added at a final concentration of 0, 5, 10, 20, 50 and 100nM. HiPerfect 
was added at 1:100, 1:200 and 1:300 for each concentration of siGLO. EP2S cells 
were incubated with transfection mix for 8h at 37ºC before washing in PBS and 
incubating with DMEM plus 10% FBS for 24h. Cells were then incubated with 
serum free DMEM overnight before checking transfection efficiency using the 




Figure 12. The mechanism of RNA interference. Short interfering RNA 
(SiRNA) constructs enter the cell with the assistance of cationic and neutral lipids. 
Short hairpin RNA (ShRNA) constructs can be transfected into cells using a vector, 
e.g. lentivirus. These ShRNA constructs are then converted to SiRNA by endogenous 
RNase III-like enzyme (Dicer). SiRNA sequences interact with the RNA induced 
silencing complex (RISC) to form single strand sequences which recognise and bind 
to complementary RNA sequences. Cleavage of target sequences prevents their 
transcription, leading to decreased protein production and “silencing” of gene 
function. 
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2.9.2 Short hairpin RNA 
RNA polymerase III can be used to drive individual transcripts to adopt stem-loop 
structures, known as short hairpin RNA (ShRNA) sequences. ShRNA can be 
transfected into a cell by means of a vector and are then processed into siRNAs by 
the RNAi machinery. Two short hairpin RNA (ShRNA) sequences against human 
HIF-1α and a scrambled control oligonucleotide (TIB MOLBIOL) were kindly 
donated by Professor T Cramer (Charité-Universitätsmedizin Berlin, Germany). Two 
different 19-nucleotide (nt) sequences derived from human HIF-1α mRNA (U22431; 
bp 1470-1489 and bp 2192-2211) were used and have been described previously 
(Mizukami et al., 2004, Sowter et al., 2003). These constructs are termed HIF-
1α/shRNA1470 and HIF-1α/shRNA2192. Approximately 6 x 104 Ishikawa 
endometrial epithelial cells (EP2S and FPS) were seeded per well in a 12 well plate. 
The next day cells were transiently transfected with lentivirus at a multiplicity of 
infection (MOI) of 10 for 24h. Cells were incubated in serum free media overnight 
before treatment with 100nM PGE2 , 100nM PGF2α or placement in the hypoxic 
chamber for 8h. Cells were washed with PBS and harvested, and RNA or protein 
extracted for PCR or Western blot analysis. 
2.10   Statistical analysis 
All statistical analysis was carried out using GraphPad Prism Software (GraphPad 
Prism Software, Inc., San Diego, CA). Details of specific statistical tests used for 
each data set are included in the relevant chapter (Chapter 3.2.6, 4.2.7, 5.2.10 and 
6.2.12). In brief, comparison of two data sets was performed using a student’s t-test 
(if normally distributed) or Mann Whitney test (if not normally distributed). 
Comparison of multiple groups with one grouping variable were compared with one 
way ANOVA or Kruskal Wallis tests, with application of appropriate post-test 
multiple comparison analyses. Comparison of multiple data sets with two grouping 
variables was carried out using a two way ANOVA. All graphs display mean ± 















3. Endometrial Repair Factors across the Menstrual 
Cycle 
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3.1 Introduction  
Throughout the reproductive years of a woman’s life the endometrium is cyclically 
subjected to inflammation and tissue breakdown during menstruation. It has a 
remarkable capacity for repeated, scar-free repair without loss of function. The 
factors involved in this efficient endometrial repair remain undefined. The processes 
involved are likely to include inflammation and its timely resolution, tissue 
formation, tissue remodelling and angiogenesis (detailed in Chapter 1). Hence, 
factors known to be involved in these processes elsewhere in the body have a 
putative role in endometrial repair.  
 
IL-8 is a cytokine present in the epithelial and perivascular cells of the human 
endometrium (Arici et al., 1998, Jones et al., 2004, Critchley et al., 1994). It is best 
known for its potent chemotaxis of neutrophils, T-cells and basophils (Larsen et al., 
1989, Mukaida et al., 1989) and mediates its actions via CXCL1/2 receptors. 
Neutrophil depletion in the mouse model of simulated menstruation resulted in a 
marked delay in endometrial repair, signifying the importance of an inflammatory 
response for efficient repair (Kaitu'u-Lino et al., 2007b). In addition, IL-8 secreted by 
human synovial tissue has been shown to have angiogenic properties (Koch et al., 
1992) and in vitro IL-8 stimulated proliferation of aortic vascular smooth muscle 
cells (Yue et al., 1994). The inflammatory, angiogenic and mitogenic effects of IL-8 
make it an attractive candidate for mediating endometrial repair.  
 
The angiogenic properties of vascular endothelial growth factor (VEGF) and 
adrenomedullin (AM) are well established (Carmeliet, 2005, Ferrara, 2004, Nayak 
and Brenner, 2002, Shindo et al., 2001, Nikitenko et al., 2000) and have been 
discussed previously (Chapter 1.3.5.3). Both have been identified in human 
endometrial epithelial, endothelial and stromal cells (Charnock-Jones et al., 1993, 
Zhao et al., 1998) and are therefore putative endometrial repair factors. VEGF acts 
through two transmembrane tyrosine kinase receptors, VEGF receptor 1 
(VEGFR1/Flt1) and VEGF receptor 2 (VEGFR2/Flk1/KDR), both of which are 
expressed in the human endometrium (Nayak et al., 2000, Punyadeera et al., 2006). 
Although VEGF binds with high affinity to both receptors, most of its biological 
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effects appear to be mediated by VEGF receptor 2 (Li et al., 2002). The complexities 
of AM signalling have also been delineated. AM acts through a G protein coupled 
receptor known as the calcitonin receptor like receptor (CLR). CLR can act as either 
a calcitonin gene-related peptide receptor or an AM receptor. Receptor activity 
modifying proteins (RAMPs) associate with CLR to determine its ligand binding 
specificity (Sexton et al., 2001). RAMP2 and RAMP3 association promotes binding 
of AM to CLR, while RAMP1 and CLR association promotes binding of the 
calcitonin gene-related peptide (McLatchie et al., 1998). 
 
CTGF is a member of a new family of structurally related proteins that have 
angiogenic, wound healing and diverse cellular functions (Brigstock, 2002). The 
angiogenic properties of CTGF have been demonstrated in vitro and in vivo (Shimo 
et al., 1999). In addition, increased levels of CTGF have been observed in areas of 
tissue injury (Igarashi et al., 1993, Schwab et al., 2001), leading to speculations that 
CTGF is involved in tissue repair. Therefore, CTGF has a potential role in initial 
endometrial repair and subsequent tissue remodelling.  
 
ET-1 is a pleiotropic molecule, best known for its actions as a potent vasoconstrictor 
(Masaki, 2004). It acts through two heptahelical G protein-coupled receptors ETA and 
ETB (Sakamoto et al., 1991, Hosoda et al., 1991). Both ETA and ETB mRNA has 
been identified in the human endometrium (O'Reilly et al., 1992). ET-1 has also been 
shown to act as a mitogenic and pro-angiogenic factor in cancer cells (Grant et al., 
2003). In addition, it may have the ability to modulate inflammatory responses. ET-1 
increased IL-6 production by rat stromal cells (Agui et al., 1994) and increased 
neutrophil adhesion to bovine endothelial cells in vitro (Lopez Farre et al., 1993). 
Hence ET-1 may not only contribute to vascular vasoconstriction at the time of 
menstruation, but may also contribute to endometrial repair.  
  
Electron microscopic and hysteroscopic analysis of the endometrial cavity has 
revealed that endometrial repair takes place during the menstrual phase of the cycle 
(Ludwig and Spornitz, 1991, Garry et al., 2009). Therefore, it was hypothesised that 
factors involved in endometrial repair would be increased during menstruation. This 
chapter details endometrial IL-8, VEGF, AM, CTGF and ET-1 and their receptors in 
biopsies from across the menstrual cycle.  
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3.2 Methods 
3.2.1 Human endometrial tissue collection 
Endometrial tissue samples (n=41) were collected as described in section 2.1. 
Samples were categorised into menstrual, proliferative, early secretory, mid secretory 
and late secretory phase based on the woman’s reported LMP, histological dating 
(Noyes et al., 1950) and serum oestradiol and progesterone levels taken at the time of 
biopsy. Endometrial samples assessed in this chapter are detailed in Table 5. 
 
 
Table 5. Endometrial biopsies used for the studies presented in Chapter 3. 
*progesterone values significantly less than those from the early- and mid-secretory 
phase (p<0.001, one way ANOVA with Tukey’s multiple comparison post-test). 
 
 




















































3.2.2 RNA extraction and Q-RT-PCR 
RNA was extracted from all the endometrial samples and cDNA prepared and Q-RT-
PCR performed as detailed in chapter 2.4. The expression of mRNA was measured 
for IL-8, CXCL2, VEGF, KDR, AM, CLR, RAMPs 1-3, CTGF, ET-1, and ETB 
(Table 3, Chapter 2). A sample of liver cDNA was also prepared and included on 
each Taqman plate as a positive control. Housekeeping gene 18S showed no 
significant difference in tissue from across the menstrual cycle. 
3.2.3 Immunohistochemistry 
IL-8, VEGF, AM and CTGF proteins were localised in endometrial sections from 
across the menstrual cycle using the immunohistochemical protocols described in 
chapter 2.6. As AM, IL-8 and CTGF protein displayed marked changes across the 
menstrual cycle, the localisation and intensity of staining for these proteins was 
scored in the semi-quantitative manner detailed previously (Chapter 2.6.8).  
3.2.4 In vitro tissue culture 
If sufficient tissue was available, a portion of the endometrial biopsy from women at 
each stage of the menstrual cycle was collected in PBS (n=20), as described in 
Chapter 2.1. Tissue was weighed and incubated on raised platforms in 1ml serum 
free RPMI 1640 medium with  penicillin (50 μg/ml, Sigma), streptomycin (50μg/ml, 
Sigma) and gentamycin (5μg/ml, Sigma) for 24h. The culture supernatant was 
collected and stored at -20°C before analysis by IL-8 ELISA (Chapter 2.7.1). Results 
were normalised to tissue weight. 
3.2.5 Capillary tube formation assay 
The angiogenic potential of human endometrial tissue and recombinant IL-8 was 
assessed using the capillary tube formation assay described in Chapter 2.8. HUVECs 
were treated with recombinant human IL-8 (R&D Systems, Oxford, UK) at a 
concentration of 0.5ng or 20ng in 250μl RPMI media. Alternatively, HUVECs were 
treated with the supernatants from weighed endometrial explants from the mid-
secretory and menstrual phase cultured in RPMI for 24h. Each dose of IL-8 and each 
culture supernatant were assessed in triplicate in three separate experiments. 
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3.2.6 Statistical analysis 
For mRNA and protein in endometrial biopsies from across the menstrual cycle, 
results were expressed as a quantity relative to a comparator, a sample of RNA from 
the liver. Significant differences in mRNA expression, protein levels and semi-
quantitative immunohistochemical scoring were determined using Kruskal-Wallis 
non-parametric tests with Dunn’s multiple comparison post-tests (GraphPad Prism 
Software, Inc., San Diego, CA). Samples that had a value more than two standard 
deviations greater or less than the mean for the group were considered outliers and 
removed from statistical analysis.  
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3.3 Results 
3.3.1 Expression of IL-8 mRNA across the menstrual cycle  
IL-8 mRNA was present at low levels in endometrium from the proliferative, early-
and mid-secretory stages of the menstrual cycle (Figure 13). A non-significant 
increase in IL-8 mRNA was seen in the late secretory phase. By the menstrual stage, 
levels of IL-8 had risen significantly when compared to endometrium from the 
proliferative (p<0.01), early secretory (p<0.001) and mid secretory stage (p<0.05).  
3.3.2 Immunolocalisation of IL-8 in the human endometrium 
Immunolocalisation of IL-8 demonstrated positive cytoplasmic staining in glandular 
epithelial (GE), surface epithelial (SE), stromal cells (St), and perivascular cells in 
endometrium from the menstrual phase of the cycle (Figure 14 C, D). In contrast, 
proliferative phase endometrium displayed negligible staining for IL-8, even in 
perivascular cells (Figure 14 E, F). During the secretory phase GE cells were 
occasionally weakly stained for IL-8 (Figure 14 G, I, K). However, perivascular 
staining was maintained in the secretory phase (Figure 14 H, J, L).  
Semi-quantitative scoring of IL-8 staining intensity revealed that the strongest 
staining was in the GE and perivascular cells (Figure 15 A, D). IL-8 perivascular 
staining was significantly increased during the menstrual phase of the cycle, when 
compared with the proliferative (p<0.05), early secretory (p<0.01) and mid secretory 
(p<0.05) stages (Figure 15 D). There was a non-significant increase in IL-8 staining 
in GE and stromal cells during the menstrual phase (Figure 15 B, C). 
3.3.3 Secretion of IL-8 protein from human endometrial biopsies 
The amount of IL-8 protein secreted from endometrial biopsies cultured in vitro for 
24h followed a similar pattern to IL-8 mRNA expression (Figure 16). Endometrium 
from the menstrual stage secreted significantly higher levels of IL-8 protein than 
tissue from the early and mid secretory phases (p<0.05). There was no significant 











Figure 13. IL-8 mRNA in endometrium from across the menstrual cycle. IL-
8 mRNA was quantified by Q-RT-PCR in endometrium from the menstrual (M), 
proliferative (P), early-secretory (ES), mid-secretory (MS) and late-secretory (LS) 
stages of the cycle. Note logarithmic scale on y-axis. (*p<0.05, **p<0.01, 
***p<0.001, KW: Kruskal Wallis statistical test). 

































         
 
 
              
Figure 14. Immunohistochemical staining for IL-8 in endometrium from 
across the menstrual cycle. (A, B) menstrual endometrium stained with 
concentration matched IgG as negative controls (C, D) IL-8 stained menstrual 
endometrium, (E, F) proliferative phase endometrium, (G, H) early secretory 
endometrium, (I, J) mid-secretory endometrium, (K, L) late-secretory endometrium.  
Scale bar = 50µm. Arrows = perivascular cells. GE: glandular epithelial cells, St: 

































         
 
  
       
 
 
Figure 15. Semi-quantitative scoring of IL-8 immunohistochemical staining 
in endometrium from across the menstrual cycle. (A) endometrial surface 
epithelial cells, (B) glandular epithelial cells, (C) the stromal compartment, (D) 
perivascular cells. M: Menstrual, P: proliferative, ES: early secretory, MS: mid 







      
 
 




Figure 16. Secreted IL-8 protein levels by endometrial explants from 
different stages of the menstrual cycle cultured in vitro for 24h.  M: menstrual, P: 
proliferative, ES: early secretory, MS: mid secretory, LS: late secretory. (*p<0.05). 





























n=    4              6               3              4              5  
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3.3.4 Angiogenic potential of endometrial tissue and IL-8 
To assess the angiogenic potential of endometrial IL-8 in vitro, human umbilical 
vascular endothelial cell (HUVEC) branching was quantified after various 
treatments. When treated with culture supernatants from menstrual tissue incubated 
for 24h in vitro, a significant increase in HUVEC capillary tube formation was 
observed when compared to cells treated with control (unconditioned) media (Figure 
17A). No significant increase in tube formation was seen with supernatants from 
mid-secretory phase explants. These endometrial explants are likely to produce 
several angiogenic factors. To assess the contribution of IL-8 alone, HUVECs were 
also treated with recombinant human IL-8. The amount of IL-8 secreted by menstrual 
endometrial explants was 18.94 ± 7.57ng (mean ± SEM, median 19.4ng). Mid-
secretory endometrium secreted the lowest levels of IL-8, 0.53 ± 0.13ng (mean ± 
SEM, median 0.44ng). Therefore, HUVECs were treated with control media, 20ng or 
0.5ng of human recombinant IL-8. Treatment with 20ng IL-8 resulted in a 
significantly higher number of capillary tube branch points when compared with 
cells treated with 0.5ng IL-8 or control media (Figure 17B). Mid-secretory levels of 
IL-8 had no significant impact on branch points when compared to control media. 
3.3.5 Expression of CXCL2 mRNA across the menstrual cycle 
IL-8 receptor (CXCL2) mRNA was detected by Q-RT-PCR in human endometrial 
samples (Figure 18). There was significant variation in expression levels of CXCL2 
across the menstrual cycle (p<0.001). Levels were maximal in menstrual 
endometrium, with significantly greater expression of CXCL2 mRNA than levels 




Figure 17. Menstrual levels of IL-8 can up-regulate network formation in 
human umbilical vascular endothelial cells (HUVECs). (A) The number of 
capillary tube branch points formed by HUVECs significantly increased when 
treated for 8h with conditioned media (CM) from menstrual endometrial biopsies 
cultured for 24h in vitro versus control media. No such increase was seen with CM 
from mid-secretory explants (n=4-5). (B) The number of capillary tube branch points 
formed by HUVECs treated with 20ng human recombinant IL-8 (M: menstrual 
levels) was significantly greater that those formed when treated with control media 












Figure 18. CXCR2 mRNA measured by Q-RT-PCR in endometrium from 
across the menstrual cycle. M: menstrual, P: proliferative, ES: early secretory, MS: 
mid secretory, LS: late secretory. Note logarithmic scale on y-axis. (**p<0.01, 
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3.3.6 VEGF mRNA across the menstrual cycle 
VEGF mRNA was present at low levels in proliferative, early secretory and mid-
secretory phase endometrial biopsies (Figure 19). There was a non-significant 
increase in VEGF mRNA expression during the late secretory phase. VEGF 
expression was maximal in menstrual phase endometrium, at levels significantly 
greater than those seen in proliferative and early secretory biopsies (p<0.05 and 
p<0.001 respectively). 
3.3.7 VEGF secreted protein levels across the cycle 
VEGF protein secreted by endometrial explants from across the menstrual cycle was 
measured by ELISA. VEGF protein secretion was significantly greater from 
proliferative endometrial explants compared with late secretory explants (Figure 
20A). Immunolocalisation of VEGF protein in menstrual endometrium (Figure 20B) 
showed positive cytoplasmic staining in the surface epithelial cells (SE), glandular 
epithelial cells (GE), stromal compartment (St), perivascular cells and endothelial 
cells (arrows).  
3.3.8 Expression of KDR mRNA across the menstrual cycle 
VEGF receptor 2 (KDR) mRNA levels varied significantly across the menstrual 
cycle (p<0.0001) (Figure 21). KDR mRNA was greatest in late secretory and 
menstrual endometrial samples. Expression at these stages of the cycle was 
significantly greater that KDR mRNA levels found in proliferative and early 











Figure 19. Vascular endothelial growth factor (VEGF) mRNA in 
endometrium from across the menstrual cycle. M: menstrual, P: proliferative, ES: 
early secretory, MS: mid secretory, LS: late secretory. (*p<0.05, ***p<0.001, KW: 


































       
       




































Figure 20. Endometrial vascular endometrial growth factor (VEGF) protein 
levels across the menstrual cycle. (A) Secreted VEGF protein levels from 
endometrial tissue explants at different stages of the menstrual cycle cultured in vitro 
for 24h. M: menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: 
late secretory. (*p<0.05). (B) Immunolocalisation of VEGF protein in menstrual 
endometrium. Scale bar = 50µm. Arrows = endothelial cells. SE: surface epithelial 
cells, GE: glandular epithelial cells, St: stromal compartment.  
 
(A) VEGF secreted protein 
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Figure 21. Kinase insert domain receptor (KDR/VEGFR2) mRNA 
expression measured by Q-RT-PCR in endometrium from across the menstrual 
cycle. M: menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
secretory. (**p<0.01, ***p<0.001, KW: Kruskal Wallis statistical test). 
 
KW p<0.0001 
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3.3.9 AM mRNA across the menstrual cycle 
AM mRNA expression was low during the proliferative and secretory phases of the 
menstrual cycle (Figure 22). Expression peaked at menstruation, when AM mRNA 
levels were significantly higher than during the proliferative phase (p<0.001).  
3.3.10 Immunolocalisation of AM in the human endometrium 
Immunostaining for AM was detected in a cytoplasmic location in the SE, GE, 
stromal compartment and endothelial cells of endometrium from the menstrual and 
proliferative phase (Figure 23A-D). Staining was less marked during the secretory 
phase (Figure 23E, F). Semi-quantitative assessment of staining revealed strongest 
staining in the SE cells, which did not vary significantly throughout the menstrual 
cycle (Figure 24E). In contrast, staining of the GE was maximal in the menstrual 
phase, being significantly increased compared to mid-secretory endometrium in both 
the functional and basal layers (p<0.05). There was also increased staining of 
proliferative phase GE cells but this did not reach statistical significance (Figure 
24A,B). There was no significant difference in staining score of the stromal cell 
compartment across the cycle. However, highest levels of stromal cell staining were 
observed in menstrual and proliferative endometrial samples (Figure 24C,D). 








               
 
Figure 22. Adrenomedullin (AM) mRNA measured by Q-RT-PCR in 
endometrium from across the menstrual cycle. M: menstrual, P: proliferative, ES: 
early secretory, MS: mid secretory, LS: late secretory. (***p<0.001, KW: Kruskal 


































Figure 23. Adrenomedullin immunohistochemical staining in endometrium 
from across the menstrual cycle. ) AM protein was present in the surface 
epithelium (SE), glandular epithelial cells (GE), the stromal compartment (St) and 
endothelial cells (arrows) during the menstrual (A, B) and proliferative (C, D) phase. 
Staining was markedly decreased during the secretory phase (E, F). Insert = negative 





Figure 24. Semi-quantitative scoring of adrenomedullin 
immunohistochemical staining. (A) glandular epithelial cells of the functional (F) 
layer (B) glandular epithelial cells in the basal (B) layer (C) the stromal compartment 
of the functional endometrial layer (D) the stromal compartment in the basal layer 
(E) surface epithelial cells and (F) endothelial cells in both endometrial layers. M: 
menstrual, P: proliferative, ES: early-secretory, MS: mid-secretory, LS: late-
secretory. KW: Kruskal Wallis statistical analysis. (*p<0.05).  
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3.3.11 CLR and RAMPs mRNA across the cycle 
CLR mRNA was present throughout the menstrual cycle. Highest levels were 
observed in the mid-secretory phase, when CLR expression was significantly higher 
than in the proliferative (p<0.01) and late-secretory stage (p<0.05) (Figure 25A). The 
accessory protein RAMP1, which forms a heterodimer with CLR to preferentially 
bind calcitonin gene-related peptide, does not vary significantly across the menstrual 
cycle (Figure 25B). In contrast RAMP2, which binds to CLR to form the receptor for 
AM, is expressed in the human endometrium in a pattern similar to that of CLR 
(Figure 25C). RAMP2 mRNA expression was significantly higher in the early 
secretory phase than levels found in proliferative (p<0.01) or late secretory 
endometrium (p<0.001). Interestingly RAMP3, which also promotes preferential 
binding of CLR to AM, has the opposite expression pattern in the endometrium 
(Figure 25D). The highest levels of expression were seen during the menstrual and 
late secretory phases. Expression of RAMP3 in proliferative and early secretory 
endometrium was significantly decreased (p<0.05 and p<0.001 respectively) when 
compared to levels during the menstrual and late secretory phase. 
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Figure 25. Calcitonin receptor like receptor (CLR) and receptor activity 
modifying protein (RAMP) mRNA in human endometrium from across the 
menstrual cycle. (A) CLR mRNA expression was highest in the mid-secretory phase 
(B) RAMP1 expression does not change significantly across the cycle (C) RAMP2 
expression peaked during the early secretory phase (D) RAMP3 mRNA expression 
was greatest in late secretory and menstrual phase endometrium. M: menstrual, P: 
proliferative, ES: early-secretory, MS: mid-secretory, LS: late secretory. (ns: no 




3.3.12 CTGF mRNA across the menstrual cycle 
CTGF mRNA was present in the endometrium and varied significantly across the 
cycle (p<0.01) (Figure 26). Low levels of CTGF mRNA were present in proliferative 
and secretory endometrium. Menstrual phase biopsies displayed significantly 
increased CTGF mRNA expression compared to early- (p<0.01), mid- (p<0.05) and 
late- (p<0.05) secretory endometrium. 
3.3.13 Immunolocalisation of CTGF in endometrial biopsies 
CTGF was immunolocalised to the cytoplasm of SE, GE, stromal and vascular 
endothelial cells at all stages of the menstrual cycle (Figure 27). There was an 
obvious reduction in staining intensity during the secretory phase (Figure 27E, F). 
Intense staining of occasional cells in the stromal compartment of proliferative 
endometrium was observed (Figure 27H). These cells were usually found in close 
proximity to the endometrial vasculature. Semi-quantitative scoring of 
immunohistochemical staining revealed significantly greater staining of the GE, SE 
and stromal cells in proliferative phase endometrium when compared to mid-






       
 
    
 
 
Figure 26. Connective tissue growth factor (CTGF) mRNA in human 
endometrium from across the menstrual cycle. M: menstrual, P: proliferative, ES: 
early-secretory, MS: mid-secretory, LS: late secretory. (*p<0.05, **p<0.01, KW: 


















































Figure 27. Connective tissue growth factor immunohistochemical staining in 
endometrium from across the menstrual cycle. (A, B) menstrual phase 
endometrium, (C, D) proliferative phase endometrium, (E, F) mid-secretory phase 
endometrium, (G) negative control menstrual endometrium incubated with the 
primary antibody pre-absorbed with blocking peptide, (H) intense staining of 
occasional cells in the stromal cell compartment of proliferative endometrium. Scale 
bar = 50µm. Arrows = endothelial cells. SE: surface epithelial cells, GE: glandular 











Figure 28. Semi-quantitative scoring of endometrial connective tissue growth 
factor immunohistochemical staining across the menstrual cycle. (A) Glandular 
epithelial cells, (B) surface epithelial cells, (C) the stromal cell compartment. M: 
menstrual, P: proliferative, ES: early-secretory, MS: mid-secretory, LS: late 
secretory. (*p<0.05, **p<0.01, ***p<0.001). 
Glandular Epithelial Cells



































































3.3.14   ET-1 mRNA across the menstrual cycle 
ET-1 mRNA levels are significantly increased in menstrual endometrium relative to 
proliferative (p<0.001) and early-secretory (p<0.001) samples. In addition, there is a 
non-significant increase in ET-1 mRNA expression in mid- and late-secretory 
endometrial samples (Figure 29).  
3.3.15 Expression of ETB mRNA across the cycle 
ETB mRNA levels changed significantly when quantified in endometrial samples 
from across the menstrual cycle (p<0.001) (Figure 30). Maximal expression was 
observed in menstrual and late-secretory endometrial samples. Low levels of ETB 
expression were observed in proliferative and early secretory endometrium, with 
increasing levels present in the mid-secretory phase. Menstrual and late secretory 
ETB mRNA levels were significantly greater than those present in proliferative and 







      
Figure 29. Endothelin-1 (ET-1) mRNA in human endometrium from across 
the menstrual cycle. M: menstrual, P: proliferative, ES: early-secretory, MS: mid-
secretory, LS: late secretory. (***p<0.001, KW: Kruskal Wallis statistical test). 
KW p<0.0001 






































Figure 30. Endothelin receptor B (ETB) mRNA in human endometrium from 
across the menstrual cycle. M: menstrual, P: proliferative, ES: early-secretory, MS: 
mid-secretory, LS: late secretory. (*p<0.05, **p<0.01, ***p<0.001, KW: Kruskal 
Wallis statistical test). 

































The results presented in this chapter describe the significant up-regulation of putative 
endometrial repair factors during the menstrual phase of the cycle. IL-8, VEGF, AM, 
CTGF and ET-1 mRNAs are all maximal during menstruation. In addition, protein 
levels of these factors are highest during the menstrual and/or proliferative phase. 
Furthermore, endometrial mRNA was detected for the receptors CXCL2, KDR, CLR 
and RAMPs 1-3, and ETB. Endometrial repair has been shown to commence on day 
two of the cycle (Ludwig and Spornitz, 1991). Hence, these findings of maximal 
repair factor expression during menstruation are consistent with a role in endometrial 
repair. Detection of endometrial expression of their receptors lends further support to 
an active role in the repair process. 
 
The data presented in this chapter were generated from examination of endometrial 
biopsies collected with an endometrial sampler (Pipelle ®). The majority of 
endometrium collected with this method is from the functional layer. As this layer is 
sloughed off during menses, it was traditionally believed that endometrial repair was 
governed by factors present in the basal layer. However, a recent study of menstrual 
endometrium revealed an increase in genes associated with extracellular matrix 
biosynthesis in stromal cells from the functional layer when compared to those from 
the basal layer (Gaide Chevronnay et al., 2009). Over expression of these genes, 
which included IL-8 (>4 fold increase), suggests that fragments of the functional 
layer of endometrium make an active contribution to the endometrial repair process.  
In addition, endometrial tissue used in this study was collected from women with a 
subjective complaint of HMB. Previous studies have shown that 64% of women with 
subjective heavy loss actually had an objective measurement of <80ml (normal 
menstrual loss) (Wyatt et al., 2001). Collection of tissue from women without this 
subjective complaint is difficult as they rarely attend gynaecological services. 
However, reproduction of these findings in women with objectively measured NMB 
would further support the role of these factors in endometrial repair. 
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3.4.1 Interleukin-8  
The significant elevation of IL-8 during menstruation described herein is in 
agreement with the findings of Jones et al.,  who reported negligible levels of IL-8 
mRNA at all stages of the cycle with the exception of a dramatic up-regulation at 
menstruation (Jones et al., 2004). This study extends these findings by also 
demonstrating significant elevations in menstrual IL-8 protein. Other studies have 
found an increase in endometrial IL-8 mRNA and protein during the late secretory 
phase of the menstrual cycle (Arici et al., 1998, Milne et al., 1999). Importantly, 
these studies did not examine tissue from the menstrual phase; therefore any increase 
in IL-8 during this stage was undetected. Consistent with findings detailed herein, 
endometrial IL-8 has been previously localised to the perivascular cells by in situ 
hybridisation (Milne et al., 1999). The exact nature of the cellular component in the 
perivascular region is still to be determined. Perivascular IL-8 production may be 
from macrophages, vascular smooth muscle cells, fibroblasts or myofibroblasts. 
Negative staining in endothelial cells means they are less likely to play a major role 
in perivascular IL-8 production. Further studies are required to determine which cell 
types are involved. The bioavailability of IL-8 in the endometrium appears to be 
regulated by aminopeptidase N (Seli et al., 2001). This IL-8 inactivating enzyme is 
produced by endometrial stromal cells, is lowest during the early proliferative phase 
and appears to be increased by oestrogen. This pattern and regulation ensures active 
IL-8 is present in the perimenstrual endometrium.  
 
IL-8 exerts its effects by binding to chemokine receptors CXCR1 and CXCR2. 
Described herein is the presence of endometrial CXCL2 mRNA expression, with 
significant up-regulation in menstrual phase biopsies. CXCR1 and CXCR2 have 
previously been immunolocalised in the human endometrium and were present in 
epithelial and stromal cells (Mulayim et al., 2003). When intensity of staining was 
examined by these authors, CXCR1 staining was found to be significantly higher in 
the mid-secretory versus the proliferative phase in both stromal and epithelial cells. 
No variation in CXCR2 staining was detected across the cycle. Mulayim et al. did 
not examine menstrual phase endometrial samples. Menstrual samples may have 
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significantly elevated CXCR2 protein levels, reflecting the raised mRNA expression 
observed herein. 
3.4.2 Vascular endothelial growth factor 
This chapter also details a significant increase in VEGF mRNA in late-secretory and 
menstrual phase biopsies. Intense immunostaining of VEGF was observed in 
menstrual and proliferative phase endometrium, particularly in GE and endothelial 
cells. This discrepancy in maximal mRNA and protein levels, with an increase in 
protein subsequent to mRNA, may be indicitative of a delay between increased 
transcription/mRNA stabilisation and protein translation. Maximal levels in the 
perimenstrual phase is consistent with findings in the rhesus macaque endometrium, 
where heightened expression of VEGF was present in the newly formed surface 
epithelium and stroma during post-menstrual repair (Nayak and Brenner, 2002). In 
addition, a limited number of human endometrial immunohistochemical and in situ 
hybridisation studies have also shown increased VEGF expression in the menstrual 
phase in the glandular epithelial cells (Zhang et al., 1998, Charnock-Jones et al., 
1993). Lack of menstrual tissue availability has resulted in many studies not 
examining VEGF at this stage of the cycle (Gargett et al., 1999, Li et al., 1994). 
Delineation of endometrial VEGF during menstruation is essential to determine its 
contribution to early endometrial repair. VEGF is a potent angiogenic factor that 
stimulates endothelial cell proliferation and migration, increases vascular 
permeability and stimulates the expression of tissue factor, an initiator of 
coagulation, (Ferrara, 2004, Blum et al., 2001, Fan et al., 2008). Therefore, it has an 
attractive role in the repair of damaged blood vessels at menstruation. A recent study 
of the decidualised mouse uterus and rhesus macaque endometrium, found that 
VEGF blockade with VEGF Trap completely inhibited neovascularisation and 
reepithelialisation during endometrial repair (Fan et al., 2008).  
 
VEGF acts through two transmembrane tyrosine kinase receptors, VEGF receptor 1 
(VEGFR1/Flt1) and VEGF receptor 2 (VEGFR2/Flk1/KDR), and both have been 
identified in the human endometrium (Nayak et al., 2000, Punyadeera et al., 2006). 
As most of the biological effects of VEGF appear to be mediated through KDR (Li et 
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al., 2002), the presence of this receptor was examined in endometrial samples from 
across the menstrual cycle. KDR mRNA correlated with VEGF expression in the 
endometrium, with highest levels expressed during the late-secretory and menstrual 
phase. This correlation of VEGF ligand and receptor has been described previously 
by immunohistochemistry in the rhesus macaque and human endometrium (Wei et 
al., 2004, Moller et al., 2001). A perimenstrual increase in KDR has also been 
previously demonstrated in the ovariectomised macaque model and in the human 
endometrium (Nayak et al., 2000). This increase in KDR was shown to be limited to 
the functional endometrial layer and was not observed for VEGF receptor type 1. Co-
ordinated expression of pro-angiogenic VEGF and its receptor in the human 
endometrium during the perimenstrual phase is consistent with a major contribution 
to the repair process. 
3.4.3 Adrenomedullin 
The data in this chapter also reveal a significant increase in AM mRNA during 
menstruation. In addition, protein levels were highest during the menstrual and 
proliferative stages; a temporal pattern consistent with a role in repair. AM has been 
detected previously in the human endometrium (Nikitenko et al., 2001, Laoag-
Fernandez et al., 2000, Michishita et al., 1999). However, its expression at well 
defined stages of the menstrual cycle has not been characterised. These results 
demonstrate that AM mRNA and protein are maximal during the menstrual phase of 
the cycle. Immunolocalisation revealed AM in the SE, GE, stromal compartment and 
endothelial cells, in agreement with previous in-situ hybridization studies (Nikitenko 
et al., 2001).  
 
Nikitenko et al. showed by RT-PCR that AM mRNA expression was present in the 
endometrium at lower levels than in the placenta (Nikitenko et al., 2000). However, 
the variation in AM mRNA levels at different stages of the cycle was not examined. 
At the protein level, Laoag-Fernandez et al. used immunohistochemistry to detect 
AM in endometrium from across the menstrual cycle (Laoag-Fernandez et al., 2000). 
They did not include menstrual endometrium in their study, presumably due to 
difficulties obtaining this tissue. In contrast to our findings, their study revealed little 
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positive staining for AM in early-mid proliferative endometrium, with more 
abundant staining in the secretory phase. These conflicting findings may be 
explained by a number of factors, including classification of tissue and antibody 
specificity. Most importantly, the endometrial samples used by Laoag-Fernandez et 
al. were from women undergoing hysterectomy for conditions such as leiomyomata, 
ovarian cancer, adenomyosis and cervical intraepithelial neoplasia. Neoplasia and 
fibroid changes have previously been shown to affect endometrial AM (Nunobiki et 
al., 2009, Hague et al., 2000). Therefore, results from this study may not be 
applicable to the normal endometrium.  
 
The findings detailed herein, of positive AM staining in endometrium from the 
proliferative phase, are consistent with findings from a DNA microarray study of the 
mouse uterus (Watanabe et al., 2006). A dose-dependent increase in AM was 
observed with oestrogen treatment (correlation coefficient >0.95). In addition, this 
study identified that the oestrogen receptor (ER) binds to the promoter region of the 
AM gene, activating its transcription. These findings suggest that AM in the 
proliferative endometrium would be expected, as oestrogen is the dominant hormone 
in this phase. However, our study also revealed high levels of AM protein during the 
menstrual phase, when E2 levels are low. This suggests an additional, E2 
independent, mechanism of AM up-regulation (see Chapter 4.3.2).  
 
The data in this chapter also demonstrate differential expression of CLR and RAMPs 
in the human endometrium at different stages of the menstrual cycle. Nikitenko et al. 
previously identified the endometrial expression of CLR, RAMP1, RAMP2 and 
RAMP3 by RT-PCR but did not assess their levels across the cycle (Nikitenko et al., 
2001). The observation of high CLR mRNA during the early-secretory phase, with 
low levels seen during the menstrual and proliferative phases, is inversely correlated 
to the pattern of endometrial AM expression. Internalisation and desensitisation of 
the endogenous CLR was observed in endothelial cells on exposure to AM 
(Nikitenko et al., 2006a), suggesting the function of CLR is tightly regulated by its 
ligand. A similar pattern of reduced CLR expression was seen in the mouse model of 
sepsis, where AM expression is markedly up-regulated (Ono et al., 2000). 
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Interestingly, the accessory protein that allows preferential binding of CGRP 
(RAMP1) does not change significantly across the cycle. However, RAMP2 and 
RAMP3, which allow AM binding when heterodimerised with CLR, show marked 
changes. RAMP2 has low expression during the menstrual and proliferative phases, 
when AM levels are high. In contrast, RAMP3 mRNA shows a similar pattern to 
AM. This switch from RAMP2 to RAMP3 expression as AM mRNA increases has 
been previously shown in human coronary artery smooth muscle cells and in the 
mouse lung (Ono et al., 2000, Nagoshi et al., 2004) but it is believed that this is the 
first report of this pattern in human endometrial tissue. Further study of this receptor 
and its binding proteins is required to confirm their functional role within the 
endometrium. These accessory proteins may affect AM responsiveness, with 
RAMP2 and RAMP3 having differential effects. The finding that their mRNA 
expression varies significantly across the menstrual cycle suggests hormonal 
responsiveness and an active role in endometrial physiology. 
3.4.4 Connective Tissue Growth Factor 
CTGF is a member of the CCN family of growth regulators and has a putative role in 
endometrial repair. Data in this chapter demonstrate maximal CTGF mRNA in 
menstrual phase endometrium. CTGF protein showed intensely positive 
immunohistochemical staining during the proliferative phase, subsequent to maximal 
mRNA expression. CTGF protein was significantly elevated in GE, SE and stromal 
cells when compared to the mid-secretory phase. This is the first description of 
CTGF mRNA and protein staining intensity in human endometrium from all stages 
of the menstrual cycle. Previous studies have immunolocalised CTGF in the human 
endometrium and found similar staining of GE, SE, stromal and endothelial cells but 
did not examine endometrium from the menstrual phase (Uzumcu et al., 2000). 
Porcine CTGF also demonstrates clear endometrial changes during oestrous. CTGF 
was detected by Northern blot in pig uterine luminal flushings on days 10 to 16 and 
during early pregnancy (Ball et al., 1998). Interestingly, intense staining of 
occasional stromal compartment cells occurred during the proliferative phase. These 
may be immune cells. Co-localisation of CTGF and inflammatory cell markers by 
immunohistochemistry may further delineate the nature of these cells and the role of 
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CTGF in the proliferative endometrium. Other members of the CCN family also 
show significant variation in human endometrial expression across the cycle. The 
pro-angiogenic factor cysteine rich protein 61 (CYR61) was found to be significantly 
elevated during menses (Gashaw et al., 2008) and authors proposed it contributes to 
repair, growth and maturation of the endometrial vasculature after menstruation.  
 
The mechanism by which CTGF exerts its effects remains undefined at a molecular 
level; therefore examination of receptors for this factor was not possible. CYR61 has 
been shown to bind to integrin ανβ3 or integrin αΠbβ3 to mediate cell adhesion and 
migration (Kireeva et al., 1998, Jedsadayanmata et al., 1999) and CTGF may elicit 
its biological effects in a similar manner. Alternatively, it has been proposed that the 
CCN family may not signal exclusively via cell surface receptors but rather are a 
component of the ECM and bridge the functional gap between structural and active 
molecules (Lau and Lam, 1999). Other components of the ECM are known to have a 
fundamental role in the repair process and have a similar endometrial pattern of 
expression to that of CTGF. Fibronectin (FN) is a large glycoprotein that interacts 
with specific integrins to enhance cell adhesion and migration during wound repair 
(Kim et al., 1992). Utilizing the ovariectomised rhesus macaque model, Cao et al. 
demonstrated a 50 fold increase in FN from the secretory to the menstrual phase 
alongside a 17 fold increase in its receptor, Integrin-β1 (Cao et al., 2007). Real-time 
PCR, in situ hybridization and immunohistochemistry confirmed these findings and 
localized the increase in FN expression to the uppermost endometrial glands and 
luminal epithelium. Significant increases in the adhesive molecules CTGF and FN in 
the functional layer of the endometrium at this time suggest an involvement in 
surface healing post-menstruation.  
3.4.5 Endothelin-1 
ET-1 is best known for its actions as a potent vasoconstrictor but it also has 
angiogenic and mitogenic properties, reviewed in (Simonson and Dunn, 1990). Data 
presented in this chapter illustrate a significant up-regulation of ET-1 mRNA 
expression in the menstrual endometrium. This finding is in agreement with previous 
studies which found significantly greater ET-1 mRNA in endometrium from the 
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perimenstrual phase (Economos et al., 1992, Kubota et al., 1995). Comprehensive 
assessment of human endometrial ET-1 protein levels by immunohistochemistry and 
radioimmunoassay has revealed significant increases during the perimenstrual phase 
(Ohbuchi et al., 1995, Salamonsen et al., 1992). ET-1 has been immunolocalised to 
the SE, GE, vascular endothelial cells throughout the cycle, with positive staining of 
stromal cells during the perimenstrual period only (Ohbuchi et al., 1995). In situ 
hybridisation studies have confirmed these findings with ET-1 mRNA identified in 
epithelial and endothelial cells, as well as decidualised, perivascular stromal cells 
present during the late secretory phase (Salamonsen et al., 1999). Inhibition of the 
passage of proteins through the Golgi apparatus with the ionophore monensin 
resulted in an accumulation of ET-1 in GE and endothelial cells but not stromal cells, 
suggesting endometrial ET-1 synthesis occurs primarily in GE and endothelial cells 
(Salamonsen et al., 1992).  
 
Neutral endopeptidase (NEP) is a membrane-bound endopeptidase that has the 
ability to degrade ET-1. NEP has been identified in the human endometrium, mainly 
in the stromal compartment of the functional layer, and its level varies across the 
menstrual cycle (Iwase et al., 2007, Head et al., 1993). Immunohistochemical 
staining revealed low levels in proliferative endometrium with increased staining 
observed during the secretory phase. Furthermore, NEP levels decrease during the 
late secretory phase, consistent with the possibility that ET-1 degradation is 
prevented at a time when vasoconstriction of the spiral arterioles is required.  
 
The ET-1 receptors, ETA and ETB, have both been identified in the human 
endometrium (O'Reilly et al., 1992, Kubota et al., 1995). ETA mRNA has previously 
been shown to be expressed throughout the menstrual cycle, whereas ETB was 
increased only during menstruation (Kubota et al., 1995, O'Reilly et al., 1992). In 
addition, array comparison of endometrial biopsies from the mid-secretory phase to 
those from the late-secretory phase revealed ETB as one of the most up-regulated 
genes and its significant increase was confirmed by Q-RT-PCR (Critchley et al., 
2006c). This switch in ETA/ETB ratio at menstruation suggests ET-1 may exert 
different physiological effects at this time. Confirmation herein, that ETB mRNA is 
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significantly increased in endometrium from the menstrual phase, lends further 
support to this hypothesis. Speculatively, one receptor may mediate the proliferative 
effects of ET-1 during the first half of the cycle and a switch in receptor signalling 
might promote more potent vasoconstrictive and angiogenic properties 
perimenstrually. However, the functional relevance of these receptor expression 
patterns remains to be established.   
3.4.6 Summary 
Data presented in this chapter confirm and extend existing literature on repair factors 
expresion in the human endometrium. Importantly, this observational study of well 
characterised human endometrium included samples from the menstrual phase, a 
prerequisite when investigating repair factors and their receptors. Expression of IL-8, 
AM, VEGF, CTGF and ET-1 mRNA was significantly increased during the 
menstrual phase. In addition, protein levels of IL-8, AM, VEGF and CTGF were 
found to have maximal secretion or immunostaining during the menstrual or 
proliferative phases. Receptor mRNA expression was identified in human 
endometrial samples for IL-8, AM, VEGF, and ET-1 and displayed significant 
variations across the cycle. These findings support a physiological role for these 
factors in the human endometrium, in particular during the perimenstrual phase when 















4. The Role of Prostaglandins and Hypoxia in the 




Throughout the menstrual cycle, the endometrial endocrine environment changes 
significantly (Chapter 1, Figure 1). The cyclical production of ovarian hormones, i.e. 
oestrogen and progesterone, controls endometrial breakdown and repair. 
 
Oestrogen is the dominant hormone of the proliferative phase and was traditionally 
thought to initiate post-menstrual repair and govern subsequent endometrial 
remodelling. However, the mouse model of simulated menstruation suggests full 
restoration of the endometrium can occur in the absence of oestrogen (Kaitu'u-Lino 
et al., 2007a). Findings in the ovariectomised macaque model are also consistent with 
an oestrogen independent phase of repair (Nayak and Brenner, 2002). Furthermore, 
the results contained in Chapter 3 of this thesis detail significant increases in putative 
repair factors at the time of menstruation. Using scanning electron microscopy, 
Ludwig and Spornitz demonstrated that epithelial cell proliferation and migration 
commenced on day two of menstruation (Ludwig and Spornitz, 1991). As oestrogen 
levels remain low throughout the menstrual phase, these observations also suggest 
oestrogen is not essential for early endometrial repair. Therefore, pre-menstrual 
endometrial events are more likely to initiate the repair process than post-menstrual 
increases in oestrogen. 
 
After ovulation, the endometrium is exposed to high levels of progesterone, secreted 
from the corpus luteum. In the absence of pregnancy the corpus luteum regresses and 
progesterone levels fall dramatically. It is well established that this progesterone 
withdrawal initiates a cascade of inflammatory mediators that culminates in tissue 
destruction and menstruation, reviewed in (Jabbour et al., 2006). This chapter tests 
the hypothesis that progesterone withdrawal, and its downstream effects, increase 
factors involved in endometrial repair. Previous studies have shown that 
progesterone withdrawal leads to up-regulation of endometrial COX-2 and 
subsequent increased synthesis of prostaglandins, namely prostaglandin E2 (PGE2) 
and prostaglandin F2α (PGF2α) (Critchley et al., 1999, Sugino et al., 2004). The role 
of prostaglandins in the pre-menstrual endometrium is not fully understood. PGF2α is 
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known to induce myometrial contractions and vasoconstriction of the endometrial 
spiral arterioles. This is thought to lead to an episode of local, transient hypoxia in 
the uppermost endometrial zones during menstruation. This hypoxic episode was 
first observed in classic experiments in the rhesus monkey (Markee, 1940) and was 
recently detected in the mouse model of menstruation (Fan et al., 2008). Use of 
pimonidazole, a marker of oxygen levels below 10mmHg, demonstrated intense 
hypoxia in the luminal portion of mouse endometrium on day 2 of the cycle, with 
negligible detection of pimonidazole by day 5. In addition, markers of tissue hypoxia 
(CAIX and HIF-1α) have been detected immunohistochemically in the human 
endometrium during menstruation (Critchley et al., 2006b, Punyadeera et al., 2006).   
 
The data presented in this chapter detail the effects of progesterone withdrawal, 
hypoxia, prostaglandin E2 and prostaglandin F2α on endometrial repair factor 
expression, using IL-8, VEGF, AM and CTGF as examples. This work is carried out 
(i) in vitro on primary endometrial stromal cells and a human endometrial epithelial 
cell line (ii) ex vivo in human endometrial tissue explants and (iii) using an in vivo 
model of progesterone “deprivation”.  
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4.2 Methods 
4.2.1 Tissue collection 
Human endometrial biopsies were collected with ethical approval and written 
informed consent as described in Chapter 2.1. The samples used for in vitro culture 
herein were categorised as proliferative, early-mid or late secretory, based on LMP, 
histological dating and serum ovarian hormone levels (Table 6). 
 
 
Table 6. Details of endometrial biopsies used for culture experiments in Chapter 4. 
 
 




































In addition, 12 women provided two endometrial biopsies; one collected immediately 
before levonorgestrel-releasing intrauterine system (LNG-IUS) insertion and the 
second 3-6 months after insertion (Chapter 2.1). LNG-IUS insertion dramatically 
down regulates endometrial progesterone receptors and provides an in vivo model of 
progesterone “deprivation” (Critchley et al., 1998). Pre-insertion biopsies were 
categorised into menstrual (n=1), proliferative (n=4), early- (n=5), mid- (n=1) and 
late-secretory (n=1) stage. 
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4.2.2 Cell culture 
4.2.2.1 Human stromal cell extraction 
Stromal cells were isolated from human endometrial tissue samples from the 
proliferative (n=3) and secretory (n=3) phases as described in Chapter 2.3.2.  
4.2.2.2 Transfection of endometrial epithelial cells 
Human Ishikawa endometrial adenocarcinoma cells previously stably transfected 
with a PGE2 receptor (EP2) or a PGF2α receptor (FP) were used for in vitro 
experiments. Details of transfection and maintenance can be found in Chapter 2.3.3.   
4.2.2.3 Treatment of cells in vitro 
Endometrial cells were seeded in 6 well plates in media supplemented with 10% fetal 
calf serum (Table 7). The following day, cells were washed in PBS and incubated in 
serum-free culture medium containing antibiotics and 8.4μM indomethacin for at 
least 16h. Cells were treated with vehicle, 100nM PGE2 (EP2S cells/HES) or 100nM 
PGF2α (FPS cells/HES) and placed in either normoxia (37°C, 21% O2, 5% CO2) or 
hypoxic conditions (37°C, 0.5% O2, 5% CO2) in a sealed chamber (Coy laboratory 
products, Michigan, USA) for 2, 4, 8, 24 and 48 h. Culture supernatant was collected 
and stored at -20°C. Cells were washed in PBS and RNA extracted and stored at 
minus 80°C. 
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4.2.2.4 Hypoxia and prostaglandin treatments 
All endometrial biopsies (Table 6) were divided into four equal explants and 
incubated on raised platforms in 24 well plates, just covered with serum free RPMI 
1640 medium and 8.4μM indomethacin for 16h. 
 
Explants were then treated for 24h as detailed in Table 8, where normoxia was 
incubation at 21% O2, 5% CO2, 37°C and hypoxia was incubation in a sealed hypoxic 
chamber (Coy laboratory products) set at 0.5% O2, 5% CO2, 37°C. 
 
 












































4.2.2.5 Ex vivo model of progesterone antagonism 
Five endometrial biopsies from the proliferative phase were divided into eight equal 
sized explants and placed on raised platforms in four wells of two 12 well plates. All 
explants were treated with 1μM medroxyprogesterone acetate (MPA) for 24h.  
Explants were then treated with: 
• Explant 1: 1μM MPA plus vehicle 
• Explant 2: 1μM MPA plus 8.4μM indomethacin (a COX enzyme inhibitor) 
• Explant 3: 1μM MPA and 1μM RU486 (a progesterone receptor antagonist, 
to simulate progesterone withdrawal) plus vehicle 
• Explant 4: 1μM MPA and RU486 plus 8.4μM indomethacin, to prevent 
prostaglandin production.  
Immediately after these treatments, one plate was placed in normoxic conditions and 
the other in hypoxic conditions for 48h, as menstruation occurs 48h after 
progesterone withdrawal in vivo. 
4.2.2.6 Ex vivo model of progesterone withdrawal 
Four further endometrial biopsies were divided into four equal explants, placed on 
raised platforms in two wells of two 12 well plates. All were treated with 1µM 
progesterone for 24h. Explants were then washed twice with PBS and treated with 
either 1µM progesterone or with vehicle (control media) to induce progesterone 
withdrawal. After these treatments plates were placed in normoxic (21% O2) or 
hypoxic (0.5% O2) conditions for 48h. 
4.2.3 RNA extraction and Q-RT-PCR 
RNA was extracted from all the endometrial samples, cDNA prepared and Q-RT-
PCR performed as detailed in Chapter 2.4. The expression of mRNA was measured 
for IL-8, VEGF, AM and CTGF (sequences detailed in Chapter 2, Table 3). A 
sample of liver cDNA was also prepared and included on each Taqman plate as a 
positive control. There was no significant change in 18S RNA expression between 
samples incubated in normoxic and hypoxic conditions. 
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4.2.4 ELISA 
Protein content (IL-8, VEGF, AM, CTGF) in the culture supernatant from cell 
culture experiments was measured by ELISA, as detailed in Chapter 2.7. Time points 
were selected subsequent to the time of maximal mRNA expression, to allow for 
protein translation and secretion into culture supernatants.  
4.2.5 Immunohistochemistry 
IL-8 and VEGF proteins were localised in endometrial sections from women pre- 
and post- LNG-IUS insertion using the protocols described in Chapter 2.6.  
4.2.6 Statistical analysis 
For mRNA in cell culture and tissue explants, results were expressed as fold 
increase, for which relative expression of mRNA in treated samples was divided by 
the relative expression in vehicle-treated samples. Data are presented as mean +/- 
SEM. Significant difference was determined using one-way ANOVA of dCt values, 
with Tukey’s post test analysis. Statistically significant differences in protein levels 
were also determined using one-way ANOVA with Tukey’s post test analysis. For 
endometrial biopsies from women pre- and post- LNG-IUS insertion, mRNA results 
were expressed as quantity relative to a comparator, a sample of RNA from the liver. 
Significant difference was determined using a Wilcoxon matched pairs test 
(GraphPad Prism Software, Inc., San Diego, CA). 
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4.3 Results 
4.3.1 Interleukin-8 (IL-8) 
4.3.1.1 PGE2 and hypoxia increased IL-8 mRNA in EP2S cells 
To investigate the role of PGE2 and hypoxia in the regulation of IL-8 expression, an 
Ishikawa endometrial epithelial cell line stably expressing the EP2 receptor was 
utilised (EP2S cells). This cell line was used to mimic primary endometrial epithelial 
cells, which express receptors for PGE2 (Milne et al., 2001) but do not proliferate 
well in culture. Cells were exposed to vehicle treatment or 100nM PGE2 for up to 48 
hours in normoxic and hypoxic conditions. Treatment with PGE2 in normoxic 
conditions (Figure 31A) showed a significant increase in IL-8 mRNA, with maximal 
up-regulation after 8 hours (p<0.01). Hypoxic conditions also significantly increased 
IL-8 mRNA (Figure 31B) but displayed a more delayed induction, reaching 
maximum up-regulation after 8-24 hours (p<0.01).  
4.3.1.2 Simultaneous treatment with PGE2 and hypoxia revealed a synergistic 
increase in IL-8 mRNA and protein in EP2S cells 
When EP2S cells were exposed to both PGE2 and hypoxic conditions for 24 hours 
(Figure 32A), there was a synergistic increase in IL-8 mRNA that was significantly 
greater than treatment with PGE2 in normoxia (p<0.05) or hypoxic conditions alone 
(p<0.05). Levels of secreted IL-8 protein showed a similar pattern, with a synergistic 
increase in IL-8 protein secretion with PGE2 treatment in hypoxic conditions (Figure 
32B).  
4.3.1.3 PGF2α and hypoxia increased IL-8 mRNA in FPS cells 
To examine the contribution of PGF2α to the regulation of IL-8, Ishikawa cells stably 
transfected with the PGF2α receptor were examined (FP2S cells) to mimic primary 
endometrial epithelial cells, which express the FP receptor in vivo (Milne and 
Jabbour, 2003). Treatment of FPS cells with 100nM PGF2α for 8h revealed a 
significant increase in IL-8 mRNA versus vehicle treated cells (p<0.01). This 







Figure 31. The regulation of IL-8 mRNA in EP2S cells. (A) Cells treated with 
vehicle or 100nM prostaglandin E2 (PGE2) for up to 48h (n=3). (B) Cells treated in 
normoxia (21% O2) or hypoxia (0.5% O2) for up to 48h (n=3).  (*p<0.05, **p<0.01). 
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Figure 32. The effect of simultaneous treatment of endometrial epithelial cells 
(EP2S cells) with 100nM prostaglandin E2 (PGE2) and hypoxia for 24h on (A) IL-8 
mRNA expression (n=3) and (B) IL-8 secreted protein levels (n=3). N: normoxia 
21% O2, H: hypoxia 0.5% O2, V: ethanol vehicle. (*p<0.05, **p<0.01). 
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Treatment of FPS cells with PGF2α and/or hypoxic conditions for 24h had no 
significant impact on IL-8 expression (Figure 33B). IL-8 secreted protein was 
significantly increased by PGF2α at 24h when compared to control cells (p<0.05) but 
was not significantly increased by hypoxia (Figure 33C).  
4.3.1.4 PGE2 increased IL-8 mRNA in human endometrial stromal (HES) cells 
Treatment of HES cells with 100nM PGE2 resulted in a significant increase in IL-8 
mRNA after 48h (p<0.05) (Figure 34A). HES cells exposed to hypoxic conditions 
showed no significant increase in IL-8 mRNA at any time-point examined (Figure 
34B). 
4.3.1.5 Simultaneous treatment of HES cells with PGE2 and hypoxia showed no 
synergistic increase in IL-8 mRNA or protein  
Based on the timecourse above, HES cells were treated with 100nM PGE2 in hypoxic 
conditions for 48h and showed a significant increase in IL-8 mRNA (p<0.05). 
However, this was not significantly different to treatment with PGE2 in normoxic 
conditions (Figure 35A). IL-8 secreted protein levels from HES cells after 48h of 
culture were not significantly changed by any treatment (Figure 35B).  
4.3.1.6 PGF2α and hypoxia have no significant impact on IL-8 mRNA and protein 
levels in HES cells 
100nM PGE2α and hypoxic conditions had no significant effect on HES cell IL-8 
mRNA (Figure 36A). HES cells treated with 100nM PGF2α in normoxic or hypoxic 
conditions had no significant increases in IL-8 protein versus vehicle treated cells in 
normoxia (Figure 36B). 
4.3.1.7 IL-8 mRNA was increased by PGE2 and hypoxia in secretory endometrial 
tissue  
To investigate the regulation of endometrial IL-8, human endometrial explants were 
cultured for 24 hours with vehicle, 100nM PGE2 or hypoxic conditions. Secretory 
endometrium from seven women showed a non-significant increase in IL-8 
expression with PGE2 treatment in normoxia. Culture of endometrial explants in  
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Figure 33. The regulation of IL-8 by prostaglandin F2α (PGF2α) and hypoxia 
in FPS cells. (A) IL-8 mRNA in FPS cells treated with vehicle, 100nM PGF2α, 
hypoxic conditions (0.5% O2) or both PGF2α and hypoxia for 8h (n=3). (B) IL-8 
mRNA in FPS cells treated in an identical manner for 24h (n=3). (C) IL-8 secreted 
protein levels from FPS cells treated for 24h (n=3). N: normoxia (21% O2), H: 
hypoxia (0.5% O2), V: ethanol vehicle. (*p<0.05, **p<0.01).   
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Figure 34. The effect of prostaglandin E2 (PGE2) and hypoxia on IL-8 
mRNA in human endometrial stromal cells (HES). (A) IL-8 expression in HES 
cells treated with 100nM PGE2 for up to 48h (n=3). (B) IL-8 expression in HES cells 
treated in normoxia or hypoxia for up to 48h (n=3). V: vehicle, N: normoxia (21% 
O2), H: hypoxia (0.5% O2). (**p<0.01, ns: non-significant). 
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Figure 35. The effect of simultaneous treatment of human endometrial stromal 
cells with prostaglandin E2 (PGE2) and hypoxic conditions for 48h on (A) IL-8 
mRNA expression (n=3) and (B) IL-8 secreted protein levels (n=3). V: vehicle 
treatment, N: normoxia (0.5% O2), H: hypoxia (0.5% O2).  (*p<0.05). 
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Figure 36. The regulation of IL-8 by prostaglandin F2α (PGF2α) and hypoxia 
in human endometrial stromal (HES) cells. (A) IL-8 mRNA in HES cells treated 
with vehicle, 100nM PGF2α, hypoxic conditions (0.5% O2) or both PGF2α and 
hypoxia for 24h (n=3). (B) IL-8 secreted protein levels from HES cells treated in an 
identical manner for 24h (n=3). N: normoxia (21% O2), H: hypoxia (0.5% O2), V: 
ethanol vehicle. (ns: non-significant). 
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hypoxic conditions significantly elevated IL-8 mRNA (p<0.05) (Figure 37B). In 
contrast, neither treatment induced up-regulation of IL-8 in endometrium from the 
proliferative phase (n=3) (Figure 37A). This suggests previous exposure to 
progesterone is essential for up-regulation of IL-8 by PGE2 and hypoxia. 
4.3.1.8 IL-8 mRNA was not significantly increased by PGF2α in endometrial tissue 
Treatment of proliferative or secretory endometrial tissue explants with 100nM 
PGF2α, hypoxic conditions or both PGF2α and hypoxia did not significantly increase 
IL-8 mRNA versus explants treated with vehicle in normoxia (Figure 38A,B).  
4.3.1.9 An in vitro model of progesterone-antagonism increased IL-8 mRNA 
expression. 
To establish if progesterone withdrawal induces endometrial IL-8 mRNA, 
proliferative endometrial biopsies were divided into 8 explants (n=5). All explants 
were treated with medroxyprogesterone acetate for 24hours. Following progesterone 
exposure, progesterone withdrawal was simulated in four of the explants by co-
treating with RU486, a progesterone receptor antagonist. Progesterone withdrawal in 
normoxic conditions did not significantly up-regulate IL-8 mRNA (Figure 39). In 
vivo, it is postulated that progesterone withdrawal in the late secretory phase induces 
synthesis of prostaglandins and constriction of spiral arterioles, resulting in an 
episode of transient hypoxia. Therefore, to mimic the in vivo situation more 
accurately, two of the endometrial explants were exposed to hypoxic conditions at 
the time of simulated progesterone withdrawal. Addition of hypoxic conditions 
induced a significant induction of IL-8 mRNA 48h after progesterone withdrawal 
(p<0.05) (Figure 39). 
To assess the contribution of prostaglandins following progesterone withdrawal, we 
co-treated explants with MPA (progestogen), RU486 (progesterone receptor 
antagonist) and indomethacin (a COX enzyme inhibitor). Addition of indomethacin 
attenuated the up-regulation of IL-8 mRNA following progesterone withdrawal in 
hypoxic conditions (Figure 39).  
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Figure 37. The effect of 100nM prostaglandin E2 and hypoxia on IL-8 mRNA 
expression in endometrial tissue explants. (A) Endometrial explants from the 
proliferative phase (n=3) treated with vehicle, 100nM PGE2, hypoxia or both PGE2 
and hypoxia for 24h. (B) Endometrial explants from the secretory phase (n=5) treated 
in an identical manner. N: normoxia (21% O2), H: hypoxia (0.5% O2), V: ethanol 
vehicle. (*p<0.05). 
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Figure 38. The effect of 100nM prostaglandin F2α and hypoxia on IL-8 
mRNA in endometrial tissue explants. (A) Endometrial explants from the 
proliferative phase (n=3) treated with vehicle, PGF2α, hypoxia or both PGF2α and 
hypoxia for 24h. (B) Endometrial explants from the secretory phase (n=3) treated in 
an identical manner. N: normoxia (21% O2), H: hypoxia (0.5% O2), V: ethanol 
vehicle. (ns: non-significant). 
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Figure 39. The effect of in vitro progesterone antagonism on endometrial IL-
8 mRNA expression. Proliferative phase explants (n=4) were pre-treated with 1μM 
medroxyprogesterone acetate (MPA) and then (i) maintained in 1μM MPA (P), (ii) 
maintained in MPA plus 8.4μM indomethacin, a COX enzyme inhibitor (P+IndoM), 
(iii) co-treated with 1μM MPA and 1μM RU486, a progesterone receptor antagonist 
(Pw/d) or (iii) co-treated with 1μM MPA, 1μM RU486 and 8.4μM indomethacin 
(Pw/d + IndoM). Identical treatments were incubated in either normoxic (21% O2) or 














































4.3.1.10 Endometrium collected after exposure to LNG-IUS had increased expression 
of IL-8 mRNA compared to pre-insertion biopsies 
To further investigate the role of progesterone and hypoxia in regulating endometrial 
IL-8 expression, endometrial biopsies were examined from nine women taken pre- 
and 3-6 months post- levonorgestrel-releasing intrauterine system (LNG-IUS) 
insertion. The LNG-IUS has been shown to markedly down-regulate the 
progesterone receptor in all components of the endometrium (Critchley et al., 1998), 
resulting in a human model of “progesterone-deficiency”. There was a significant up-
regulation of IL-8 mRNA after LNG-IUS exposure when compared to pre-insertion 
biopsies from the proliferative, early and mid secretory phases (n=7) (p<0.05) 
(Figure 40A). Interestingly, endometrial biopsies taken during the late-secretory and 
menstrual phases (n=2) showed no significant change in IL-8 mRNA on exposure to 
the LNG-IUS (Figure 40B). This suggests endometrium already exposed to 
progesterone withdrawal in vivo has no further capacity for IL-8 induction on 
insertion of LNG-IUS.  
4.3.1.11 IL-8 immunohistochemical staining is increased in endometrium that has been 
exposed to LNG-IUS 
This increase in endometrial IL-8 after LNG-IUS insertion was also identified at the 
protein level. Increased IL-8 immunohistochemical staining was visible in the 
decidualised stromal cells present after LNG-IUS exposure (Figure 41). 
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Figure 40. The effect of a levonorgestrel releasing intra uterine system 
(LNG-IUS) on IL-8 mRNA. (A) IL-8 mRNA in proliferative, early- and mid-
secretory endometrium prior to LNG-IUS insertion was compared to paired samples 
collected 3-6 months after insertion. (B) Pre- and post-insertion samples in 
endometrium from the menstrual and late secretory phase. Note logarithmic scale on 
y-axis.  




























   
             
             
 
 
Figure 41. Immunohistochemical staining for IL-8 in (A) mid-secretory 
endometrium prior to LNG-IUS insertion and (B) in endometrium from the same 
woman 4 months after LNG-IUS insertion. GE: glandular epithelial cells, St: stromal 
cell compartment, arrows = endothelial cells, dSt: decidualised stromal cells. Scale 
bar = 50µm. 
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4.3.2 Adrenomedullin (AM) 
4.3.2.1 PGF2α and hypoxic conditions up-regulate AM expression in endometrial 
epithelial cells 
Treatment of EP2S cells with 100nM PGE2 had no significant impact on AM 
expression at 8h (Figure 46A) or 2, 4, 24 or 48h (data not shown). EP2S cells placed 
in hypoxic conditions (0.5% O2) displayed a significant up-regulation of AM mRNA, 
with a 50 fold increase over cells in normoxic conditions (p<0.001) (Figure 42A). 
There was no further increase when cells were co-treated with hypoxia and 100nM 
PGE2. Treatment with 100nM PGF2α significantly increased AM mRNA in FPS cells, 
resulting in a >11 fold increase over vehicle treated cells after 8h (p<0.001) (Figure 
42B). Hypoxic conditions also significantly increased AM expression in FPS cells >6 
fold (p<0.001). Interestingly, co-treatment of FPS cells with PGF2α and hypoxia 
resulted in a synergistic increase in AM mRNA (>28 fold increase over normoxic 
vehicle) that was significantly greater than treatment with PGF2α or hypoxia alone 
(p<0.05, p<0.001 respectively). Analysis of FPS cell culture supernatants by ELISA 
revealed no significant differences in AM secreted protein levels after 24 h but a 
similar pattern emerged, with maximal secreted AM protein from cells treated with 
both PGF2α and hypoxia (Figure 42C).  
4.3.2.2 PGF2α and hypoxia up-regulate AM expression in secretory endometrial tissue 
To further investigate PGF2α and hypoxia mediated AM expression, endometrial 
tissue explants were treated with (i) vehicle, (ii) 100nM PGF2α, (iii) hypoxic 
conditions, or (iv) PGF2α and hypoxia. Proliferative biopsies revealed no significant 
differences in AM mRNA with these treatments (n=3) (Figure 43A). In contrast, 
endometrial tissue from the secretory phase did show a significant increase in AM 
expression when placed in hypoxic conditions (n=4) ( >4 fold, p<0.05) (Figure 43B). 
In addition, there was a non-significant two-fold increase in AM mRNA after 
















Figure 42. The regulation of adrenomedullin (AM) mRNA in endometrial 
epithelial cells. (A) Ishikawa EP2S cells were treated with vehicle, 100nM 
prostaglandin E2 (PGE2), hypoxic conditions or both PGE2 and hypoxia for 8h. (B) 
Ishikawa FPS cells were treated with 100nM prostaglandin F2α (PGF2α), hypoxia or 
both PGF2α and hypoxia for 8h. (C) ELISA analysis of AM secreted protein levels in 
FPS cell culture supernatants after 24h. All experiments were carried out n=3. N: 
normoxia (21% O2), H: hypoxia (0.5% O2), V: ethanol vehicle. (a-b p<0.001, c-d 
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Figure 43. Adrenomedullin (AM) mRNA in endometrial tissue explants. (A) 
Endometrial explants from the proliferative phase treated with vehicle, 100nM 
PGF2α, hypoxia or both PGF2α and hypoxia for 24h (n=3). (B) Secretory phase 
endometrial explants treated in an identical manner for 24h (n=3). N: normoxia (21% 
O2), H: hypoxia (0.5% O2), V: ethanol vehicle. (ns: non-significant, *p<0.05). 
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exposure to progesterone is a pre-requisite to enable up-regulation of AM mRNA by 
PGF2α and hypoxia. 
4.3.2.3 Progesterone withdrawal, in the presence of hypoxia and prostaglandins, up-
regulates AM expression in proliferative endometrial tissue 
To examine the contribution of progesterone exposure and withdrawal, an in vitro 
model of progesterone antagonism was used. Proliferative explants were treated with 
progesterone followed by progesterone and mifepristone (RU486, a progesterone 
receptor antagonist), to mimic progesterone withdrawal. There was no significant 
difference in endometrial AM mRNA in explants subjected to progesterone 
withdrawal when compared to those maintained in progesterone. However, when 
progesterone withdrawal was carried out in hypoxic conditions to simulate the in 
vivo scenario, a significant increase in AM mRNA was observed (p<0.05) (Figure 
44). The contribution of prostaglandins, which are up-regulated downstream of 
progesterone withdrawal, was assessed by co-culture of explants with indomethacin, 
a COX enzyme inhibitor. Addition of indomethacin resulted in abrogation of the AM 
increase observed following progesterone withdrawal in hypoxic conditions (Figure 
44). These data suggest that progesterone withdrawal, with subsequent prostaglandin 
production and induction of hypoxia, results in up-regulation of AM mRNA at 
menstruation. 
4.3.2.4 Endometrium collected after LNG-IUS exposure had increased AM mRNA 
versus pre-insertion biopsies 
Endometrial biopsies were performed prior to and 3-6 months after LNG-IUS 
insertion. Biopsies taken after LNG-IUS insertion had significantly increased AM 
mRNA when compared to pre-insertion biopsies taken during the proliferative and 
























Figure 44. The effect of in vitro progesterone antagonism on endometrial 
adrenomedullin (AM) mRNA. Proliferative phase explants (n=4) were pre-treated 
with1μM medroxyprogesterone acetate (MPA) and then (i) maintained in 1μM MPA 
(P), (ii) maintained in MPA plus 8.4μM indomethacin, a COX enzyme inhibitor 
(P+IndoM), (iii) co-treated with 1μM MPA and 1μM RU486, a progesterone 
receptor antagonist (Pw/d) or (iii) co-treated with 1μM MPA, 1μM RU486 and 
8.4μM indomethacin (Pw/d + IndoM). Identical treatments were incubated in either 















































   
    





























Figure 45. The effect of a levonorgestrel releasing intra uterine system 
(LNG-IUS) on adrenomedullin (AM) mRNA expression. AM mRNA in 
proliferative, early- and mid-secretory endometrium prior to IUS insertion was 
compared to paired samples collected 3-6 months after IUS insertion. Note 




4.3.3 Vascular endothelial growth factor (VEGF) 
4.3.3.1  Regulation of VEGF in endometrial epithelial cells by hypoxia and 
prostaglandins E2 and F2α 
An endometrial epithelial cell line stably transfected with either the PGE2 receptor 
(EP2S cells) or the PGF2α receptor (FPS cells) was used to investigate the role of 
prostaglandins and hypoxia on VEGF expression. Treatment of EP2S cells with 
100nM PGE2 for 24h did not increase VEGF mRNA over vehicle treatment (Figure 
50A). However, an increase in VEGF secreted protein was observed with this 
treatment (p<0.01) (Figure 46B). Incubation of these cells in hypoxia (0.5% O2) for 
24h showed a non-significant increase in VEGF mRNA (Figure 50A), with 
significant increases in secreted protein levels over vehicle treated cells (p<0.001) 
(Figure 46B). Maximal increases in VEGF mRNA and protein levels was observed 
when EP2S cells were co-treated with PGE2 and hypoxic conditions (p<0.05, 
p<0.001) (Figure 46A,B).  
 
FPS cells treated with 100nM PGF2α or hypoxia showed a non-significant increase in 
VEGF mRNA, this increase reached significance when both factors were present 
simultaneously (p<0.05) (Figure 46C). VEGF secreted protein levels were 
significantly increased in the culture supernatants from FPS cells treated for 24h with 
PGF2α, hypoxia or both treatments together (p<0.001) (Figure 46D). 
4.3.3.2 Regulation of VEGF levels in primary human endometrial stromal (HES) 
cells 
HES cells treated with 100nM PGE2 in normoxia or hypoxia showed a non-
significant increase in VEGF mRNA expression over vehicle treated cells in 
normoxia (Figure 47A). There was a significant increase in VEGF secreted protein in 
culture supernatants from HES cells treated with PGE2 in hypoxia for 24h (p<0.05) 
(Figure 47B). HES cells treated with 100nM PGF2α in normoxia did not show 
increased VEGF secreted protein levels versus vehicle treated cells (Figure 47C). 
However, HES cells incubated in hypoxic conditions, with and without PGF2α, had 
significantly elevated VEGF mRNA levels after 24h culture (p<0.01) (Figure 47C). 








































































































Figure 46. The expression of vascular endothelial growth factor (VEGF) in 
endometrial epithelial cells treated with prostaglandins and hypoxia. (A) VEGF 
mRNA in EP2S cells measured by Q-RT-PCR after 24h treatment with vehicle, 
100nM prostaglandin E2 (PGE2), hypoxic conditions or both PGE2 and hypoxia 
(n=3). (B) VEGF secreted protein levels measured by ELISA in the culture 
supernatants from these EP2S cells (n=3). (C) VEGF mRNA in FPS cells after 24h 
treatment with vehicle, prostaglandin F2α (PGF2α), hypoxic conditions or both PGF2α 
and hypoxia (n=3). (D) VEGF secreted protein levels measured by ELISA in the 
culture supernatants from these FPS cells (n=3). N: normoxia (21% O2), H: hypoxia 
(0.5% O2), V: ethanol vehicle. (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 47. The expression of vascular endothelial growth factor (VEGF) in 
primary human endometrial stromal (HES) cells treated with prostaglandins 
and hypoxia. (A) VEGF mRNA in HES cells measured by Q-RT-PCR after 24h 
treatment with vehicle, 100nM prostaglandin E2 (PGE2), hypoxic conditions or both 
PGE2 and hypoxia (n=3). (B) VEGF secreted protein levels measured by ELISA in 
the culture supernatants from these PGE2/hypoxia treated HES cells (n=3). (C) 
VEGF mRNA in HES cells after 24h treatment with vehicle, prostaglandin F2α 
(PGF2α), hypoxic conditions or both PGF2α and hypoxia (n=3). (D) VEGF secreted 
protein levels measured by ELISA in the culture supernatants from these 
PGF2α/hypoxia treated HES cells (n=3). N: normoxia (21% O2), H: hypoxia (0.5% 
O2), V: ethanol vehicle. (ns: non-significant, *p<0.05, **p<0.01). 
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from HES cells incubated for 24h with PGF2α in hypoxic conditions versus vehicle 
treated cells in normoxia (p<0.05) (Figure 47D). 
4.3.3.3 Regulation of VEGF levels in human endometrial tissue explants 
Proliferative endometrial explants treated with 100nM PGE2 or PGF2α in normoxia 
or hypoxia showed no significant changes in VEGF mRNA (Figure 48A,B). 
Although changes were not significant, secretory tissue treated with prostaglandins 
and/or hypoxia showed a trend towards increased VEGF mRNA (Figure 48C,D). 
These differences between proliferative and secretory endometrium, suggest that 
prior progesterone exposure may influence the ability of tissue to respond to hypoxia 
and prostaglandin treatment. 
4.3.3.4 The effect of in vitro progesterone, and its withdrawal, on VEGF expression 
To test the hypothesis that prior progesterone exposure is necessary to increase 
endometrial VEGF expression, an in vitro model of progesterone withdrawal was 
utilised. Proliferative endometrial biopsies were divided into eight equal explants and 
pre-treated for 24h with synthetic progesterone (MPA). Explants were then co-
treated with MPA plus (i) vehicle, (ii) indomethacin, a cyclo-oxygenase inhibitor, 
(iii) a progesterone receptor antagonist (RU486) or (iv) RU486 and indomethacin for 
48h in either normoxic or hypoxic conditions. Tissue explants subjected to in vitro 
progesterone withdrawal in normoxia did not show significant up-regulation of 
VEGF mRNA (Figure 49A). However, in vivo progesterone withdrawal is followed 
by an episode of hypoxia as a result of spiral arteriole vasoconstriction. When 
progesterone antagonism was performed in vitro in hypoxic conditions to mimic the 
in vivo scenario more accurately, there was a significant increase in VEGF mRNA 
(Figure 49A). This increase was abrogated by co-treatment with indomethacin, 
suggesting that hypoxia and prostaglandin production are necessary for a significant 
increase in endometrial VEGF expression following progesterone withdrawal.  
 
As progestins and RU486 may have off target effects, further endometrial explants 
were incubated with natural progesterone before withdrawal or maintenance of 
progesterone exposure. These experiments yielded similar results, with significantly 
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increased VEGF mRNA when explants were exposed to progesterone withdrawal in 
hypoxic conditions (Figure 49B). 
4.3.3.5 The effect of local delivery of levonorgestrel on endometrial VEGF expression 
To further examine the effect of progesterone exposure on VEGF expression, paired 
endometrial biopsies collected from the same woman before and 3-6 months after 
levonorgestrel-releasing intrauterine system (LNG-IUS) insertion (n=7) were 
examined. There was a significant up-regulation of VEGF mRNA in endometrium 
collected after LNG-IUS insertion when compared to pre-insertion biopsies taken in 




Figure 48. The effect of prostaglandins E2/F2α and hypoxia on VEGF 
expression in endometrial explants. VEGF mRNA in endometrial explants from 
the proliferative phase treated with (A) vehicle, 100nM PGE2, hypoxia and both 
PGE2 and hypoxia (n=3) or (B) vehicle, 100nM PGF2α, hypoxia or both hypoxia and 
PGF2α (n=3) for 24h. (C) VEGF mRNA in secretory endometrial explants treated 
with vehicle, 100nM PGE2, hypoxia and both PGE2 (n=4). (D) VEGF mRNA in 
secretory endometrial explants treated with vehicle, 100nM PGF2α, hypoxia or both 
hypoxia and PGF2α (n=3) for 24h. N: normoxia (21% O2), H: hypoxia (0.5% O2), V: 
ethanol vehicle. 
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Figure 49. The effect of in vitro progesterone antagonism and withdrawal on 
endometrial VEGF expression.  (A) Proliferative phase explants (n=4) were pre-
treated with1μM medroxyprogesterone acetate (MPA)  and then (i) maintained in 
1μM MPA, (ii) treated with MPA and indomethacin (MPA+IndoM), (iii) co-treated 
with 1μM MPA and 1μM RU486, a progesterone receptor antagonist (MPA+RU486) 
or (iv) co-treated with 1μM MPA, 1μM RU486 and 8.4μM indomethacin, a COX 
enzyme inhibitor (MPA+RU486+IndoM). Identical treatments were incubated in 
either normoxia (21% O2) or hypoxia (0.5% O2). (B) Four further endometrial 
biopsies were pre-treated with progesterone (1µM) before maintenance in 
progesterone (P) or incubation with control media to induce progesterone withdrawal 
(Pw/d) in normoxia and hypoxia. (*p<0.05, **p<0.01). 
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Figure 50. The effect of a levonorgestrel releasing intra uterine system 
(LNG-IUS) on VEGF mRNA. Insertion of the LNG-IUS, with consequent local “P-
deprivation” analogous to local “P-withdrawal”, resulted in a significant increase in 
VEGF mRNA, note logarithmic scale on y-axis. 
 

























4.3.4 Connective tissue growth factor (CTGF) 
4.3.4.1 The effect of PGE2 and hypoxia on CTGF expression in EP2S cells 
A time course experiment in EP2S cells revealed a significant increase in CTGF 
mRNA on treatment with 100nM PGE2 compared to vehicle at 4 and 8h (p<0.01) 
(Figure 51A). Hypoxic conditions (0.5% O2) also significantly increased CTGF 
mRNA in these cells at 2h versus normoxic controls (p<0.001) (Figure 51B). 
Interestingly, in prolonged hypoxic conditions this up-regulation did not take place. 
When cells were treated with both PGE2 and hypoxia for 2h there was a synergistic 
increase in CTGF mRNA, that was significantly greater than that seen with either 
treatment alone (p<0.05) (Figure 52A). As maximal CTGF mRNA occurred between 
2 and 4h, the amount of CTGF protein secreted into culture supernatants was 
assessed by ELISA at a 6h time point. CTGF secreted protein was significantly 
increased over vehicle treated cells when EP2S cells were co-treated with PGE2 and 
hypoxia (p<0.05) (Figure 52B). 
4.3.4.2 The effect of PGF2α and hypoxia on CTGF expression in FPS cells 
Treatment of FPS cells with 100nM PGF2α for 6 and 24h resulted in significant up-
regulation of CTGF mRNA versus vehicle treated cells (p<0.05 and p<0.001 
respectively) (Figure 53A). As in EP2S cells, hypoxic conditions did not 
significantly increase CTGF mRNA at 6 or 24h in FPS cells (Figure 53A). Secreted 
protein levels in culture supernatants at 6 and 24h demonstrated significant increases 
in CTGF protein over controls after treatment with PGF2α (p<0.001) (Figure 53B). 
4.3.4.3 The effect of prostaglandins and hypoxia on CTGF expression in endometrial 
tissue explants 
As 100nM PGF2α had the most marked effect on CTGF expression in endometrial 
cells, endometrial tissue explants were cultured with this prostaglandin for 24h. This 
did not result in a significant increase in CTGF expression, regardless of the cycle 
stage of the tissue (Figure 54A,B). In contrast, hypoxic conditions did produce a 
significant increase in CTGF mRNA over controls in both proliferative (p<0.05) and 






Figure 51. Connective tissue growth factor mRNA in endometrial epithelial 
cells (Ishikawa EP2S cells) treated with prostaglandin E2 and hypoxia. (A) 
CTGF mRNA measured by Q-RT-PCR in EP2S cells treated with vehicle or 100nM 
PGE2 for up to 48h in normoxic conditions (21% O2) (n=3). (B) EP2S cells cultured 
in normoxic (21% O2) and hypoxic (0.5% O2) conditions for up to 48h (n=3). 
(**p<0.01, ***p<0.001).   
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Figure 52. The impact of simultaneous treatment of EP2S cells with 100nM 
prostaglandin E2 and hypoxia on (A) connective tissue growth factor (CTGF) mRNA 
expression measured by Q-RT-PCR at 2h (n=3) and (B) secreted CTGF protein 
levels measured by ELISA in EP2S culture supernatants at 6h (n=3). N: normoxia 
(21% O2), H: hypoxia (0.5% O2), V: ethanol vehicle, PGE2: prostaglandin E2. 
(*p<0.05). 
A EP2S cells 
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Figure 53. The impact of prostaglandin F2α and hypoxia on connective tissue 
growth factor (CTGF) mRNA in endometrial epithelial cells (Ishikawa FPS 
cells). (A) CTGF mRNA measured by Q-RT-PCR in FPS cells treated with vehicle, 
100nM PGF2α , hypoxia or PGF2α and hypoxia for 6h and 24h (n=3). (B) CTGF 
secreted protein levels measured by ELISA in culture supernatants from FPS cells 
treated for 24h with vehicle, PGF2α or hypoxia (n=3). N: normoxia (21% O2), H: 
hypoxia (0.5% O2), V: ethanol vehicle, PGF2α: 100nM prostaglandin F2α 
(***p<0.001).   
6h 24h 
B FPS cells 
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Figure 54. The effect of prostaglandin F2α and hypoxia on CTGF expression 
in endometrial tissue explants. (A) Endometrial explants from the proliferative 
phase treated with vehicle, 100nM PGF2α, hypoxia or PGF2α and hypoxia for 24h 
(n=3). (B) Endometrial tissue explants from the secretory phase treated in an 
identical manner (n=3). N: normoxia (21% O2), H: hypoxia (0.5% O2), V: ethanol 
vehicle, PGF2α: 100nM prostaglandin F2α. (*p<0.05, ***p<0.001). 
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endometrial tissue availability, the effects of PGE2 on endometrial tissue explants at 
2h could not be assessed. 
4.3.4.4 The effect of in vitro progesterone and its antagonism on CTGF expression 
 Endometrial explants subjected to an in vitro model of progesterone withdrawal 
showed no significant changes in CTGF mRNA (Figure 55). These explants were 
maintained in progesterone before co-treatment with RU486 in normoxic and 
hypoxic conditions to mimic progesterone withdrawal. Antagonism of progesterone 
in normoxic conditions revealed a non-significant increase in CTGF expression, 
which was abrogated when COX-2 was inhibited with indomethacin. Interestingly, in 
contrast to other repair factors examined, hypoxic conditions significantly reduced 
CTGF mRNA when compared to normoxic explants, regardless of co-treatments. 
4.3.4.5 The effect of LNG-IUS insertion on endometrial CTGF expression 
To further examine the effect of progesterone exposure on CTGF expression, paired 
endometrial biopsies collected from the same woman before and 3-6 months after 
levonorgestrel-releasing intrauterine system (LNG-IUS) insertion (n=7) were 
examined as an in vivo model of progesterone “deprivation”. In contrast to the other 
repair factors examined, there was no significant up-regulation of CTGF mRNA in 
endometrium collected after LNG-IUS insertion when compared to pre-insertion 






    
 
 
Figure 55. The effect of in vitro progesterone antagonism on endometrial 
CTGF expression.  Proliferative phase explants (n=4) were pre-treated with1μM 
medroxyprogesterone acetate (MPA) and then (i) maintained in 1μM MPA (P), (ii) 
co-treated with 1μM MPA and 1μM RU486, a progesterone receptor antagonist 
(Pw/d) or (iii) co-treated with 1μM MPA, 1μM RU486 and 8.4μM indomethacin, a 
COX enzyme inhibitor (Pw/d + IndoM). Identical treatments were incubated in either 























































              
        




























Figure 56. The effect of a levonorgestrel releasing intra uterine system 
(LNG-IUS) on CTGF mRNA. Insertion of the levonorgestrel releasing intra uterine 
system (IUS), with consequent local “P-deprivation” analogous to local “P-




4.3.5 Prostaglandin receptor expression in endometrial explants 
To assess the impact of hypoxia and prostaglandin treatment on prostaglandin 
receptor expression, EP2 and FP mRNA was measured in proliferative and secretory 
endometrial explants after 24h culture. There were no significant changes in EP2 or 
FP mRNA after treatment with 100nM PGE2, 100nM PGF2α, hypoxia (0.5% O2) or 
prostaglandins and hypoxia (Figure 57A-D). 
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Figure 57. The effect of prostaglandins and hypoxia on endometrial explant 
prostaglandin receptor expression. (A) EP2 mRNA in endometrial explants from 
the proliferative phase treated with vehicle, 100nM PGE2, hypoxia or PGE2 and 
hypoxia for 24h (n=3). (B) EP2 mRNA in secretory tissue explants treated in an 
identical manner (n=3). (C) FPS mRNA in endometrial explants from the 
proliferative phase treated with vehicle, 100nM prostaglandin F2α, hypoxia or PGF2α -
and hypoxia for 24h (n=3). (D) FPS mRNA in secretory phase explants treated 
identically (n=3). N: normoxia (21% O2), H: hypoxia (0.5% O2), V: ethanol vehicle, 
PGE2: 100nM prostaglandin E2, PGF2α: 100nM prostaglandin F2α. 
Proliferative Explants (EP2)








































































































The in vitro, ex vivo and in vivo experiments described in this chapter reveal that 
endometrial repair factors are increased after treatment with prostaglandins and 
hypoxia. Exposure to progesterone and its subsequent withdrawal appears essential 
before prostaglandins and hypoxia can initiate expression of IL-8, AM and VEGF for 
endometrial repair. Although data in the results section of this chapter are presented 
by gene, this discussion focuses on the application of these individual results to 
overall endometrial processes and their regulation.  
4.4.1 The role of oestrogen in endometrial repair 
As oestradiol is the dominant hormone in the proliferative phase, it was traditionally 
thought to regulate endometrial repair and remodelling. However, there is mounting 
evidence that oestrogen is not required for the initial stages of repair. Firstly, electron 
microscopy and hysteroscopy studies of the human endometrium have revealed that 
endometrial repair commences during active bleeding, when oestrogen levels remain 
low (Ludwig and Spornitz, 1991, Garry et al., 2009). In addition, early human 
endometrial repair takes place in the absence of ovarian hormones, e.g. after 
ovariectomy. 
 
Ovariectomised animal models provide further support for the oestrogen independent 
nature of endometrial repair. In the mouse model of simulated menstruation (Kaitu'u-
Lino et al., 2007a), ovariectomised mice were exposed to cyclical E2 and 
progesterone. After initiation of decidualisation, progesterone implants were 
withdrawn to simulate menstruation. One group of mice were given subcutaneous 
injections of 17β oestradiol from the time of progesterone withdrawal. The other 
group were given injections of letrozole, a third generation aromatase inhibitor, in 
place of E2. In addition, the oestrogen deplete group were maintained on a soy free 
diet to prevent extra ovarian oestrogen exposure. No significant difference in the rate 
of endometrial repair was observed between the two groups.  
 
Studies in the ovariectomised macaque model concur with findings in the mouse. On 
examination of the endometrial repair factor VEGF, there were three peaks of mRNA 
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expression; in the surface epithelium during the simulated early proliferative phase, 
in the stroma during the mid proliferative phase and in the glands during the late 
secretory phase. Comparison of hormone deprived and E2 exposed animals revealed 
that E2 was not essential for the early proliferative phase peak but was necessary for 
the increase in stromal VEGF during the mid-proliferative phase. Authors concluded 
that VEGF played a dual role in the endometrium. Firstly, to repair vessels damaged 
at menstruation, which occurs during the early proliferative phase. This does not 
require the presence of oestrogen. Secondly, that VEGF contributes to endometrial 
remodelling during the mid-proliferative stage of the cycle; an event with an absolute 
requirement for oestrogen (Nayak and Brenner, 2002). The same ovariectomised 
macaque model revealed that fibronectin, a large glycoprotein that interacts with 
specific integrins to enhance cell adhesion and migration during wound repair (Kim 
et al., 1992), is also up-regulated by progesterone withdrawal (Cao et al., 2007). 
Again, the 50 fold increase in fibronectin expression observed in menstrual versus 
secretory phase endometrium, was independent of oestrogen. 
4.4.2 Progesterone withdrawal in the regulation of endometrial repair 
As initial endometrial repair appears to occur in the absence of E2, it was 
hypothesized that progesterone withdrawal was the trigger for endometrial repair 
factor expression. Herein, we have demonstrated that prostaglandins and hypoxia 
independently up-regulate IL-8 and AM mRNA in endometrial explants that have 
had prior progesterone exposure. To test this hypothesis, proliferative phase 
endometrial explants were subjected to a previously described ex vivo model of 
progesterone antagonism (Critchley et al., 2003), to mimic the progesterone 
withdrawal that occurs in vivo during the late secretory phase. When explants were 
co-treated with progesterone and a progesterone receptor antagonist, there was no 
significant increase in IL-8, VEGF, AM or CTGF mRNA when compared to 
explants maintained in progesterone. However, when progesterone is withdrawn in 
vivo the spiral arterioles constrict, resulting in a hypoxic episode that was not 
accounted for in this ex vivo model. Further explants from the same biopsies, 
therefore, were treated in an identical manner but placed in a hypoxic chamber. 
Progesterone withdrawal in hypoxic conditions significantly increased IL-8, VEGF 
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and AM expression when compared to explants treated in normoxic conditions. 
Addition of the COX inhibitor indomethacin abrogated this up-regulation. These data 
suggest that progesterone withdrawal does up-regulate endometrial repair factors but 
only in the presence of hypoxia and prostaglandins. An alternative explanation for 
the findings in this ex vivo progesterone antagonism model may be that increased 
endometrial repair factor expression is secondary to inhibition of the glucocorticoid 
receptor (GR). Mifepristone (RU486) is not only a progesterone receptor antagonist 
but also a GR antagonist.  To further explore this, tissue explants were exposed to 
natural progesterone, followed by its withdrawal. In this model, VEGF mRNA was 
only significantly increased when progesterone was withdrawn in hypoxic 
conditions. These results are consistent with findings following progesterone 
antagonism. Further analysis of AM, IL-8 and CTGF expression in the progesterone 
withdrawal model is necessary. Interestingly, CTGF mRNA was significantly 
decreased by hypoxic conditions in the progesterone antagonism model. Data from 
cell experiments revealed that hypoxic induction of CTGF was rapid, occurring by 
2h. Therefore, exposure of endometrial tissue to prolonged hypoxia may mask the 
induction of CTGF. Unfortunately, due to limited tissue availability, these 
experiments could not be repeated with shorter incubation times.  
 
To further examine the contribution of progesterone to endometrial repair, 
endometrial biopsies were collected from women before and 3-6 months after LNG-
IUS insertion for treatment of HMB. LNG-IUS insertion has been shown to 
dramatically down-regulate endometrial progesterone receptors, hence provides an in 
vivo model of “progesterone deficiency” (Critchley et al., 1998) (Critchley et al., 
2006a). In addition, progestogen exposure has been shown to reduce endometrial 
perfusion and profoundly decrease vasomotion (Hickey et al., 2006). This may lead 
to endometrial hypoxia. Endometrial samples collected 3-6 months after LNG-IUS 
insertion showed significant increases in IL-8, AM and VEGF expression. As the 
normal endometrial architecture is maintained in this in vivo model, these findings 
support the role of progesterone withdrawal and downstream hypoxia in the up-
regulation of endometrial repair factors. Alternatively, the increased expression of 
these endometrial factors after local exposure to levonorgestrel may be due to 
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induction of decidualisation. Angiogenic factors appear essential for implantation 
and early pregnancy and have been identified in first trimester decidua tissue 
(Marinoni et al., 2004, Wei et al., 2004). The LNG-IUS is well established as a 
treatment for HMB and its stimulation of repair factor production may contribute to 
its efficacy. 
 
The elevation in IL-8 mRNA seen in this LNG-IUS in vivo model of progesterone 
“deprivation” is comparable to the findings in endometrial samples from women 
taken 48h after withdrawal of vaginal progesterone administration, versus 
endometrium from controls during the normal mid-secretory phase (Critchley et al., 
1999). This study detected significantly increased IL-8 and COX-2 mRNA 48h after 
progesterone withdrawal. However, findings in this chapter are in contrast to 
microarray analysis of endometrium taken from women 24h after a single dose of 
mifepristone, to simulate progesterone withdrawal in vivo (Catalano et al., 2007). IL-
8, AM or VEGF were not found to be differentially expressed between the treated 
group and normal controls in the mid-secretory phase. This discrepancy may be 
explained by the timing of the endometrial biopsy. If progesterone withdrawal 
stimulates COX-2 to induce synthesis of prostaglandins and a hypoxic episode, 
which in turn increase the expression of repair factors, it follows that the time from 
progesterone withdrawal to repair factor up-regulation is likely to exceed 24h. 
Sampling of endometrium pre- and 48h post-mifepristone administration may reveal 
significant increases in IL-8, AM and VEGF mRNA, similar to that seen in 
endometrium exposed to the LNG-IUS. Similarly, another study examined gene 
expression in mid- versus late-secretory endometrial biopsies as a model of 
physiologic progesterone withdrawal (Critchley et al., 2006c). Gene array technology 
failed to identify significant increases in IL-8, AM or VEGF mRNA between the two 
groups. Functional analysis of the genes that were differentially expressed between 
mid- and late-secretory endometrium identified bioprocesses such as haemostasis, 
steroid biosynthesis and prostaglandin metabolism. These processes are consistent 
with the early response to progesterone withdrawal and support the hypothesis that 
endometrial repair factors are induced greater than 48h after progesterone 
withdrawal.  
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4.4.3 The role of hypoxia in the regulation of endometrial repair factors 
Although the contribution of hypoxia to the initiation of menstruation is currently 
controversial (Zhang and Salamonsen, 2002), the results described in this chapter 
support an important role for hypoxia in the initiation of endometrial repair, through 
IL-8, AM and VEGF induction. Evidence for the presence of a transient hypoxia in 
the uppermost endometrial zones during the peri-menstrual phase is discussed in 
Chapter 1.5.1.  The hypoxic regulation of angiogenic factors is well described in 
pathological conditions, such as the hypoxic environment within a tumour (Sivridis 
et al., 2002, Carmeliet, 2005, Nikitenko et al., 2006b). Hypoxic regulation of IL-8 
has been demonstrated in lung macrophages (Hirani et al., 2001) and may be 
associated with the onset of acute respiratory distress syndrome. Induction of AM 
expression by hypoxia has been seen in canine kidney cells (Nagata et al., 1999) and 
has also been identified in the placenta of women with pre-eclampsia (Gratton et al., 
2003). The role of hypoxia in the regulation of angiogenic factors in physiological 
situations is less well documented. Previous studies have shown hypoxic induction of 
VEGF in isolated endometrial stromal and epithelial cells (Sharkey et al., 2000) and 
results herein support these findings. Of note, the response to hypoxia differed 
between EP2S and FPS cells. Reasons for this variation are unclear but may be 
secondary to the transfection process; therefore findings were confirmed with 
endometrial explant studies where possible. The hypoxic induction of IL-8, AM, 
VEGF and CTGF in an endometrial cell line, primary human endometrial cells and 
endometrial tissue, support a role for local hypoxia in endometrial repair.   
4.4.4 The role of prostaglandins in the regulation of endometrial repair 
factors 
Following the decline in progesterone levels during the late secretory phase, 
endometrial COX-2 mRNA is increased and subsequently stimulates prostaglandin 
synthesis (Critchley et al., 1999, Baird et al., 1996) (See Figure 3, Chapter 1). 
Examination of COX-2 deficient mice revealed multiple reproductive failures, 
including ovulation, fertilization, implantation and decidualisation (Langenbach et 
al., 1999a, Langenbach et al., 1999b, Dinchuk et al., 1995). COX-2 and subsequent 
production of PGE2 has been demonstrated to have a role in the regulation of 
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endometrial cell survival and migration (Banu et al., 2008). Endometrial PGE 
synthase, PGE2 and the EP2/EP4 receptors have all been detected in the human 
endometrium throughout the menstrual cycle (Milne et al., 2001). Endometrial 
cAMP generation in response to PGE2 was significantly greater in proliferative 
versus early- to mid-secretory tissue. Similarly, the PGF2α receptor (FP) has also 
been identified in the  human endometrium, with significantly greater mRNA 
expression during the proliferative versus secretory phase (Milne and Jabbour, 2003). 
PGE2 and PGF2α are emerging as potential key players in the initiation of endometrial 
repair factors. Both of these prostaglandins have previously been shown to increase 
angiogenic factors in cancer cells (Sales et al., 2005, Sales et al., 2004, Fukuda et al., 
2003, Keightley et al., 2010, Sales et al., 2009). The findings described in this 
chapter support and extend these studies, by describing increases in IL-8, AM and 
VEGF on exposure to PGE2/ PGF2α in normal human endometrial explants. 
Interestingly, PGF2α significantly up-regulated endometrial AM expression but PGE2 
had no such effect, suggesting each prostaglandin has a specific endometrial action. 
Inflammatory cytokines, such as tumour necrosis factor alpha and interleukin 1β, 
have previously been shown to regulate AM expression (Hofbauer et al., 2002), but 
data presented in this chapter is the first report of AM regulation by PGF2α. Due to 
time and the constraints of tissue availability, the contribution of prostacyclin (PGI) 
was not examined herein. A previous study of endometrial tissue explants treated 
with 100nM iloprost (a PGI analogue) revealed significant increases in the 
expression of the angiogenic genes bFGF, Ang-1 and Ang-2 (Smith et al., 2006), 
suggesting it may also contribute to the induction of endometrial repair. Interestingly, 
the increases in endometrial repair factors described in this chapter were limited to 
endometrial tissue that had been exposed to progesterone. To determine if this effect 
was due to differences in prostaglandin receptor expression, EP2 and FP gene 
expression was examined in explants after 24h treatment. There were no significant 
differences in receptor expression after treatment with PGE2, PGF2α or hypoxia 
(Figure 57). These results suggest that the differences in repair gene expression were 
not a consequence of varied prostaglandin receptor expression. These findings are 
supported by the identification of EP2 and FP protein by immunohistochemistry in 
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both proliferative and secretory endometrial tissue (Milne and Jabbour, 2003, Milne 
et al., 2001). 
4.4.5 Summary 
The in vitro, ex vivo and in vivo models detailed in this chapter demonstrate that 
PGE2, PGF2α and hypoxic conditions have a role in the endometrial expression of the 
repair factors IL-8, AM, VEGF and CTGF. Tissue explant studies have revealed that 
exposure to progesterone, followed by its withdrawal, is necessary to allow 
prostaglandins and hypoxia to take effect. These experiments detail a potential 
mechanism for the initiation of repair factors in the perimenstrual human 




Figure 58. Up-regulation of repair factors in the perimenstrual 
endometrium. Elevated COX-2 following progesterone withdrawal induces 
synthesis of PGE2 and PG F2α. PG F2α is a potent vasoconstrictor and, alongside 
other vasoconstrictors, causes an episode of transient hypoxia in the superficial 
endometrial zones. Progesterone withdrawal, prostaglandins and hypoxic conditions 
are required to increase endometrial repair factors. Interaction between these 
pathways may lead to synergistic increases in repair factor mRNA expression.  
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As detailed in Chapter 4, hypoxic conditions and prostaglandins can significantly 
increase endometrial repair factors. These effects may be mediated via hypoxia 
inducible factor-1 (HIF-1), a heterodimeric transcription factor known to regulate the 
cellular response to hypoxia at other tissue sites. HIF was first identified in the 
kidney, where it was found to have a role in the regulation of erythropoietin 
transcription (Wang et al., 1995). Subsequently, over one hundred genes have been 
identified as transcriptional targets of HIF, reviewed in (Wiesener and Maxwell, 
2003). These downstream targets include genes involved in glucose uptake and 
metabolism, extracellular matrix remodelling/digesting proteinases (Krishnamachary 
et al., 2003) and angiogenic/tissue repair genes such as vascular endothelial growth 
factor (VEGF), connective tissue growth factor (CTGF), endothelin (ET), and 
angiopoietin 2 (Ang-2) (Semenza, 2000, Smith, 2001, Higgins et al., 2004).  
 
The HIF complex is composed of an α and a β subunit. The α subunit is oxygen-
regulated (Wang et al., 1995, Jiang et al., 1997), whereas the β subunit is 
constitutively expressed. When oxygen is abundant, the HIF-1α subunit is 
hydroxylated at two proline residues by a group of prolyl hydroxylases (PHDs). 
These enzymes utilize oxygen and the tricyclic acid cycle intermediate 2-
oxyglutarate as substrates (Bruick and McKnight, 2001). Hydroxylation facilitates 
binding of the von Hippel-Lindau (VHL) protein and the VHL-HIF complex is 
rendered a target for the E3 ubiquitin-protein ligase, leading to proteasomal 
degradation (Jaakkola et al., 2001, Maxwell et al., 1999). During hypoxic conditions 
hydroxylation cannot take place and HIF-1α escapes proteasomal degradation. This 
allows dimerisation with HIF-1β to form an active transcription complex. In the 
ferret lung, it has been demonstrated that HIF-1α protein is stabilised in an oxygen 
concentration-dependent manner, with maximal expression after 4h of 0-1% oxygen 
ventilation (Yu et al., 1998). On reoxygenation, HIF-1α was rapidly degraded, with a 
half life of less than 1 minute. This tight regulation of HIF-1α gives it an attractive 
role in the induction of endometrial repair factors, allowing their specific up-
regulation during menstruation. 
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Although hypoxia is the archetypal stimulus for HIF-1α, normoxic mechanisms of 
HIF-1α induction have also been identified. A number of inflammatory stimuli, such 
as TNF-α, endotoxin, IL-1β and prostaglandins have been shown to increase HIF-1α 
translocation, translation or transcription to overcome proteosomal degradation in 
normoxic conditions at other tissue sites (Haddad and Land, 2001, Blouin et al., 
2004, Fukuda et al., 2003, Frede et al., 2005). In the endometrium, HIF-1α protein 
has been co-localised with the EP2 receptor using dual immunohistochemistry 
(Critchley et al., 2006b). Furthermore, this study revealed that PGE2 stimulated HIF-
1α mRNA and protein in endometrial cells in normoxia. In contrast, other studies of 
endometrial tissue have failed to identify nuclear HIF-1α protein immunostaining 
(Zhang and Salamonsen, 2002), making its role in endometrial physiology 
controversial. 
 
The working hypothesis for this chapter was that hypoxia and prostaglandins 
increase endometrial repair factors via induction of the transcription factor HIF-1. 
The aim of this chapter was to identify nuclear HIF-1α in the human endometrium by 
studying endometrial biopsies collected at well defined stages of the menstrual cycle. 
In addition, the induction of HIF-1α mRNA and protein in endometrial cells was 
examined. Finally, the effect of inhibition of HIF-1 on endometrial repair factor 
expression was investigated using HIF-1α silencing and pharmacological inhibition 
of HIF-1 binding. 
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5.2 Methods 
5.2.1 Tissue collection 
Endometrial tissue was collected and classified as menstrual, proliferative, early 
secretory, mid secretory and late secretory as described in Chapter 2.1. The 
endometrial biopsies used in Q-RT-PCR studies in this chapter (n=41) are detailed in 
table 5 (Chapter 3.2.1). Endometrial tissue samples examined for HIF-1α protein are 























Menstrual 2 2, 3 308 (102-514) 3.90 (1.24-6.49) 
Proliferative 4 8-16 484 (1.3-1105) 2.07 (1.51-2.47) 
Early secretory 3 16-20 684 (547-841) 52.63 (32.79-65.19) 
Mid secretory 3 21-23 415 (301-613) 62.76 (42.74-82.5) 




5.2.2 Cell culture 
Human endometrial epithelial cells (Ishikawa) were transfected with the EP2 or FP 
receptor (EP2S and FPS respectively) and maintained in culture as described in 
Chapter 2.3.3.  
• Approximately 4 x 105 EP2S or FPS cells were seeded in 6 well plates. The 
following day, cells were washed in PBS and incubated in serum-free culture 
medium containing antibiotics and 8.4 μM indomethacin for at least 16h. To 
determine the contribution of HIF-1, cells were pre-treated with vehicle or 1, 
2, 5 or 10nM echinomycin (an inhibitor of HIF-1 DNA binding activity) for 1 
h. Cells were then stimulated with vehicle, 100nM PGF2α or PGE2 ± 
echinomycin, or placed in a hypoxic chamber (Coy laboratory products, 0.5% 
O2, 5% CO2)  ± echinomycin for 8h (n=3 separate experiments). 
• Approximately 1x106 EP2S or FPS cells were seeded in 10cm petri dishes. 
The next day, cells were washed in PBS and incubated with 8.4µM 
indomethacin as above. Cells were then treated with vehicle, 100nM PGE2, 
hypoxic conditions (0.5% O2, 5% CO2) or with 8.4µM indomethacin and 
hypoxia for 2, 4, 8, and 24h. Cells were then washed with ice cold PBS, 
scraped into a 1ml eppendorf, centrifuged at 13000rpm for 30s and the pellet 
resuspended in cytoplasmic protein lysis buffer to commence the nuclear 
protein extraction protocol (Chapter 2.5.1). 
5.2.3 HIF-1α silencing 
EP2S and FPS cells were transfected with SiRNA or ShRNA constructs against HIF-
1α as described in Chapter 2.9. To confirm the efficiency of HIF-1α mRNA 
knockdown and its specificity, cells were washed in PBS 24h after the end of the 
transfection period (i.e. prior to time of PG/hypoxic stimulation) and RNA extracted. 
To confirm knockdown at the protein level, cells were incubated in hypoxic 
conditions (0.5% O2) for 8h prior to nuclear protein extraction. 
5.2.4 Inhibition of NFkB 
To determine the contribution of NFκB to endometrial repair factor expression, EP2S 
cells were seeded at a density of 1x105. The following day, cells were infected with 
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an adenovirus containing a dominant negative IκBα mutant, which maintains NFκB 
in a cytoplasmic location, or control adenovirus (Ad-d1703) at a total MOI of 50 for 
8h. Ad-d1703 and Ad-IκBα have been described previously (Jobin et al., 1997, 
Henriksen et al., 2004). Cells were then serum starved with 8.4μM indomethacin for 
at least 16h before treatment with 100nM PGE2 or hypoxic conditions for 6h.  
5.2.5 RNA extraction and Q-RT-PCR 
RNA was extracted from endometrial biopsies (n=41) and endometrial cells after 
culture. cDNA was prepared and Q-RT-PCR performed as detailed in general 
materials and methods (Chapter 2.4). Expression of mRNA for HIF-1α was 
measured in endometrial biopsies and IL-8, AM and VEGF mRNA levels quantified 
in cultured cells (see Table 3, Chapter 2 for primer/probe sequences). 
5.2.6 Nuclear Protein extraction  
Nuclear protein was extracted from endometrial cells and tissue biopsies, using the 
methodology described in Chapter 2.5.1. Nuclear protein extracts were also obtained 
from endometrial tissue using the protocol described in Chapter 2.5.2. 
5.2.7 Immunohistochemical staining for HIF-1α 
HIF-1α protein was localised in endometrium using the protocol described in 
Chapter 2.6. and Table 4. Endometrial explants from the proliferative phase were 
incubated in serum free RPMI media in a sealed hypoxic chamber (0.5% O2, 5% 
CO2, Coy laboratory products) for 24h before wax embedding. This “hypoxia 
exposed” endometrium was included as a positive control for HIF-1α 
immunohistochemistry staining. 
5.2.8 Western Blot HIF-1α 
HIF-1α protein was detected by Western blotting in endometrial tissue from across 
the menstrual cycle (n=8) using methods described in Chapter 2.5.3, 2.5.4 and 2.5.5. 
β-actin was detected in nuclear extracts as a housekeeping control protein. 
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5.2.9 Immunoprecipitation of HIF-1α 
15µl of nuclear protein extract was diluted in 150µl PBS with protease inhibitors 
(Roche, UK). 1µl rabbit anti-human HIF-1α antibody (Santa Cruz, CA, USA) or 
mouse anti-human HIF-1α (NB 100-105) (Novus Biological, Cambridge, UK) was 
added and incubated on ice on a rocking platform for 1h. 20µg of IgG agarose beads 
(Santa Cruz) were added and incubated for a further 2h on ice. The samples were 
then centrifuged at 14000rpm for 1min, the supernatant discarded and the sample 
resuspended in 100µl PBS/protease inhibitor. This centrifugation process was 
repeated twice before resuspending the pellet in 30µl Laemmli buffer (See 2.5.3) and 
performing Western blotting for HIF-1α (Chapter 2.5.4 and 2.5.5). 
5.2.10 Statistical analysis 
For mRNA data results are expressed as fold increase, for which relative expression 
of mRNA in treated samples was divided by the relative expression in vehicle-treated 
samples. Data are presented as mean +/- SEM. Significant difference was determined 
using one-way ANOVA of dCt values, with Tukey’s post test analysis. 
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5.3 Results 
5.3.1 HIF-1α immunohistochemical staining 
Endometrium from different phases of the menstrual cycle was stained with an anti-
human HIF-1α rabbit polyclonal antibody. Even after optimisation, this revealed 
nuclear staining and non-specific cytoplasmic staining for HIF-1α (Figure 59). 
Proliferative endometrial tissue pre-incubated in hypoxic conditions for 24h before 
wax embedding was used as a positive control. HIF-1α was detected in the glandular 
epithelial (GE) cells and in very occasional stromal cells of this tissue (Figure 59A). 
When this tissue was stained with concentration matched IgG as a negative control 
(Figure 59B) there was strong cytoplasmic staining in the GE and some stromal cells 
but no nuclear staining. Staining of menstrual phase endometrium (Figure 59C and 
E) did show occasional nuclear staining for HIF-1α in GE cells. Assessment of the 
stromal cell compartment was difficult due to poor tissue quality at this cycle stage. 
Menstrual tissue stained with concentration matched IgG, displayed non-specific 
cytoplasmic staining of the stromal cells but no nuclear staining (Figure 59D). 
Proliferative, mid-secretory and late secretory endometrium (Figures 59E-G 
respectively) showed minimal cytoplasmic staining only, with no positive nuclear 
cells identified. Although positive nuclear staining for HIF-1α was only observed in 
menstrual endometrial tissue, the lack of specificity of the antibody used necessitated 
further analysis of endometrial HIF-1α protein (section 5.3.2). 
5.3.2 HIF-1α Western blot 
Due to the lack of specificity of immunohistochemical staining, a Western blot for 
HIF-1α was optimised to assess and quantify HIF-1α in nuclear protein extracts from 
endometrium at different stages of the menstrual cycle. Optimisation was carried out 
on nuclear extract from EP2S cells incubated in normoxic or hypoxic conditions for 
24h (Figure 60A, B). Reduction of the concentration of the secondary antibody and a 
change of detergent wash buffer resulted in a clean band at 120kDa that was specific 
to hypoxic cells (Figure 60B). Unfortunately, adaptation of the cellular nuclear 
extraction and Western blot protocols for frozen endometrial tissue biopsies was 











Figure 59. Immunohistochemical staining for hypoxia inducible factor-1α 
(HIF-1α) in the human endometrium. (A) Positive control: proliferative 
endometrium cultured in hypoxic conditions (0.5% O2) for 24h prior to wax 
embedding and stained with anti-HIF-1α antibody, (B) Negative control: the same 
hypoxic proliferative tissue stained with concentration matched IgG, (C) Menstrual 
endometrium (D) Negative control: the same menstrual tissue stained with IgG, (E) 
Menstrual endometrium, (F) Proliferative endometrium, (G) Mid-secretory 
endometrium, (H) Late-secretory endometrium. GE: glandular epithelial cells, SE: 







































Figure 60. Optimisation of Western blot protocol for examination of HIF-1α 
in endometrial cell nuclear protein extracts. (A) Initial Western blot for HIF-1α in 
EP2S cells cultured for 24h in normoxic (N: 21% O2) and hypoxic (H: 0.5% O2) 
conditions, (B) Optimised Western blot for HIF-1α in EP2S cells, with beta actin as 
housekeeping control. Note the specific band at 120kDa when cells were incubated 
in hypoxic conditions, indicating stabilisation of HIF-1α. 
120kDa (HIF-1α) 
42kDa (β-actin) 















Figure 61. Western blot for HIF-1α in human endometrial tissue. Nuclear 
protein was extracted from endometrial biopsies using the protocol described in 
Chapter 2.5.1 before performing a Western blot for HIF-1α. Minimal HIF-1α protein 
was detected using these methods. M: menstrual, P: proliferative, MS: mid secretory, 
LS: late secretory, H: hypoxic EP2S cells as a positive control.  
120kDa (HIF-1α) 
42kDa (β-actin)
     P         MS           LS           M            M            LS           H 
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As endometrial HIF-1α may be present in very low levels, immunoprecipitation of 
HIF-1α protein from endometrial tissue nuclear protein extracts was attempted. 
Despite trial of two different antibody combinations and inclusion of protease 
inhibitors to prevent HIF-1α degradation during the IP process, this method was also 
unsuccessful in obtaining a clean 120kDa band and yielded inconclusive results 
(Figure 62).  
Finally, an alternate nuclear protein extraction protocol was adapted from the Active 
Motif nuclear extraction kit. Using this protocol (Chapter 2.5.2), nuclear protein 
extract was obtained from further endometrial samples from across the menstrual 
cycle.  When these extracts were subjected to Western blot for HIF-1α, an interesting 
pattern emerged. Nuclear extracts from late secretory, menstrual and very early 
proliferative (day 8) phase endometrium showed evidence of HIF-1α induction 
(Figure 63A). In contrast, there was no evidence for the presence of HIF-1α in 
extracts from the mid-late proliferative and early-mid secretory phases. 
Densitometric analysis, using β-actin as a control, revealed that maximal HIF-1α 
protein was present in menstrual phase endometrial extracts (Figure 63B).  
5.3.3 Regulation of endometrial HIF-1α protein 
Endometrial epithelial cells (EP2S) exposed to 0.5% O2 for 2, 4, 8, and 24h 
demonstrated induction of HIF-1α protein (Figure 64A). In contrast, cells exposed to 
100nM PGE2 for 2, 4, 8, and 24h before nuclear protein extraction did not display a 
band for HIF-1α on Western blot (Figure 64B). Cells exposed to hypoxia, PGE2 and 
both hypoxia and PGE2 for 8 and 24h revealed no additional increases in HIF-1α 
protein with simultaneous exposure to low oxygen levels and PGE2 (Figure 64C). To 
determine if the hypoxic induction of HIF-1α was dependent on prostaglandin 
production, EP2S cells were incubated in hypoxic conditions with and without 
8.4µM indomethacin, a COX-2 inhibitor. There was no visible difference in HIF-1α 
















Figure 62. Unsuccessful immunoprecipitation (IP) of HIF-1α using two 
different antibodies against HIF-1α (A) Santa Cruz, CA, USA and (B) Novus 
biological, Cambridge, UK. (1) proliferative nuclear extract, (2) proliferative IP, (3) 
menstrual IP, (4) mid-secretory nuclear extract, (5) mid-secretory IP, (6) menstrual 
nuclear extract, (7) menstrual IP, (8) nuclear extract from hypoxic EP2S cells as a 
positive control. (i) Menstrual nuclear extract, (ii) menstrual IP, (iii) Hypoxic EP2S 
cells IP, (iv) menstrual nuclear extract, (v) menstrual IP, (iv) hypoxic EP2S cells 
nuclear extract, (vi) hypoxic EP2S cells IP. 
 








Figure 63.  The presence of HIF-1α in nuclear protein extracts from 
endometrial tissue collected at different times during the menstrual cycle. (A) 
Western blot for HIF-1α and beta-actin in endometrial tissue from the menstrual (M), 
proliferative (P), early-secretory (ES), mid-secretory (MS) and late secretory (LS) 
phase. Numbers indicate the day of the cycle when the biopsy was collected. (B) 
Densitometric analysis of HIF-1α protein normalised against beta-actin.  
42 kDa 
(β-actin) 
     M        P         P        P      ES     ES     MS     LS   
        2            8             16          16         18          20          23         29 














































Figure 64. Hypoxia inducible factor -1α (HIF-1α) in human endometrial 
epithelial cells. (A) EP2S cells were incubated in normoxic and hypoxic conditions 
for up to 24h before nuclear protein extraction and Western blotting for HIF-1α and 
β-actin. (B) EP2S cells were incubated with vehicle or 100nM prostaglandin E2 
(PGE2) for up to 24h before nuclear protein extraction and Western blotting for HIF-
1α and β-actin. (C) EP2S cells incubated with vehicle, 100nM PGE2, hypoxic 
conditions and PGE2 plus hypoxia for 8 and 24h had nuclear protein extracts 
subjected to Western blotting for HIF-1α and β-actin. Human endometrial stromal 
(HES) cells incubated in hypoxia for 24h were used as a positive control. H: hypoxia 
(0.5% O2), N: normoxia (21% O2), V: vehicle treatment. 
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Figure 65. Hypoxic induction of HIF-1α in EP2S cells is independent of 
prostaglandin production. EP2S cells were pre-treated with vehicle or 8.4µM 
indomethacin (a COX-2 inhibitor) for 1h before treatments were replenished and 
cells placed in hypoxic conditions for up to 24h. Nuclear protein was extracted and 
subjected to Western blot for HIF-1α and β-actin. N: normoxia (21% O2), H: hypoxia 
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5.3.4 Regulation of endometrial HIF-1α mRNA  
Endometrial epithelial cells showed no significant difference in HIF-1α mRNA when 
treated with vehicle, 100nM PGE2 (EP2S cells) or PGF2α (FPS cells), hypoxic 
conditions or both hypoxia and prostaglandins simultaneously (Figure 66).  
5.3.5 Pharmacological inhibition of HIF-1 binding 
To assess the contribution of HIF-1α to endometrial repair factor expression, 
endometrial epithelial cells (EP2S and FPS) were treated with echinomycin. This 
small molecule inhibits HIF-1 binding to hypoxic response elements on target genes, 
thereby preventing HIF-1-induced transcription (Kong et al., 2005). 
EP2S cells co-treated with 5nM echinomycin and 100nM PGE2 revealed a significant 
abrogation of IL-8 mRNA, compared to cells treated with PGE2 alone (p<0.05) 
(Figure 67B). Echinomycin also reduced the hypoxic induction of IL-8 mRNA in 
these cells (p<0.05) (Figure 67C).  
Co-treatment of FPS cells with 100nM PGF2α and 1-10nM echinomycin had no 
significant effect on AM mRNA (Figure 68A). In contrast, echinomycin prevented 
AM up-regulation by hypoxia in a dose-dependent manner (Figure 68B). AM 
expression was significantly reduced in cells treated with hypoxia and 5nM-10nM 
echinomycin when compared to hypoxia treatment in the absence of echinomycin 
(p<0.01 and p<0.001 respectively). 
FPS cells in normoxia revealed a significant reduction of VEGF mRNA when co-
treated with PGF2α and 5-10nM echinomycin, versus PGF2α alone (p<0.01) (Figure 
69A). Hypoxic induction of VEGF mRNA was significantly abrogated by 5nM and 



















































































































Figure 66. The regulation of HIF-1α mRNA by hypoxia and prostaglandins. 
(A) HIF-1α mRNA in EP2S cells treated with vehicle, 100nM prostaglandin E2 
(PGE2), hypoxic conditions or PGE2 and hypoxia for 8h. (B) HIF-1α mRNA in EP2S 
cells treated with vehicle, 100nM prostaglandin E2 (PGE2), hypoxic conditions or 
PGE2 and hypoxia for 24h. (C) HIF-1α mRNA expression in FPS cells treated with 
vehicle, 100nM prostaglandin F2α (PGF2α), hypoxia or both PGF2α and hypoxia for 
8h. (D) HIF-1α mRNA in FPS cells treated with vehicle, 100nM prostaglandin F2α 
(PGF2α), hypoxia or both PGF2α and hypoxia for 24h. V: vehicle, H: hypoxia (0.5% 

























Figure 67. The impact of pharmacological inhibition of HIF-1α on 
endometrial cell IL-8 mRNA. (A) EP2S cells incubated with and without 5nM 
echinomycin in normoxic conditions showed no significant difference in IL-8 mRNA 
expression. (B) Echinomycin significantly abrogated prostaglandin E2 (PGE2) 
induced IL-8 mRNA. (C) Hypoxia induced IL-8 mRNA was significantly reduced 
when cells were treated with echinomycin. N: normoxia (21% O2), H: hypoxia (0.5% 
O2), V: vehicle, EC: 5nM echinomycin. ns: non-significant, *p<0.05. 














































































           
           
 
Figure 68. The impact of pharmacological inhibition of HIF-1α on 
adrenomedullin (AM) mRNA in endometrial epithelial cells (FPS cells). (A) 
Prostaglandin F2α (PGF2α) induced AM mRNA was not significantly reduced when 
cells were co-treated with 1-10nM echinomycin. (B) Hypoxia induced AM mRNA 
expression was significantly abrogated by co-treatment of cells with 5 and 10nM 













































































































               
Figure 69. The impact of pharmacological inhibition of HIF-1α on vascular 
endothelial growth factor (VEGF) mRNA in FPS cells. (A) Co-treatment of FPS 
cells with 100nM prostaglandin F2α (PGF2α) and 5-10nM echinomycin (EC) 
significantly abrogated the PGF2α mediated induction of VEGF expression. (B) 
Hypoxia induced VEGF mRNA was also significantly reduced with treatment of 






































































































5.3.6 Silencing of HIF-1α with RNA interference 
To confirm the findings obtained after pharmacological inhibition of HIF-1 binding, 
HIF-1α was silenced using RNA interference. First, the transfection efficiency of 
siRNA constructs into EP2S cells was tested using siGLO, an oligonucleotide 
labelled with 6-FAM fluorescent indicator. Even with siGLO concentrations of 
100nM, there were few fluorescently labelled cells 36h after transfection (Figure 70). 
Increased concentration of HiPerfect(R) transfection reagent and lengthened 
transfection times had no effect on the amount of cells transfected with siGLO. 
 
As SiRNA transfection efficiency was found to be suboptimal, short-hairpin RNA 
sequences were transfected into EP2S and FPS cells using a plasmid vector in a 
lentivirus. A lentivirus containing green fluorescent protein (GFP) was incubated 
with EP2S cells at a MOI of 1, 2, 5, and 10. This titre experiment revealed maximal 
transfection efficiency at an MOI of 10 (Figure 71). 
 
Based on these findings, two different ShRNA sequences against HIF-1α (HIF-
1α/Sh1470 and HIF-1α/Sh2192) were transfected into EP2S and FPS cells at an MOI 
of 10. Figure 72 shows the transfection efficiency of EP2S cells transfected with no 
construct (A-C), HIF-1α/Sh1470 (D-F), HIF-1α/Sh2192 (G-I) and HIF-1α/ShSCR (J-
L). FPS cells had a very similar pattern of transfection (data not shown).  
HIF-1α silencing in EP2S cells was confirmed by Western blot analysis (Figure 
73A), revealing a visible reduction in HIF-1α protein with both HIF-1α/ShRNA 
constructs compared to untransfected cells and cells transfected with HIF-1α/ShSCR.  
These findings were confirmed at the mRNA level using Taqman Q-RT-PCR (Figure 
73B). Specificity of the EP2S cell HIF-1α knockdown was confirmed with 
measurement of Lamin A/C mRNA levels, which showed no significant differences 
with transfection of any construct (Figure 73C). Very similar findings were found on 
transfection of FPS cells (Figure 74A-C). 
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Figure 70. Transfection of EP2S cells with short interfering RNA (siRNA) 
constructs. EP2S cells were incubated with 100nM SiGLO and 1:100 HiPerfect 
transfection reagent for 8h and photographed 36h after transfection. (A) Phase 
contrast image (B) GFP expression (C) Superimposed images to show number of 





                            
                             
                                




Figure 71. Transfection of EP2S cells with short hairpin RNA (ShRNA) 
constructs.  ShRNA constructs labelled with green fluorescent protein (GFP) were 
incorporated into lentiviral vectors and incubated with EP2S cells for 24h at a 
multiplicity of infection of (A) 2, (B) 5 or (C) 10. Photographs were taken 24h after 







Figure 72. Confirmation of transfection efficiency of ShRNA constructs 
against HIF-1α in EP2S cells. (A) Untransfected control cells in phase contrast (B) 
GFP expression in untransfected control cells (C) Superimposed images of 
untransfected control cells (D) Cells transfected with HIF-1α/Sh1470 in phase 
contrast (E) GFP expression in cells transfected with HIF-1α/Sh1470 (F) 
Superimposed images of cells transfected with HIF-1α/Sh1470 (G) Cells transfected 
with HIF-1α/Sh2192 in phase contrast (H) GFP expression in cells transfected with 
HIF-1α/Sh2192 (I) Superimposed images of cells transfected with HIF-1α/Sh2192 
(J) Cells transfected with ShSCR in phase contrast (K) GFP expression in cells 
transfected with ShSCR (L) Superimposed images of cells transfected with ShSCR. 
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Figure 73. Confirmation of hypoxia inducible factor-1α (HIF-1α) silencing in 
endometrial epithelial (EP2S) cells. (A) Confirmation of HIF-1α protein 
knockdown by two short hairpin sequences against HIF-1α (HIF-1/Sh1470 and HIF-
1α/Sh2192), compared to a scrambled sequence (ShSCR) or untransfected cells after 
8h in hypoxic conditions (0.5% O2). (B) Confirmation of HIF-1α mRNA knockdown 
by the same sequences. (C) Specificity of the knockdown was confirmed by 
examining Lamin A/C mRNA, which showed no significant changes with 
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Figure 74. Confirmation of hypoxia inducible factor silencing in FPS cells. 
(A) Confirmation of HIF-1α protein knockdown by two short hairpin sequences 
against HIF-1α (HIF-1/Sh1470 and HIF-1α/Sh2192), compared to a scrambled 
sequence (ShSCR) or untransfected cells after 8h in hypoxic conditions (0.5% O2). 
(B) Confirmation of HIF-1α mRNA knockdown by the same sequences. (C) 
Specificity of the knockdown was confirmed by examining Lamin A/C mRNA 
expression, which showed no significant changes with transfection of any construct. 
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IL-8 mRNA did not differ significantly between untransfected EP2S cells and cells 
transfected with a scrambled ShRNA sequence when exposed to PGE2 or hypoxia 
(Figure 75). Silencing of HIF-1α did not significantly alter PGE2 mediated IL-8 
mRNA when compared to untransfected cells. There was a reduction in IL-8 mRNA 
with HIF-1α/Sh1470 transfection but this was only significantly reduced compared to 
ShSCR transfected cells (p<0.001). Hypoxia mediated IL-8 mRNA was significantly 
reduced upon transfection with HIF-1α/Sh1470 versus non-transfected cells (p<0.05) 
and those transfected with ShSCR (p<0.01). Transfection of the second ShRNA 
sequence against HIF-1α (HIF-1α/Sh2192) did not result in a significant change in 
hypoxia mediated IL-8 mRNA expression when compared to untransfected cells or 
ShSCR transfected cells (Figure 75). 
 
Consistent with data generated using echinomycin, HIF-1α silencing had no 
significant impact on PGF2α induced AM mRNA in FPS cells (Figure 76A). 
However, hypoxic induction of AM was significantly lower in those cells in which 
HIF-1α was silenced, when compared to untransfected cells or cells transfected with 
HIF-1α/ShSCR (p<0.05) (Figure 76B). 
 
In discordance with the data generated using echinomycin, HIF-1α silencing in FPS 
cells resulted in no significant differences in PGF2α-induced VEGF mRNA 
expression (Figure 77A). Hypoxic induction of VEGF mRNA was significantly 
abrogated in cells transfected with HIF-1α/Sh1470 and HIF-1α/Sh2192 when 
compared to untransfected or HIF-1α/ShSCR transfected FPS cells (Figure 77B).  
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Figure 75. The impact of hypoxia inducible factor-1α (HIF-1α) silencing on 
EP2S cell IL-8 mRNA. (A) Silencing of HIF-1α with two short hairpin sequences 
against HIF-1α (Sh1470 and Sh2192) had no significant effect on prostaglandin E2 
(PGE2) mediated IL-8 mRNA when compared to untransfected cells. (B) Hypoxia 
mediated IL-8 mRNA expression was significantly reduced by transfection with 
Sh1470 but not Sh2192. ShSCR: scrambled ShRNA sequence, hypoxia: 0.5% O2, ns: 


























































































           
           
 
Figure 76. The impact of hypoxia inducible factor-1α (HIF-1α) silencing on 
FPS cell adrenomedullin (AM) mRNA. (A) Silencing of HIF-1α with two different 
ShRNA constructs (Sh1470 and Sh2192) had no significant impact on prostaglandin 
F2α (PGF2α) induced AM mRNA. (B) Hypoxia induced AM mRNA was significantly 
reduced by HIF-1α silencing when compared to untransfected cells or cells 
transfected with a scrambled sequence (ShSCR). ns: non-significant, a-b p<0.001, b-


























































































           
            
 
 
Figure 77. The impact of hypoxia inducible factor-1α (HIF-1α) silencing on 
FPS cell vascular endothelial growth factor (VEGF) mRNA expression. (A) 
Silencing of HIF-1α with two different ShRNA constructs (Sh1470 and Sh2192) had 
no significant impact on prostaglandin F2α (PGF2α) induced VEGF mRNA 
expression. (B) Hypoxia induced VEGF mRNA was significantly reduced by HIF-1α 
silencing when compared to untransfected cells or cells transfected with a scrambled 





























































































5.3.7 Inhibition of NFkB in EP2S cells 
To determine the contribution of NFκB to the up-regulation of endometrial IL-8, 
cells were infected with a dominant negative inhibitor of NFκB, adenovirus IκBα 
(Ad-IκBα) and subsequently cultured with vehicle, PGE2 or in hypoxic conditions for 
6h. Infection of cells with Ad-IκBα resulted in significant reduction of PGE2 induced 
IL-8 mRNA (p<0.05), when compared to uninfected cells or cells infected with 
control adenovirus-d1730 (Figure 78B). Hypoxia induced IL-8 mRNA was not 













Figure 78. The impact of inhibition of nuclear factor kappa B (NF-κB) on 
IL-8 mRNA in endometrial epithelial cells (EP2S). (A) Infection of EP2S cells 
with a dominant-negative inhibitor of NF-κB (Ad-IκBα) or control adenovirus (Ad-
d1730) had no significant impact on basal IL-8 mRNA. (B) Cells infected with Ad-
IκBα demonstrated significant abrogation of prostaglandin E2 (PGE2) induced IL-8 
mRNA when compared to uninfected cells or those infected with Ad-d1703. (C) 
Infection of cells with Ad- IκBα had no significant effect on the hypoxic induction of 





               


















































               
































These data confirm the presence of nuclear HIF-1α protein in the human 
endometrium. Importantly, HIF-1α could only be detected during the perimenstrual 
phase. In addition, novel results detailed in this chapter demonstrate two pathways of 
endometrial repair factor regulation; a hypoxia mediated pathway that is dependent 
upon HIF-1α and a HIF-1α independent pathway that is activated by PGF2α. 
5.4.1 Endometrial HIF 
HIF-1α has previously been detected in the human endometrium. In a study of 
angiogenesis in endometrial carcinoma tissue, normal endometrial controls 
demonstrated positive nuclear HIF-1α immunostaining (Sivridis et al., 2002). HIF-1α 
was detected in the glandular epithelial and stromal cells of very early proliferative 
samples, with decreased staining in tissues from the mid-late proliferative and 
secretory phases. In a study of normal endometrial tissue from across the menstrual 
cycle, HIF-1α was detected by immunohistochemistry exclusively in the secretory 
and menstrual phases, with maximal levels after progesterone withdrawal (Critchley 
et al., 2006b). A further study of normal endometrium from the menstrual and 
proliferative phases revealed maximal positive immunohistochemical HIF-1α 
staining in the glandular and stromal compartments of endometrium from cycle days 
2-5 (Punyadeera et al., 2006). However, another study found very little staining for 
HIF-1α in endometrial tissue, regardless of cycle stage (Zhang and Salamonsen, 
2002). These authors reported that 20 out of 34 endometrial tissues examined had no 
positive immunohistochemical staining for HIF-1α, including two full thickness 
hysterectomy specimens from the perimenstrual phase.  
 
These studies consistently show that localisation of HIF-1α is maximal in glandular 
epithelial cells but results are conflicting in regard to the timing of its presence. This 
may be due to varied tissue collection techniques, antibody sensitivity and specificity 
or classification of the tissue samples studied. The poor quality 
immunohistochemical results detailed in this chapter, alongside the conflicting 
results in the published literature, suggest that immunohistochemistry is not the most 
robust method of assessing endometrial HIF-1α. Therefore, protocols for nuclear 
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protein extraction from frozen endometrial samples and Western blotting for HIF-1α 
were optimised. This revealed a tightly controlled temporal and spatial pattern of 
HIF-1α in the human endometrium, exclusively in the perimenstrual phase. The HIF-
1β subunit is a constitutively expressed nuclear protein and has previously been 
detected in the human endometrium throughout the menstrual cycle (Critchley et al., 
2006b).  
5.4.2 Hypoxic repair factor induction 
The contribution of HIF-1α to the hypoxic induction of endometrial repair factors 
was assessed using echinomycin, a small molecule that inhibits the DNA binding of 
HIF to the hypoxic response element sequence but does not affect NFκB binding 
(Kong et al., 2005). In addition, HIF-1α was silenced with RNA interference. Both of 
these methods significantly abrogated the hypoxic induction of IL-8, AM and VEGF, 
suggesting that hypoxia is dependent on the presence of active HIF-1α for the 
regulation of these factors. The Western blot findings detailed herein show that 
hypoxic conditions stabilise HIF-1α protein in endometrial cells and provide further 
support for the involvement of HIF-1α in hypoxic repair factor induction.  
 
These findings concur with data from other tissue sites. A hypoxic response element 
is present in the VEGF promoter region and HIF-1 has been shown to regulate VEGF 
expression in hypoxia treated cells from the liver, pancreas and prostate (Forsythe et 
al., 1996, Gray et al., 2005). In contrast, HIF-1 independent hypoxic regulation of 
VEGF has been described in colon cancer cells, where NFkB is thought to play an 
active role in its regulation (Mizukami et al., 2004). The findings in this chapter 
confirm that hypoxic regulation of endometrial VEGF is mediated by HIF-1α. 
Hypoxia has also been shown to increase AM expression via HIF-1 in 
cardiomyocytes and human tumour cell lines (Cormier-Regard et al., 1998, Garayoa 
et al., 2000), consistent with findings herein. The hypoxic response element has also 
been previously identified in the IL-8 promoter (Kim et al., 2006). HIF-1 has been 
shown to up-regulate IL-8 mRNA in human fibroblast-like synoviocytes (Ahn et al., 
2008). Our findings in endometrial cells revealed a significant reduction in hypoxia 
mediated IL-8 mRNA with pharmacological inhibition of HIF-1 binding. However, 
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silencing of HIF-1α revealed inconsistent results, with one construct against HIF-1α 
significantly abrogating the hypoxic induction of IL-8 and the other construct having 
no impact on IL-8 expression. In colon cancer cells, IL-8 was shown to have a 
complex regulation in hypoxic conditions, with compensatory pathways activated 
when HIF-1α was silenced (Mizukami et al., 2005). Therefore, in endometrial cells 
HIF-1α may be sufficient to induce IL-8 in hypoxia but may not be necessary. 
5.4.3 Prostaglandin repair factor induction 
The contribution of HIF-1 to prostaglandin induction of endometrial repair factor 
expression was also assessed. Firstly, endometrial cells were treated with PGE2 in 
normoxic conditions to assess its effect on HIF-1α protein. Although 100nM PGE2 
significantly increased IL-8 expression in normoxic conditions, it did not induce 
HIF-1α protein at any of the time points examined. However, inhibition of HIF-1 
binding using echinomycin significantly abrogated the PGE2 induced IL-8 expression 
and PGF2α induced VEGF mRNA. These results suggest that HIF-1α may play a role 
in the normoxic induction of repair factors. However, as well as inhibition of HIF-1 
binding, echinomycin has also been shown to reduce c-Myc and AP-1 binding by 
30% and 50% respectively (Vlaminck et al., 2007). Inhibition of these transcription 
factors may also contribute to the decreased IL-8 and VEGF mRNA observed when 
endometrial cells are co-treated with echinomycin and prostaglandins.  
 
To specifically assess the contribution of HIF-1α, RNA interference experiments 
were carried out. In contract to echinomycin experiments, these data revealed that 
PGF2α induced endometrial VEGF mRNA was independent of HIF-1α. A previous 
study of endometrial adenocarcinoma explants and cells showed that PGF2α activates 
the extracellular signal-regulated kinase 1/2 signaling pathway in an epidermal 
growth factor receptor dependent manner to increase VEGF promoter activity (Sales 
et al., 2005). Further studies are required to determine if a similar mechanism of 
action is present in normal endometrial tissue. Similarly, AM mRNA up-regulation 
on exposure of endometrial cells to PGF2α was also found to be independent of HIF-
1α. These results in endometrial cells differ from those in preadipocytes, where 
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treatment with PGF2α in normoxia resulted in increased HIF-1α protein due to 
increased HIF-1α transcription (Liu and Clipstone, 2008).  
 
The contribution of HIF-1α to the up-regulation of IL-8 by PGE2 was more difficult 
to define. Two ShRNA constructs against HIF-1α were used and neither resulted in a 
significant abrogation of PGE2 induction of IL-8, although one construct did lead to a 
marked decrease in IL-8 expression. NFκB is a nuclear transcription factor present in 
the endometrium during the perimenstrual phase (King et al., 2001) and the NFκB 
binding site has been identified in the IL-8 promoter (Kunsch and Rosen, 1993). 
NFκB has been shown to up-regulate IL-8 mRNA expression in cells from other 
tissue sites in the body, even in the absence of HIF-1α (Mizukami et al., 2005). To 
assess the contribution of NFκB in both hypoxic and PGE2 mediated endometrial IL-
8 expression, an adenoviral dominant negative inhibitor of NFκB (Ad-IκBα) was 
utilised. This inhibitor maintains NFκB in a cytoplasmic location, preventing the 
transcription of its target genes. On infection of endometrial epithelial cells with Ad-
IκBα, a significant decrease in PGE2 mediated IL-8 mRNA up-regulation was 
demonstrated, with no significant decrease in hypoxic induction. Therefore, although 
both HIF-1α and NFκB may impact on endometrial IL-8 mRNA, HIF-1α appears to 
be dominant in hypoxic conditions and NFκB dominant in the regulation of IL-8 by 
PGE2 in normoxia. Interactions between these two transcription factors may take 
place in the perimenstrual endometrium. There is mounting evidence for cross talk 
between NFκB and HIF-1 in other tissue sites (Walmsley et al., 2005, Frede et al., 
2006, van Uden et al., 2008, Belaiba et al., 2007). Therefore, the presence of both of 
these transcription factors, and possible cross-talk between them, may explain the 
synergistic up-regulation of IL-8 mRNA seen in endometrial cells exposed to PGE2 
and hypoxic conditions simultaneously (Chapter 4.3.1.2).  
 
These observations in human endometrial cells are not consistent with those in 
prostate cancer cells (Liu et al., 2002). In these cells, treatment with 1µM PGE2 did 
significantly increase HIF-1α protein levels. A COX-2 inhibitor prevented this 
accumulation of nuclear HIF-1α in prostate cells in normoxic and hypoxic 
conditions. In colon cancer cells, PGE2 also significantly increased HIF-1α protein, 
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and a SiRNA against HIF-1α abrogated the PGE2 mediated VEGF mRNA increase 
(Fukuda et al., 2003). In contrast, the findings described in this chapter revealed that 
PGE2 did not increase HIF-1α protein and indomethacin (a COX-2 inhibitor) had no 
effect on endometrial HIF-1α protein levels in hypoxia. These conflicting findings 
may be due to differences in cell type or may reflect the higher concentrations of 
prostaglandins used in in vitro cancer models, levels that would not be physiological 
in the endometrium. A study examining the induction of the angiogenic factor 
CYR61 in endometrial cells revealed by using SiRNA that its hypoxic induction was 
HIF-1α dependent (Gashaw et al., 2008). Interestingly, although this study showed 
that CYR61 was also up-regulated by PGE2 and PGF2α, it did not examine if these 
effects were HIF-1α mediated. Although HIF-1α  has not been shown to have a 
significant role downstream of PGE2 action in the endometrium, a recent study found 
that hypoxic induction of HIF-1α stimulated PGE2 production, through stimulation of 
PGE synthase (Lee et al., 2010). Therefore, in vivo hypoxia in the perimenstrual 
endometrium may influence the synthesis of PGE2, to enhance the induction of repair 
factors. 
 
Whilst contributing to the existing literature on the role of HIF-1α in endometrial 
repair, these data also prompt further interesting questions. The presence of HIF-1α 
was examined in endometrial biopsies from across the cycle but HIF-2α was not 
studied. This alternative alpha subunit in the HIF-1 complex has a similar structure 
and regulation as HIF-1α but they appear to have differing transcriptional targets 
(Ratcliffe, 2007, Raval et al., 2005, Warnecke et al., 2004). Study of the functional 
responses to HIF-1α and HIF-2α across the genome revealed that, although HIF-2α 
binding affinity was similar to that of HIF-1α at some HRE target sites, it contributed 
very little to the overall HIF response (Mole et al., 2009). Delineation of the presence 
of HIF-2α across the menstrual cycle may provide insight into the functional impact 
of the endometrial hypoxic response.  
 
The role of NFκB in the induction of IL-8 by PGE2 was examined using a dominant 
negative inhibitor. Time restrictions meant the role of this transcription factor in 
PGF2α mediated repair factor induction could not be assessed. For the same reason, 
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the contribution of HIF-1α and NFκB to the production of prostaglandins was not 
examined. The mechanisms involved in prostaglandin repair factor induction are also 
still to be determined in the normal endometrium. These areas provide a focus for 
future research. 
5.4.4 Summary 
The results detailed in this chapter confirm the presence of HIF-1α protein in the 
perimenstrual endometrium. Hypoxia appears to regulate the expression of 
endometrial repair factors via induction of HIF-1α. PGF2α acts independently of HIF-
1α to increase AM and VEGF mRNA. IL-8 appears to have a more complex 
















6. Differences in Menstrual Phase Endometrium 




Historically women of reproductive age had high parity and long periods of lactation, 
therefore menses were relatively infrequent. In contrast, women living in developed 
countries today have easy access to contraception and may expect to menstruate over 
400 times during their reproductive life span. Hence, the gynaecological complaint of 
heavy menstrual bleeding (HMB) has become increasingly common in modern 
society. Over 800 000 women seek treatment per year in the UK alone (NICE, 2007) 
and menstrual complaints constitute greater than 20% of all secondary referrals to 
gynaecology outpatient clinics (Santer et al., 2005). 
 
As discussed in Chapter 1.6.1, the definition of HMB may be subjective or objective. 
In the clinical setting, the subjective definition of “excessive menstrual blood loss 
that interferes with a woman’s physical, emotional, social and/or material quality of 
life” (NICE, 2007) is most appropriate. However, to permit research into the 
pathogenesis of HMB, an objective definition is required. Early studies of menstrual 
blood loss (MBL) demonstrated that 90% of women had a loss of less than 80ml per 
menses (Hallberg et al., 1966a, Hallberg et al., 1966b, Hallberg and Nilsson, 1964). 
Therefore, 80ml has been adopted as the higher limit of normal menstrual bleeding 
(NMB). Conversely, the objective definition of HMB is a monthly MBL of greater 
than 80ml.  
 
HMB may be caused by anatomical anomalies such as fibroids, adenomyosis or 
malignancy. However, a significant proportion of women with HMB have no 
structural abnormalities on investigation. These women were previously categorised 
as having “dysfunctional uterine bleeding”. More recently, these women have been 
subclassified as having (i) a coagulopathy, (ii) ovulatory dysfunction, (iii) an 
iatrogenic cause or (iv) an endometrial cause for their HMB (Munro, 2010, Munro et 
al., 2011). The precise local mechanisms that are aberrant in women with 
endometrial HMB remain undefined. A host of local disturbances have previously 
been identified in women with HMB (Marsh et al., 1997, Smith et al., 1981b, Malik 
et al., 2006, Hewett et al., 2002, Mints et al., 2007, Rae et al., 2009, Smith et al., 
2007). These studies have focused on factors involved in inflammation, haemostasis, 
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vasoconstriction and angiogenesis (see chapter 1.6.3); processes known to be 
involved in endometrial shedding and repair. An unbiased comparison of gene 
expression in the endometrium of women with HMB and NMB may identify novel 
causal factors but such a comparison is unavailable in the published literature to date. 
 
As detailed in Chapter 3, factors with a putative role in endometrial repair are 
significantly increased during the menstrual phase of the cycle. Therefore, the 
experiments detailed herein focus on menstrual endometrium from women with 
HMB and NMB. A whole genome array was performed, analysed and partially 
validated to provide an unbiased comparison of menstrual endometrial gene 
expression between women with HMB and normal controls. In addition, as Hypoxia 
Inducible Factor (HIF) has been identified as an endometrial transcription factor with 
a potential role in repair (Chapter 5), its endometrial expression was examined in 
women with HMB and NMB. HIF-1α and HIF-1β mRNA and protein levels were 
measured in the two groups to elicit any aberrations in women with HMB. The 
expression of vascular endothelial growth factor (VEGF) was also examined, as an 
example of a downstream target gene of HIF. Furthermore, the functional impact of 







6.2.1 Tissue collection 
Endometrial tissue samples (n=71) were collected with written consent and approval 
from the local ethical committee as described in chapter 2.1. These women also 
collected their menstrual blood loss over one menses (Figure 11), using methods 
described in chapter 2.2. Further details of the endometrial biopsies utilised in this 
chapter can be found in tables 10 and 11.  
6.2.2 Objective measurement of menstrual blood loss 
Objective quantification of menstrual blood loss was carried out for each participant 
using a modified alkaline-haematin method, described in detail in chapter 2.2. 
6.2.3 Menstrual pictogram chart analysis 
Menstrual pictograms (Appendix 4) were completed by 32 of the 71 women who 
collected their menstrual blood loss. Five charts were excluded as they were filled 
out incorrectly or were not complete. Charts were scored as detailed in Chapter 2.2.2 
using the scoring system outlined in Appendix 5.  
6.2.4 RNA preparation 











































































Table 11. Circulating oestradiol and progesterone levels at time of biopsy in women with heavy 
































 HMB 11 725 (152-2004) 6.0 (1.2-16.7) 
 
 
Early Secretory  NMB 8 600 (282-919) 31.4 (21.9-46.0) 
 HMB 11 597 (321-817) 31.0 (25.3-36.3) 
 
 
Mid Secretory NMB 5 436 (228-780) 47.1 (8.5-118.9) 
 HMB 5 486 (253-863) 57.7 (19.0-124.8) 
 
 
Late Secretory  NMB 6 183 (65-371) 10.9 (8.9-20.6) 
 HMB 4 224 (71-316) 14.3 (3.89-26.5) 
 
 
Menstrual  NMB 7 196 (95-392) 3.1 (1.2-5.2) 
 HMB 4 103 (61-144) 7.4 (1.5-18.4) 
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6.2.5 Illumina gene expression profiling 
To perform an unbiased comparison of menstrual endometrial gene expression in 
women with objectively measured heavy and normal blood loss, whole genome array 
analysis was carried out (Finnish DNA Microarray Centre (FDMC), Turku Centre 
for Biotechnology). RNA from eight endometrial biopsies from the menstrual phase 
(four HMB and four NMB) was sent to FDMC for comparison (Table 12). The RNA 
quality was assessed for each sample using the Agilent Bioanalyser and quantified 
using the Nanodrop spectrophotometer as described previously (section 2.4.1) (Table 
12). RNA was diluted to a concentration of 150ng/μl with RNase free water and 
frozen at -80°C before packaging in 5kg of dry ice for transport to the FDMC.   
 
Array analysis was carried out by the FDMC using the Illumina Human HT-12 v.3 
Expression BeadChip. Each array on this chip targets more than 25 000 annotated 
genes with more than 48 000 probes and the expression value for each of the probe 
types is calculated from approximately 15 measurements. Amplification was carried 
out on 300ng total RNA with Ambion's Illumina RNA TotalPrep Amplification kit. 
The centre confirmed RNA/cRNA quality prior to and following amplification with 
the Nanodrop ND-1000 and experion electrophoresis station (BioRad).   
 
750ng of biotin labelled cRNA of each sample was hybridized to Illumina’s 
Sentrix® HumanHT-12 Expression BeadChips, version 3 (cat no BD-103-0603) at 
58 °C overnight (18 h) according to Illumina® Whole-Genome Gene Expression 
Direct Hybridization protocol, revision A. Hybridization was detected with 1 μg/ml 
Cyanine3-streptavidine (GE Healthcare Limited, UK). Chips were then scanned with 
Illumina BeadArray Reader, BeadScan software version 3.5. Numerical results were 
extracted with GenomeStudio2008v1. The data were normalised using the quantile 
normalisation method to remove variation between samples caused by non-biological 







Table 12. Classification of menstrual endometrial biopsies analysed using the Illumina Human 















































































































































Figure 79. Box plots of expression intensity value distributions showing 
hybridisation of samples to Illumina array BeadChips. (A) Log2-transformed 
signal intensity distributions of samples before normalisation. (B) Normalised data. 
N1-4: four samples from women with normal menstrual bleeding (<80ml). H1-4: 
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Sample relations were examined by correlation and cluster analysis using Pearson’s 
metrics and by Principal Component Analysis (PCA). Following the explorative 
analysis, a rigorous statistical approach was utilised to identify a subset of 
differentially expressed genes. R package LIMMA was used to perform statistical 
testing of changes in gene expression in endometrium from women with normal and 
heavy menstrual loss. Thresholds used for filtering the differentially expressed (DE) 
genes are shown in Table 13 and are based on the statistical significance (p-value) 
and the size of the difference in the mean expression levels between the groups 
(FC/logFC). 
6.2.6 Functional “in silico” analysis 
To obtain further insight into the functional and clinical significance of the 
differentially regulated genes identified by microarray analysis, the FDMC 
performed global testing using the globaltest package in R, utilising the gene 
ontology (GO) project. A known limitation of the GO project is that it assumes array 
targets are independent and relies on the hierarchical structure of the GO annotation. 
Therefore, with the help of Dr Elaine Marshall, further functional analysis was 
carried out using GeneGo, a commercial server data mining tool. This tool allows for 
the comparison of gene sets derived from experiments such as microarrays and 
predicts relationships between gene products based on peer-reviewed literature in the 
public domain. Functional GeneGo processes and functional gene networks were 
obtained by uploading differentially expressed gene lists to MetaCore™ version 5.4 










Table 13. Thresholds used in filtering differentially expressed transcripts and corresponding 











































6.2.7 Validation of microarray data by Q-RT-PCR 
To confirm the results of the statistical analysis and the validity of the gene list, Q-
RT-PCR was performed on a subset of candidate genes. cDNA was prepared from 
RNA samples and Taqman Q-RT-PCR performed as previously described (Chapter 
2.4). Menstrual endometrial biopsies from at least four different women were 
assessed in each blood loss group. PCR primers and probes used in this chapter are 
detailed in Chapter 2, Table 3. Levels of CXCR4, ESM1, HEY-1, SMAD-3, ACTG2, 
ESR1, PNKD and IDH1 mRNA expression were measured. These candidates were 
selected as they were identified as the most differentially expressed genes between 
the two groups. Levels of HIF-1α, HIF-1β and VEGF mRNA were also examined. 
6.2.8 HIF-1α Western blot  
Nuclear protein was extracted from eight menstrual phase endometrial biopsies 
(NMB n=4, HMB n=4) as described previously (chapter 2.5.2). HIF-1α protein was 
detected in these samples by Western blot (chapter 2.5.3 to 2.5.5) with β-actin used 
as an internal loading control. Densitometric analysis was carried out as described in 
chapter 2.5.6. 
6.2.9 VEGF Immunohistochemistry  
VEGF was immunolocalised in menstrual endometrial biopsies from women with 
objectively measured MBL using the protocol described in chapter 2.6.  
6.2.10 VEGF ELISA 
Four women in the menstrual phase with objectively measured blood loss (HMB 
n=2, and NMB n=2) provided enough tissue for in vitro culture. Tissue was weighed 
and incubated on a raised platform in 1ml of RPMI for 24h. Endometrial explant 
supernatants were pre-diluted to normalise for tissue weight. VEGF levels in the 
culture supernatant were then measured using a commercially available VEGF 
ELISA as previously described (chapter 2.7.3).  
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6.2.11 In vitro capillary tube formation assay 
To assess the angiogenic impact of endometrial HIF-1α production we utilised an 
endometrial epithelial cell line (Ishikawa) and human umbilical vascular endothelial 
cells (HUVECs). HIF-1α was silenced in endometrial cells using lentiviral ShRNA 
constructs, as described in Chapter 2.9. Untransfected cells and cells transfected with 
HIF-1α/shRNA1470, HIF-1α/shRNA2192 or HIF-1α/shRNASCR were covered with 
1ml of serum free DMEM media and placed in hypoxic conditions (0.5% O2) for 8h. 
The conditioned media (CM) was harvested and stored at -20°C.  
A HUVEC capillary tube formation assay was carried out and analysed as described 
in chapter 2.8. HUVECs were treated with 200μl of CM from (i) untransfected cells, 
(ii) HIF-1α/shRNA1470 transfected cells, (iii) HIF-1α/shRNA2192 transfected cells, 
(iv) HIF-1α/shRNASCR transfected cells (v) HIF-1α/shRNA1470 transfected cells 
plus 300ng/ml VEGF protein or (vi) HIF-1α/shRNA2192 transfected cells plus 
300ng/ml VEGF protein. Assays were carried out in triplicate and with CM from 
three separate experiments.  
6.2.12 Statistical analysis 
Statistical analysis carried out by the FDMC on Illumina microarray data is discussed 
in section 6.2.5. For mRNA expression in endometrial tissue, results for each gene 
were expressed as a quantity relative to a comparator; a sample of RNA from the 
liver or placenta depending on gene expression. Tissue samples with a 2^ddCt value 
greater than two standard deviations from the mean of a group were defined as 
outliers and excluded from statistical analysis. Statistical differences in menstrual 
gene expression between women with HMB versus NMB were determined using a 
Mann Whitney non-parametric test. Statistical analyses of differences across the 
cycle between women with HMB and NMB were determined using a two-way 
ANOVA with Bonferroni post-test analysis. Differences in capillary formation 
between culture supernatants were assessed using one-way ANOVA, with Tukey’s 
post test analysis. Comparison of VEGF ELISA results and Western blot 
densitometry was carried out using Mann-Whitney non-parametric tests.  
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6.3 Results 
6.3.1 MBL chart analysis 
Menstrual pictogram scores (n=32) ranged from 11ml to 145ml (mean 76.2 ml, 
median 72.5ml). The objective alkaline-haematin measurements ranged from 21ml to 
227ml (mean 74.9 ml, median 62.5ml). There was no significant difference in mean 
blood loss value between these two methods (p=0.87).  
 
Assessment of linear regression between the two sets of values revealed R squared = 
0.4131 (Figure 80). The agreement between the scores from the menstrual pictogram 
and the modified alkaline haematin measurement is shown in Figure 81. The 
menstrual pictogram had a sensitivity of 80% and a specificity of 81% in diagnosing 
HMB (as defined by modified alkaline haematin method values of >80ml). The 
associated κ statistic for the comparison between the menstrual pictogram and the 
modified alkaline haematin method was 0.60. 
 
Importantly, women with objectively measured normal menstrual bleeding had a 
median duration of bleeding of 4 days, which was significantly shorter than women 
with HMB, median 6 days (p<0.01) (Figure 82). 
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Figure 80. Correlation between objective measurements of MBL by the 
modified alkaline haematin method and menstrual pictogram scores. Dotted 
lines represent the arbitrary limit of 80ml by objective score (horizontal line) and 
pictogram score (vertical line). 
 
      











































Figure 81. Difference between menstrual pictogram and alkaline hematin 







            
 





























Figure 82. Duration of menstrual bleeding in women with objectively 
measured normal (<80ml) and heavy (>80ml) blood loss. **p<0.01. 
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6.3.2 Identification of differentially expressed genes in the endometrium 
of women with HMB 
Analysis of the microarray dataset identified 259 transcripts displaying significant 
changes in the menstrual endometrium from women with heavy and normal 
menstrual blood loss (p<0.01) (Table 13). The relationship between the fold changes 
and average intensities of the filtered targets in the compared groups can be 
visualised in figures 83 and 84. There is no indication of an intensity dependency of 
log ratios. Of these differentially expressed (DE) targets, 171 transcripts were found 
to be up-regulated in the endometrium of women with HMB versus NMB and 88 







Figure 83. MA plot. The log2-transformed fold change (Y-axis) is plotted 
against the log2-transformed average intensity of the compared groups (X-axis). The 
differentially expressed targets are coloured red, the filtering threshold for log fold 









Figure 84. Volcano plot. The -log10 of the p-values (Y-axis) are plotted against 
the logFC (fold change) calculated for the normal versus heavy group (X-axis). 
Genes significantly expressed according to the t-test lie above the horizontal dashed 
line, genes with large FC lie outside the vertical lines. Red dots: up-regulated genes. 
Green dots: down-regulated genes. 
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Table 14. Transcripts identified by Illumina microarray analysis as being up-regulated in the 









































ACTG2 NM_001615.3 434 172 117 27 3.518 1.815 0.000445 
C15orf52 NM_207380.1 271 58 109 9 2.447 1.291 3.29E-05 
FOLR1 NM_016731.2 141 23 62 6 2.253 1.172 1.99E-05 
ATP6V0E2 NM_145230.2 451 144 170 57 2.638 1.399 0.002435 
LRRC20 NM_018239.2 392 79 194 41 2.033 1.024 0.000678 
MYH11 NM_002474.2 932 299 374 154 2.601 1.379 0.003705 
NTHL1 NM_002528.4 281 96 123 18 2.177 1.122 0.002772 
HLA-DQA1 XM_936128.2 1170 140 575 260 2.168 1.116 0.00298 
MGC57346 XM_377476.4 318 92 154 30 2.018 1.013 0.001969 
CD163 NM_203416.2 551 196 232 69 2.362 1.24 0.004486 
FOLR1 NM_016724.1 127 42 62 8 1.971 0.979 0.001969 
C10orf116 NM_006829.2 305 102 140 23 2.099 1.069 0.004134 
CERCAM NM_016174.3 167 42 89 12 1.838 0.878 0.001012 
GINS2 NM_016095.1 182 77 77 26 2.298 1.201 0.005375 
IDH1 NM_005896.2 1148 151 602 248 2 1 0.003487 
COL24A1 NM_152890.4 278 91 130 44 2.139 1.097 0.00502 
KDELR3 NM_006855.2 346 58 189 45 1.853 0.89 0.001803 
RHOD NM_014578.2 309 57 172 34 1.801 0.849 0.001845 
 Hs.579631 813 526 199 67 3.545 1.826 0.008225 
THRA NM_003250.4 202 39 109 38 1.919 0.94 0.004425 
GAMT NM_000156.4 169 41 90 17 1.841 0.88 0.00305 
CAPN13 NM_144575.2 133 17 75 27 1.848 0.886 0.003332 
SLCO2B1 NM_007256.2 634 153 334 108 1.925 0.945 0.004579 
GAMT NM_000156.4 131 42 64 11 1.972 0.979 0.004986 
OLFML3 NM_020190.2 333 41 182 56 1.899 0.925 0.004459 
ETFB NM_001014763.1 940 150 542 100 1.741 0.8 0.000901 
COL5A2 NM_000393.3 3306 624 1838 526 1.822 0.865 0.003369 
QDPR NM_000320.1 627 61 367 89 1.74 0.799 0.001529 
RPESP NM_153225.2 858 555 269 92 2.881 1.526 0.009279 
ANGPTL2 NM_012098.2 1597 408 858 231 1.87 0.903 0.005677 
ALDH3B2 NM_001031615.1 126 31 73 5 1.697 0.763 0.001084 
PDGFRA NM_006206.3 1384 176 814 191 1.73 0.791 0.002515 
C16orf35 NM_001039476.1 737 148 431 68 1.703 0.768 0.001583 
HLA-DMB NM_002118.3 2682 258 1591 442 1.73 0.791 0.003055 
C6orf64 NM_018322.1 331 57 194 49 1.737 0.797 0.003866 
TMEM14A NM_014051.3 517 116 278 96 1.918 0.94 0.008455 
LSM5 NM_012322.1 1205 216 725 93 1.65 0.723 0.001356 
HCFC1R1 NM_001002018.1 124 31 73 10 1.672 0.741 0.002827 
RNASEH2A NM_006397.2 142 25 87 9 1.618 0.694 0.000793 
HLA-DRA NM_019111.3 5973 907 3680 591 1.625 0.7 0.001344 
NUDT18 NM_024815.3 283 66 160 45 1.799 0.847 0.007618 
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CETN3 NM_004365.2 260 46 159 29 1.635 0.709 0.002482 
KDELR3 NM_016657.1 569 82 339 102 1.726 0.788 0.006511 
MCM2 NM_004526.2 246 73 133 42 1.846 0.884 0.009651 
C1QA NM_015991.1 186 37 111 37 1.718 0.781 0.00755 
PCCB NM_000532.3 1044 112 663 156 1.598 0.676 0.00257 
CD163 NM_004244.4 120 25 74 13 1.622 0.698 0.004002 
LOC642989 XM_926370.1 397 87 244 48 1.626 0.702 0.004525 
LOC401115 XM_937968.2 4245 912 2546 566 1.67 0.74 0.006503 
ZNF74 NM_003426.2 231 63 134 25 1.69 0.757 0.007444 
REEP6 NM_138393.1 186 56 107 10 1.684 0.752 0.007281 
UBE2L6 NM_004223.3 2161 102 1406 155 1.542 0.625 9.08E-05 
MCM6 NM_005915.4 1069 309 621 148 1.71 0.774 0.008801 
FANCG NM_004629.1 210 17 137 20 1.544 0.627 0.000584 
KCTD12 NM_138444.3 434 106 263 54 1.64 0.713 0.006332 
KITLG NM_000899.3 111 46 62 4 1.711 0.775 0.009092 
C1orf54 NM_024579.2 1108 132 719 98 1.542 0.625 0.000738 
THEM2 NM_018473.2 540 163 310 63 1.709 0.773 0.009355 
FLJ10986 NM_018291.2 342 9 222 54 1.57 0.651 0.003123 
C3orf14 NM_020685.3 414 62 266 54 1.571 0.651 0.003559 
CYBB NM_000397.2 159 17 103 22 1.573 0.654 0.003714 
CDK5 NM_004935.2 210 57 127 24 1.638 0.712 0.007215 
HRSP12 NM_005836.2 230 31 150 19 1.534 0.618 0.001021 
CD74 NM_004355.2 1120 223 718 94 1.548 0.63 0.002825 
BST2 NM_004335.2 320 59 205 18 1.545 0.628 0.0025 
TP53I3 NM_147184.1 698 172 416 119 1.691 0.758 0.009878 
LRRC20 NM_018239.2 117 15 76 17 1.567 0.648 0.004739 
EEF2K NM_013302.3 449 84 290 27 1.533 0.616 0.002253 
RAD51AP1 NM_006479.3 128 17 81 25 1.615 0.691 0.007478 
PPA2 NM_176866.2 481 65 316 58 1.528 0.612 0.002569 
LPXN NM_004811.1 579 98 370 78 1.577 0.657 0.007043 
C16orf53 NM_024516.2 192 44 119 25 1.619 0.695 0.008993 
WDR51A NM_015426.2 284 69 176 26 1.59 0.669 0.008143 
C2orf79 NM_001013663.1 188 24 126 18 1.495 0.58 0.002045 
TMEM160 NM_017854.1 990 82 671 108 1.488 0.573 0.001435 
GALM NM_138801.1 231 47 150 23 1.53 0.614 0.005378 
FASTK NM_033015.2 406 65 268 54 1.521 0.605 0.004792 
LSM4 NM_012321.2 979 191 641 85 1.514 0.599 0.004541 
DNASE2 NM_001375.2 1272 144 824 272 1.591 0.67 0.009929 
CNFN NM_032488.2 161 34 105 7 1.511 0.596 0.004554 
MCM4 NM_005914.2 388 114 245 15 1.542 0.625 0.007254 
ANKRD33 NM_182608.2 429 77 278 68 1.557 0.639 0.00878 
ME2 NM_002396.3 221 47 145 23 1.521 0.605 0.006205 
TIMELESS NM_003920.2 277 33 188 23 1.473 0.558 0.001216 
RAD51L3 NM_002878.2 115 11 78 5 1.466 0.552 0.000185 
LOC728635 XM_001131304.1 261 58 168 36 1.551 0.633 0.009558 
HLA-DRA NM_019111.3 6265 937 4224 685 1.487 0.572 0.00403 
PSEN2 NM_012486.1 231 34 154 35 1.516 0.6 0.007222 
COMMD9 NM_014186.2 361 32 248 17 1.455 0.541 0.000201 
SDSL NM_138432.2 355 63 238 35 1.485 0.571 0.004662 
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C1orf53 NM_001024594.1 231 72 146 5 1.534 0.617 0.009384 
ASAP3 NM_017707.2 367 30 245 62 1.529 0.613 0.009051 
APRT NM_000485.2 496 60 341 44 1.457 0.543 0.001627 
SFXN4 NM_213649.1 628 135 414 61 1.504 0.589 0.007706 
CATSPER2P1 NR_002318.2 118 20 81 3 1.452 0.538 0.001758 
SNRPF NM_003095.2 2632 500 1776 79 1.461 0.547 0.003387 
LSMD1 NM_032356.3 240 47 164 13 1.452 0.538 0.003093 
C7orf50 NM_032350.4 1453 264 984 133 1.469 0.555 0.005633 
TMEM118 NM_032814.2 110 12 77 9 1.441 0.527 0.001668 
GLYCTK NM_145262.2 162 14 114 18 1.439 0.525 0.001835 
KIAA1324L NM_152748.2 131 19 91 6 1.421 0.507 0.001306 
PSEN2 NM_000447.1 152 10 107 16 1.424 0.51 0.001698 
MRPL37 NM_016491.2 2197 323 1530 154 1.429 0.515 0.0029 
RPP40 NM_006638.2 514 96 352 32 1.444 0.53 0.006603 
RIMS3 NM_014747.2 132 26 90 13 1.46 0.546 0.009091 
PCBD1 NM_001001939.1 322 49 224 44 1.447 0.533 0.008171 
LSM2 NM_021177.3 1553 206 1097 108 1.41 0.496 0.00272 
YIF1B NM_033557.1 249 52 170 23 1.458 0.544 0.009937 
C16orf75 NM_152308.1 180 11 127 26 1.439 0.525 0.007747 
C12orf48 NM_017915.2 104 15 72 14 1.445 0.531 0.00886 
C1orf85 NM_144580.1 1519 379 1035 48 1.439 0.525 0.0083 
PNKD NM_015488.4 143 18 100 19 1.438 0.524 0.008803 
FLJ23584 NM_024588.3 117 12 84 3 1.385 0.47 0.000296 
RASSF4 NM_032023.3 137 23 97 5 1.398 0.483 0.003649 
GLE1 NM_001003722.1 484 56 346 62 1.409 0.495 0.006281 
C17orf53 NM_024032.2 115 13 83 10 1.388 0.473 0.002626 
TRAPPC2L NM_016209.2 1440 293 1002 85 1.418 0.503 0.009441 
C8orf59 NM_001099672.1 577 92 416 25 1.378 0.463 0.003012 
MCM4 NM_182746.1 120 21 85 6 1.398 0.483 0.007662 
PET112L NM_004564.1 182 18 131 25 1.394 0.48 0.007236 
C5orf39 NM_001014279.1 260 36 186 30 1.402 0.488 0.008724 
SLC27A3 NM_024330.1 193 19 141 15 1.364 0.448 0.002083 
ME2 NM_002396.3 412 34 302 51 1.376 0.46 0.005827 
COQ3 NM_017421.3 129 22 93 10 1.384 0.469 0.008055 
EIF3K NM_013234.2 1727 239 1261 142 1.367 0.451 0.004685 
TSPAN4 NM_001025238.1 572 38 424 47 1.353 0.436 0.001404 
CCDC51 NM_024661.3 122 13 90 7 1.351 0.434 0.00153 
ATP5J2 NM_001003714.1 1539 222 1127 110 1.361 0.445 0.004563 
C10orf61 NM_001013840.1 245 30 179 25 1.367 0.451 0.006457 
CKS1B NM_001826.1 487 91 351 32 1.373 0.457 0.008485 
AIFM1 NM_145813.1 180 5 134 24 1.36 0.443 0.006042 
CYP2R1 NM_024514.4 169 23 124 13 1.357 0.441 0.006347 
UBLCP1 NM_145049.1 225 32 165 20 1.359 0.442 0.007806 
ACOT11 NM_147161.2 170 31 124 9 1.358 0.441 0.008663 
UQCRQ NM_014402.4 7269 1086 5386 458 1.342 0.424 0.006119 
LSM1 NM_014462.1 4299 211 3257 251 1.322 0.403 0.000602 
C14orf143 NM_145231.2 126 10 95 12 1.325 0.406 0.003821 
EBI3 NM_005755.2 104 16 77 9 1.341 0.423 0.00863 
GTPBP8 NM_014170.2 102 14 77 10 1.329 0.411 0.009038 
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PNPO NM_018129.2 546 63 412 55 1.326 0.407 0.008473 
TSPAN17 NM_130465.3 129 5 99 17 1.324 0.405 0.009659 
LOC550112 XR_001037.1 106 4 81 13 1.314 0.394 0.009329 
NDUFB2 NM_004546.2 3925 488 3006 172 1.3 0.378 0.004394 
COX10 NM_001303.2 705 28 546 69 1.298 0.376 0.003663 
CCBL2 NM_001008661.1 266 14 205 30 1.304 0.383 0.007151 
MRPS11 NM_176805.1 1125 178 857 57 1.304 0.382 0.008656 
HIST1H4C NM_003542.3 8315 597 6463 606 1.288 0.366 0.002761 
TMEM188 NM_153261.4 442 28 344 28 1.286 0.363 0.001647 
C1orf91 NM_019118.2 120 12 93 9 1.293 0.371 0.005641 
PSMB6 NM_002798.1 5160 491 3993 481 1.296 0.374 0.008102 
BRP44 NM_015415.2 520 69 401 28 1.29 0.367 0.006519 
MFSD1 NM_022736.1 1015 111 790 33 1.28 0.356 0.003263 
ASTE1 NM_014065.2 118 10 93 8 1.277 0.353 0.003869 
SLC37A4 NM_001467.4 456 16 362 37 1.266 0.34 0.002611 
CKAP5 NM_001008938.1 1127 65 894 63 1.26 0.334 0.001711 
MRPL11 NM_170738.1 238 29 187 13 1.265 0.339 0.008819 
FAM104A NM_032837.1 629 41 502 31 1.251 0.323 0.002111 
FBXO22 NM_012170.2 179 14 143 10 1.253 0.326 0.003726 
SLC25A14 NM_003951.2 149 8 119 14 1.255 0.328 0.006921 
 Hs.489254 146 8 117 11 1.249 0.321 0.004518 
NEDD8 NM_006156.1 10116 743 8103 749 1.25 0.322 0.00635 
FAM10A4 NR_002183.1 735 35 593 33 1.241 0.312 0.001404 
SERF2 NM_001018108.2 4821 337 3870 456 1.25 0.322 0.009521 
MCEE NM_032601.2 419 37 336 35 1.248 0.32 0.009916 
CEP63 NM_025180.3 344 17 278 32 1.242 0.313 0.007647 
NDUFB8 NM_005004.2 5902 623 4735 368 1.244 0.315 0.009037 
HEATR1 NM_018072.4 383 31 310 10 1.23 0.299 0.002678 
37500 NM_004404.3 8693 552 7028 749 1.241 0.311 0.009421 
CCDC72 NM_015933.3 2184 221 1783 61 1.22 0.287 0.007651 
DIABLO NM_019887.3 462 27 383 30 1.21 0.275 0.006712 
ZFP161 NM_003409.2 240 16 199 9 1.201 0.264 0.004916 
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Table 15. Transcripts identified by Illumina microarray analysis as being significantly down-


















































CXCR4 NM_003467.2 799 108 2776 624 -3.436 -1.781 4.15E-06 
ESM1 NM_007036.3 100 16 445 231 -4.012 -2.004 0.000499 
CXCR4 NM_001008540.1 323 95 920 328 -2.786 -1.478 0.001214 
ATP6V1C2 NM_144583.3 82 18 196 61 -2.351 -1.233 0.000927 
LOC732075 XM_001131797.1 113 24 242 71 -2.106 -1.075 0.001933 
LOC653583 XM_928224.2 107 25 231 75 -2.12 -1.084 0.002343 
HEY1 NM_001040708.1 244 68 469 63 -1.967 -0.976 0.001091 
SMAD3 NM_005902.3 352 124 795 243 -2.263 -1.178 0.00401 
SLC3A2 NM_001013251.1 175 61 372 86 -2.203 -1.14 0.005095 
BDKRB2 NM_000623.2 100 17 218 90 -2.072 -1.051 0.0046 
LOC440895 XM_290985.6 110 14 212 69 -1.868 -0.902 0.002083 
CHRNA3 NM_000743.2 84 21 157 42 -1.865 -0.899 0.002951 
DUSP16 NM_030640.1 80 4 139 30 -1.706 -0.771 0.000531 
MOAP1 NM_022151.4 378 62 640 95 -1.698 -0.764 0.000753 
EFNA1 NM_004428.2 194 54 370 112 -1.888 -0.917 0.006709 
TBX2 NM_005994.3 257 30 431 86 -1.66 -0.731 0.001328 
HSPA5 NM_005347.2 952 184 1622 355 -1.698 -0.764 0.004065 
IL6R NM_000565.2 64 8 107 22 -1.64 -0.713 0.00147 
LIMS1 NM_004987.3 656 162 1096 187 -1.696 -0.762 0.004548 
ZNF295 NM_001098402.1 226 36 427 147 -1.82 -0.864 0.008146 
YPEL2 NM_001005404.3 312 67 503 62 -1.632 -0.706 0.0021 
DHRS3 NM_004753.4 1116 167 1860 450 -1.645 -0.718 0.004514 
DAAM1 NM_014992.1 318 43 509 98 -1.591 -0.67 0.001811 
BMP6 NM_001718.4 73 13 116 18 -1.589 -0.668 0.002255 
NXF1 NM_006362.4 573 116 894 105 -1.579 -0.659 0.003146 
CRY1 NM_004075.2 308 60 468 22 -1.541 -0.624 0.00103 
ETS2 NM_005239.4 2120 343 3355 638 -1.575 -0.655 0.004303 
TOM1 NM_005488.1 924 78 1451 299 -1.548 -0.631 0.002528 
ARSD NM_001669.2 134 28 224 52 -1.67 -0.74 0.008708 
DDX21 NM_004728.2 730 140 1171 246 -1.596 -0.675 0.00606 
UGT2B7 XM_943434.1 171 48 270 38 -1.619 -0.695 0.008685 
SOX7 NM_031439.2 99 18 152 26 -1.528 -0.612 0.005135 
ZNF654 NM_018293.2 115 8 167 13 -1.447 -0.533 0.000131 
 Hs.492187 126 10 191 40 -1.496 -0.581 0.007185 
UFM1 NM_016617.1 676 99 998 172 -1.473 -0.559 0.006512 
EIF4A3 NM_014740.2 2373 210 3423 486 -1.436 -0.522 0.001692 
HIST2H2BE NM_003528.2 112 12 166 31 -1.459 -0.545 0.004891 
CRY1 NM_004075.2 190 21 273 33 -1.434 -0.521 0.001509 
CLN8 NM_018941.3 86 11 127 24 -1.458 -0.544 0.005326 
DPY19L1 NM_015283.1 576 127 843 124 -1.479 -0.565 0.009606 
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LSM12 NM_152344.2 159 37 226 8 -1.451 -0.537 0.007183 
OTUD4 NM_199324.1 227 44 327 43 -1.452 -0.538 0.007866 
C6orf106 NM_024294.2 87 8 124 21 -1.421 -0.507 0.004473 
YWHAG NM_012479.2 78 8 111 16 -1.413 -0.499 0.003402 
PANX2 NM_052839.2 116 9 166 28 -1.41 -0.496 0.003907 
ICA1 NM_004968.2 266 32 378 64 -1.414 -0.5 0.005918 
C20orf111 NM_016470.6 835 127 1180 158 -1.417 -0.503 0.006288 
NUP153 NM_005124.2 235 35 331 47 -1.412 -0.498 0.005286 
ZNF562 NM_017656.2 279 22 389 47 -1.387 -0.472 0.001433 
UBR7 NM_001100417.1 123 7 175 36 -1.407 -0.492 0.006162 
ACSL3 NM_203372.1 472 78 668 99 -1.417 -0.503 0.008089 
RIPK4 NM_020639.2 139 19 195 29 -1.404 -0.489 0.007121 
KIF1B NM_015074.2 490 57 686 108 -1.394 -0.479 0.006773 
SENP2 NM_021627.2 147 16 208 40 -1.404 -0.49 0.009598 
ANAPC1 NM_022662.2 76 6 108 23 -1.4 -0.485 0.009011 
TMEM165 NM_018475.2 217 30 292 11 -1.36 -0.443 0.002458 
 Hs.24119 103 15 141 12 -1.37 -0.454 0.005029 
BCL2L1 NM_138578.1 99 16 136 17 -1.382 -0.467 0.009319 
DDX39 NM_005804.2 1322 154 1832 292 -1.379 -0.464 0.009045 
SH3RF1 NM_020870.3 131 12 176 11 -1.341 -0.424 0.000795 
AP2A2 NM_012305.2 161 28 218 18 -1.368 -0.452 0.008047 
BRWD1 NM_033656.2 93 9 125 11 -1.342 -0.424 0.001587 
C14orf43 NM_194278.3 106 18 144 16 -1.365 -0.448 0.008516 
PPFIBP1 NM_003622.2 165 20 223 26 -1.349 -0.431 0.005159 
SEH1L NM_001013437.1 182 23 245 26 -1.343 -0.426 0.00484 
RPS6KA3 NM_004586.2 76 11 101 8 -1.346 -0.429 0.00589 
ATP2A2 NM_001681.2 998 90 1344 186 -1.34 -0.422 0.005493 
LOC730820 XM_001127763.1 392 60 525 58 -1.346 -0.429 0.008277 
FAM13A1 NM_014883.2 77 4 104 19 -1.337 -0.419 0.008633 
PREI3 NM_015387.2 86 15 113 4 -1.328 -0.409 0.008217 
LHFPL2 NM_005779.1 503 73 660 53 -1.318 -0.398 0.006003 
YWHAE NM_006761.3 118 14 154 9 -1.308 -0.387 0.002687 
KIT NM_000222.1 94 10 125 17 -1.318 -0.399 0.008826 
RAP2C NM_021183.3 96 8 124 11 -1.297 -0.375 0.002846 
CSDA NM_003651.3 2981 332 3852 353 -1.294 -0.372 0.006111 
POFUT2 NM_133635.4 420 59 540 36 -1.291 -0.368 0.008756 
RAD23B NM_002874.3 442 58 570 54 -1.292 -0.37 0.009791 
P2RX4 NM_002560.2 370 48 472 23 -1.281 -0.357 0.005591 
CRK NM_016823.2 636 53 811 71 -1.274 -0.349 0.003729 
DHX32 NM_018180.2 795 63 1006 38 -1.267 -0.342 0.001368 
HINT3 NM_138571.3 153 11 193 13 -1.267 -0.341 0.001775 
CPEB3 NM_014912.3 113 8 144 15 -1.273 -0.348 0.005053 
PAN3 NM_175854.5 560 84 708 18 -1.275 -0.35 0.008877 
PRPF40A NM_017892.3 244 13 308 37 -1.255 -0.327 0.007518 
TAF5L NM_014409.3 97 6 120 10 -1.24 -0.31 0.004639 
CDCA4 NM_017955.2 106 5 131 12 -1.239 -0.309 0.004949 
MDK NM_001012334.1 82 5 100 10 -1.22 -0.286 0.00905 
CTTN NM_005231.2 1350 118 1626 81 -1.207 -0.272 0.008001 
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6.3.3 Cluster analysis 
The DE transcripts from all patients were evaluated further with blind explorative 
hierarchical clustering using Pearson’s metrics. Principle component analysis (PCA) 
depicts the variance in gene expression profiles in samples (Figure 85). On the three 
dimensional graph, the distance between two points is proportional to the degree of 
similarity of gene expression between them. The samples clustered into four groups, 
two groups from women with HMB and two with NMB. The heatmap of sample 
clustering (Figure 86) confirms that the samples demonstrate segregation into normal 







Figure 85. Principle component analysis (PCA). PCA was applied to all 8 
endometrial samples that were characterised by gene expression on the Human TR-
12 v3 Expression BeadChip and confirms sample segregation based on the statistics 











Figure 86. Heat map.  Red represents high intensity and green low intensity. 
Samples included in each comparison at a time have been hierarchically clustered for 
the differentially expressed array targets. Each row in the plot represents one array 
target and they are organised by intensity measurement similarity.  
 
 H4     H1     H2     H3      N3     N4     N1     N2
Green: low intensity
Red: high intensity 
Menstrual endometrium 
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6.3.4 Global test analysis 
Statistical testing for over-representation of GO terms using globaltest package R 
revealed four categories with a p value of less than 0.05 (Table 16). Interestingly, the 
response to hypoxia was included in the top 10 global test GO results, although this 
category did not reach statistical significance. On examination of the 72 genes from 
the differentially expressed gene list that were targets for this term, there was 
evidence of a higher expression of genes known to have a role in the response to 
hypoxia in the endometrium of women with NMB than in those with HMB (Figure 

















GO: 0000184 0.016 20 Nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
GO:0002026 0.019 10 Regulation of the force of heart 
contraction 
GO:0000387 0.035 24 Spliceosomal snRNP biogenesis 
GO:0000209 0.042 14 Protein polyubiquitination 
GO:0000045 0.064 8 Autophagic vacuole formation 
GO:0001710 0.066 7 Mesodermal cell fate commitment 
GO:0001666 0.077 72 Response to hypoxia 
GO:0000956 0.080 23 Nuclear-transcribed mRNA catabolic 
process 
GO:0000578 0.081 7 Embryonic axis specification 











Figure 87. Global test result for the 7th most significant GO pathway as a 
Gene Plot. Red: higher expression in women with normal menstrual bleeding 
(<80ml). Green: higher expression in women with heavy menstrual bleeding 
(>80ml).  
              HSP90B1           THBS1     SMAD3      EPAS1 
        PLOD2 
                CXCR4 
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6.3.5 GeneGO analysis 
To further define the functional differences in gene expression in the menstrual 
endometrium of women with NMB and HMB, GeneGO analysis of the differentially 
expressed gene set was carried out with the help of Dr Elaine Marshall. This analysis 
employs evidence-based interactions published in the literature and predicts 
functional networks and processes. Many of the bioprocesses identified were 
concerned with physiological events associated with repair, such as positive 
regulation of biological and cellular processes, leukocyte differentiation, regulation 
of apoptosis and response to stress/hypoxia. This finding of a pattern of consistent 
dysregulation among multiple genes in a pathway or network improves the validity 
of the microarray results. 
 
 A summary of the top ten GeneGo process networks is detailed in Figure 88. These 
are compiled by mapping the differentially expressed gene set onto approximately 
110 cellular and molecular processes whose content is defined and annotated by 
GeneGo. Each process represents a pre-set network of protein interactions 
characteristic for the process. The most relevant network processes were determined 
using the parameters of (1) relative enrichment with the uploaded data and (2) 
relative saturation of networks with canonical pathways and are detailed in Table 17. 
 
Further analysis using MetaCoreTM network building algorithms revealed 30 sub-
networks (Table 17) that were ranked according to p-value (calculated using the 
basic formula for hypergenometric distribution), z-score (rank of sub-network 
according to saturation with the objects from the differentially expressed gene list) 
and g-score (modification of the z-score based on the number of canonical pathways 
used to build the sub-network). The network diagrams for the 2nd, 3rd and 24th ranked 
sub-networks are shown in Figures 89, 90 and 91. These diagrams detail the 
interactions between genes involved in a biological process, including their up-
stream and down-stream targets. Differentially expressed genes in the comparison of 
menstrual endometrium from women with HMB and NMB are marked with a blue 










Figure 88. Top ten GeneGo process networks.  
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Table 17. Most Relevant GeneGo Networks 
 
No Processes Size Target Pathways p-Value zScore gScore 
 
1 Response to steroid hormone stimulus (20.9%), interspecies 
interaction between organisms (20.9%), translation (20.9%) 
50 19 6 6.09e-34   43.77   51.27 
2 DNA metabolic process (32.4%), recombinational repair 
(11.8%), double-strand break repair via homologous 
recombination (11.8%) 
50 19 0 7.08e-35   45.80   45.80 
3 Regulation of cell cycle (35.6%), cell cycle process (35.6%), 
cell cycle (40.0%) 
50 14 4 4.47e-23   32.14   37.14 
4 Neuron differentiation (22.7%), cell communication (59.1%), 
system development (45.5%) 
50 16 0 8.72e-27   35.64   35.64 
5 Transmembrane receptor protein tyrosine kinase signalling 
pathway (40.8%), enzyme linked receptor protein signalling 
pathway (40.8%), cell communication (83.7%) 
50 8 8 2.42e-11   17.60   27.60 
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Table 18.The most relevant sub-networks, compiled using GeneGo functional analysis of the differential expressed gene set from the comparison of menstrual 
endometrium from women with normal and heavy menstrual bleeding. Sub-networks subjected to further analysis in this chapter are highlighted in yellow.  
 
No Key network 
objects 




Pathways p-Value zScore gScore 
1 PNPO, DDX48, 
NXF1, APRT, 
MCM4 
cellular nitrogen compound metabolic process (66.7%), nitrogen 
compound metabolic process (66.7%), nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process (61.5%), mRNA transport (15.4%), 
establishment of RNA localization (15.4%) 
 
50 18 0 3.49e-33  45.13   45.13 
2 SMAD3, c-Kit, 
DDEFL1 (ACAP4), 
MGF, DDX21 
regulation of signal transduction (34.0%), regulation of signalling process 
(34.0%), response to organic substance (36.2%), positive regulation of 
cellular process (46.8%), regulation of multicellular organismal process 
(36.2%) 
 





regulation of biological quality (48.7%), regulation of multicellular 
organismal process (41.0%), regulation of anatomical structure size 
(25.6%), biological regulation (87.2%), regulation of system process 
(25.6%) 
 
50 15 2 3.41e-26  37.10   39.60 
4 SMAD3, TBX2, 
HEY1, TR-alpha, 
CRK 
positive regulation of biological process (72.0%), positive regulation of 
cellular process (68.0%), positive regulation of macromolecule 
biosynthetic process (44.0%), positive regulation of cellular biosynthetic 
process (44.0%), positive regulation of biosynthetic process (44.0%) 
 
50 14 0 4.00e-23  32.41   32.41 
5 CSDA, MHC class 
II, HLA-DM, 
CKS1, TBX2 
positive regulation of biological process (68.0%), positive regulation of 
cellular process (64.0%), positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process (44.0%), positive 
regulation of nitrogen compound metabolic process (44.0%), positive 
regulation of macromolecule metabolic process (48.0%) 
 





signalling (65.2%), regulation of cell communication (39.1%), anatomical 
structure morphogenesis (39.1%), signalling process (56.5%), signal 
transmission (56.5%) 
 
50 13 0 1.76e-21  31.03   31.03 
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No Key network 
objects 




Pathways p-Value zScore gScore 
7 SLC27A3, GAMT, 
DHRS3, OATP-B, 
FBX22 
small molecule metabolic process (55.6%), creatine biosynthetic process 
(11.1%), cellular amino acid and derivative metabolic process (33.3%), 
amine metabolic process (33.3%), phosphagen biosynthetic process 
(11.1%) 
 
50 10 0 2.87e-16  28.96   28.96 
8 DDX21, RAD23B, 
MCM2, NTH1, 
RNASEH2A 
DNA metabolic process (38.5%), macromolecule metabolic process 
(84.6%), primary metabolic process (89.7%), cellular macromolecule 
metabolic process (79.5%), cellular nitrogen compound metabolic process 
(66.7%) 
 
50 12 0 1.42e-19  28.93   28.93 





multi-organism process (36.4%), positive regulation of biological process 
(52.3%), T cell differentiation (13.6%), lymphocyte differentiation 
(15.9%), regulation of phosphorylation (25.0%) 
50 12 0 3.33e-19  28.01   28.01 
10 Cortactin, ZF5, 
c-Kit, CRK, ESM-1 
positive regulation of cellular process (59.2%), positive regulation of 
biological process (59.2%), biological regulation (87.8%), regulation of 
cellular process (83.7%), regulation of biological process (83.7%) 
 
50 12 0 4.37e-19  27.72   27.72 
11 CRY1, Midkine, 
AL3B2, NCU-G1 
(C1orf85), TIM 
circadian rhythm (23.7%), rhythmic process (26.3%), regulation of 
gene-specific transcription from RNA polymerase II promoter (21.1%), 
negative regulation of cellular process (50.0%), primary metabolic 
process (84.2%) 
 




regulation of apoptosis (47.9%), regulation of programmed cell death 
(47.9%), regulation of cell death (47.9%), regulation of cellular process 
(91.7%), positive regulation of biological process (60.4%) 
 
50 11 0 3.88e-17  25.37   25.37 
13 ZF5, TBX2, P2X4, 
CRY1, Midkine 
negative regulation of biological process (51.2%), negative regulation of 
cellular process (46.3%), cellular nitrogen compound metabolic process 
(58.5%), nitrogen compound metabolic process (58.5%), multicellular 
organismal process (65.9%) 
 
50 11 0 1.56e-15  23.78   23.78 
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No Key network 
objects 




Pathways p-Value zScore gScore 
14 14-3-3 epsilon, 
CD163, CSDA, 
PSP, P2X4 
response to stimulus (72.5%), biological regulation (90.0%), response to 
abiotic stimulus (30.0%), regulation of cellular process (85.0%), 
regulation of biological process (85.0%) 
 
 




CRK, Presenilin 2 
 
regulation of apoptosis (63.3%), regulation of programmed cell death 
(63.3%), regulation of cell death (63.3%), positive regulation of cellular 
process (71.4%), positive regulation of biological process (71.4%) 
50 9 0 2.13e-13  20.68   20.68 
16 Cortactin, SH3RF, 
ETS2, CRK, CKS1 
regulation of cellular process (94.0%), positive regulation of cellular 
process (62.0%), regulation of molecular function (48.0%), biological 
regulation (96.0%), regulation of biological process (94.0%) 
 





intracellular signalling pathway (40.0%), enzyme linked receptor protein 
signalling pathway (28.0%), transmembrane receptor protein tyrosine 
kinase signaling pathway (24.0%), protein amino acid phosphorylation 
(32.0%), signalling (66.0%) 
 





negative regulation of apoptosis (39.4%), negative regulation of 
programmed cell death (39.4%), negative regulation of cell death 
(39.4%), regulation of apoptosis (45.5%), regulation of programmed cell 
death (45.5%) 
 
50 8 0 4.82e-11  19.26   19.26 
19 MKP-7, gp91-phox, 
P2X4, C16orf75, 
Ca-ATPase2 
DNA metabolic process (35.5%), DNA repair (29.0%), cellular response 
to stimulus (45.2%), cellular response to stress (35.5%), response to DNA 
damage stimulus (29.0%) 
 
50 8 0 1.09e-11  18.53   18.53 
20 SMAD3, HEY1, 
NEDD8, PIG3, 
BDKRB2 
positive regulation of biological process (70.8%), regulation of apoptosis 
(50.0%), positive regulation of cellular process (66.7%), regulation of 
programmed cell death (50.0%), regulation of cell death (50.0%) 
 
 
50 8 0 1.30e-11  18.34   18.34 
252 
No Key network 
objects 










positive regulation of biological process (71.4%), positive regulation of 
cellular process (67.3%), regulation of cell communication (53.1%), 
regulation of signal transduction (49.0%), regulation of signalling process 
(49.0%) 
50 8 0 1.30e-11  18.34   18.34 
22 BDKRB2, c-Kit, 
Cortactin, SH3RF, 
PDGF-R-alpha 
positive regulation of biological process (73.5%), positive regulation of 
cellular process (69.4%), regulation of programmed cell death (51.0%), 
regulation of cell death (51.0%), regulation of cell communication 
(55.1%) 
 
50 8 0 1.30e-11  18.34   18.34 
23 Presenilin 2, ETS2, 
PIR51, CSDA, 
PINCH 
positive regulation of biological process (63.8%), positive regulation of 
cellular process (57.4%), regulation of biological process (91.5%), 
regulation of metabolic process (70.2%), regulation of cellular process 
(89.4%) 
50 8 0 1.30e-11  18.34   18.34 
24 SMAD3, ETS2, 
CSDA, CXCR4, 
CKS1 
positive regulation of biological process (83.3%), positive regulation of 
cellular process (79.2%), regulation of programmed cell death (58.3%), 
regulation of cell death (58.3%), regulation of apoptosis (56.2%) 
 
50 8 0 1.30e-11  18.34   18.34 
25 CXCR4, SMAD3, 
c-Kit, CRK, 
TR-alpha 
positive regulation of cellular process (69.4%), regulation of cell 
communication (57.1%), positive regulation of biological process 
(69.4%), cell differentiation (61.2%), leukocyte differentiation (28.6%) 
 
50 7 0 6.84e-10  15.99   15.99 
26 DHPR, Septin 2, 
Ca-ATPase2, 
SENP2, NEDD8 
dihydrobiopterin metabolic process (8.7%), regulation of microtubule 
depolymerization (13.0%), negative regulation of microtubule 
depolymerization (13.0%), regeneration (21.7%), cellular aromatic 
compound metabolic process (21.7%) 
 
50 5 1 2.13e-07  13.46   14.71 
27 ME2, MCEE, 
Histone H4, p300, 
Succinyl-CoA 
response to stress (55.6%), response to hypoxia (22.2%), cellular 





50 3 0 1.47e-04   9.08    9.08 
253 
No Key network 
objects 




Pathways p-Value zScore gScore 
28 CXCR4, CRK, 
SMAD3, BDKRB2, 
FAK1 
intracellular signaling pathway (70.0%), protein amino acid 
phosphorylation (60.0%), phosphorylation (60.0%), positive regulation of 
cellular process (80.0%), positive regulation of biological process 
(82.0%) 
 
50 4 0 3.49e-05   8.95    8.95 




regulation of apoptosis (63.3%), regulation of programmed cell death 
(63.3%), regulation of cell death (63.3%), positive regulation of 
biological process (79.6%), positive regulation of cellular process 
(73.5%) 
 
50 2 0 1.45e-02   4.26    4.26 
30 14-3-3 gamma, 
CRK, EGFR, p53, 
c-Src 
regulation of programmed cell death (64.0%), regulation of cell death 
(64.0%), regulation of apoptosis (62.0%), response to stimulus (92.0%), 
positive regulation of cellular process (76.0%) 
 
50 2 0 1.45e-02   4.26    4.26 
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Figure 89. Subnetwork 2 (Table 18) detailing the interactions between genes 
involved in regulation of signal transduction, regulation of signalling process, 
response to organic substance, positive regulation of cellular process and regulation 
of multicellular organismal process. Red circles indicate genes up-regulated and blue 
circles genes down-regulated in menstrual endometrium from women with heavy 









Figure 90. Subnetwork 3 (Table 18) detailing the interactions between genes 
involved in regulation of biological quality, regulation of multicellular organismal 
process, regulation of anatomical structure size, biological regulation and regulation 
of system process. Red circles indicate genes up-regulated and blue circles genes 
down-regulated in menstrual endometrium from women with heavy menstrual 















Figure 91. Subnetwork 24 (Table 18) detailing the interactions between genes 
involved in positive regulation of biological process, positive regulation of cellular 
process, regulation of programmed cell death, regulation of cell death and regulation 
of apoptosis. Blue circles indicate genes down-regulated in menstrual endometrium 
from women with heavy menstrual bleeding versus normal controls.  See key on 
page 290. 
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6.3.6 Q-RT-PCR validation of microarray data 
Four up-regulated and three down-regulated genes that showed statistical 
significance in the microarray dataset were selected for validation by Q-RT-PCR 
(Figures 92-98). These genes were selected as they showed the greatest fold changes 
of the differentially expressed dataset (Tables 14, 15) and appeared in functional 
subnetworks (Figures 89-91). Five out of the seven selected genes were confirmed to 
demonstrate statistically significant regulation in the same direction as microarray 
data (71% concordance). Endothelial cell-specific molecule 1 (ESM-1), chemokine 
receptor 4 (CXCR4) and SMAD family member 3 (SMAD-3) mRNA was 
significantly lower in the menstrual endometrium from women with objectively 
measured HMB versus controls (p<0.05) (Figure 92-94). Hairy and enhancer of split-
related protein 1 (HEY-1) mRNA did not show statistically significant changes 
between the two groups in the menstrual phase (p=0.91) (Figure 95). Actin-gamma 2 
(ACTG2) and isocitrate dehydrogenase 1 (IDH1) mRNA expression was found to be 
significantly elevated in menstrual endometrium from women with HMB versus 
normal controls (p<0.05) (Figure 96 and 97). Paroxysmal nonkinesiogenic 
dyskinesia (PNKD) mRNA in menstrual phase endometrium was not significantly 
different between the two groups (Figure 98).  
 
On examination of these factors in endometrium at all stages of the menstrual cycle 
from women with HMB/NMB, there was confirmation of significantly lower mRNA 
of ESM-1 and CXCR4 in women with HMB (Two-way ANOVA) (Figure 92 and 
93). SMAD-3 mRNA was not found to be significantly different between women 
with HMB versus NMB at any stage of the cycle using these analysis parameters. 
However, there was a non-significant decrease in SMAD-3 expression in women 
with HMB during the menstrual and proliferative phases (Figure 94). ACTG2 and 
IDH1 mRNA was not found to be significantly different between women with HMB 
and NMB when corrected for multiple comparisons using a two-way ANOVA. 
Interestingly, there were significantly elevated levels of ACTG2 and IDH1 mRNA 
expression in women with HMB versus normal controls during the early secretory 
phase (Figures 96 and 97). The impact of the stage of cycle was analysed as a 
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secondary variable and p-values for the change in mRNA across the cycle for each of 
the genes examined can be found in Table 19. 
 
Oestrogen receptor 1 (ESR1) was identified in the top scoring networks from 
GeneGo analysis (Figure 89). ESR1 was mapped on a canonical pathway (green line) 
and eight genes known to be regulated by ESR1, including SMAD3 and IDH1, were 
differentially regulated between women with HMB and NMB. Hence, the expression 
of ESR1 mRNA was also examined by Q-RT-PCR in the endometrium of women 
with HMB and NMB. There were no significant differences in ESR1 mRNA 
between women with HMB and normal controls at any stage of the menstrual cycle 
(Figure 99). However, there was a non-significant increase in ESR1 mRNA during 
the menstrual phase in women with HMB compared to those with NMB.  
 
As CXCR4 mRNA was confirmed to be significantly increased in menstrual 
endometrium from women with HMB versus normal controls, the expression of this 
receptor’s ligand, CXCL12 was also examined. There was no significant difference 
in CXCL12 mRNA between the two groups at any stage of the menstrual cycle 
(Figure 100).  
6.3.7 HIF mRNA in women with HMB  
Hypoxia inducible factor (HIF) mRNA was assessed in the endometrium from 
women with objectively measured HMB and NMB by Q-RT-PCR. HIF-1α mRNA 
was not significantly different between women with HMB and normal controls at 
any stage of the menstrual cycle (Figure 101). There was significant variation in 
HIF-1α mRNA at different phases of the cycle (p<0.001). Lowest expression 
occurred in proliferative phase biopsies with maximal expression during the 
menstrual phase.  
 
Endometrial HIF-1β mRNA also showed no significant differences between women 
with HMB and NMB but significant variation between stages of the menstrual cycle 
(p<0.0001) (Figure 102). Again, lowest mRNA levels were observed in proliferative 
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phase endometrium. Maximal expression occurred in secretory phase biopsies and 
low expression of HIF-1β mRNA was observed during menstruation.  
    
 
 
Table 19.  P-values for change in gene expression across the cycle analysed as a secondary 





















Figure 92. ESM-1 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) ESM-1 mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) ESM-1 mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
secretory. *p<0.05, ***p<0.001. 
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Figure 93. CXCR4 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) CXCR4 mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) CXCR4 mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 94. SMAD3 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) SMAD3 mRNA 
expression in menstrual endometrium from women with normal (<80ml) and heavy 
(>80ml) menstrual blood loss. (B) SMAD3 mRNA in endometrium from across the 
menstrual cycle in women with heavy and normal loss subjected to two-way 
ANOVA. M: menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: 
late secretory. *p<0.05. 
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Figure 95. HEY-1 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) HEY-1 mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) HEY-1 mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 96. ACTG2 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) ACTG2 mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) ACTG2 mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 



































































Figure 97. IDH-1 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) IDH-1 mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) IDH-1 mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 98. PNKD mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) PNKD mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) PNKD mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 99. ESR-1 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) ESR-1 mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) ESR-1 mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 100. CXCL12 mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) CXCL12 mRNA 
expression in menstrual endometrium from women with normal (<80ml) and heavy 
(>80ml) menstrual blood loss. (B) CXCL12 mRNA in endometrium from across the 
menstrual cycle in women with heavy and normal loss subjected to two-way 
ANOVA. M: menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: 
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Figure 101. HIF-1α mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) HIF-1α mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) HIF-1α mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 102. HIF-1β mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) HIF-1β mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) HIF-1β mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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6.3.8 HIF protein levels in women with HMB 
HIF-1α protein levels were assessed in menstrual endometrial biopsies from women 
with HMB and NMB. Nuclear protein was extracted from eight menstrual biopsies 
(NMB n=4, HMB n=4) and HIF-1α protein identified by Western blot analysis 
(Figure 103A). Densitometric quantification revealed significantly lower levels of 
HIF-1α protein in women with HMB versus normal controls (p<0.05) (Figure 103B). 
 
HIF-1β protein levels were assessed by immunohistochemistry in endometrial tissue 
from across the menstrual cycle. HIF-1β was immunolocalised to the nucleus of 
endometrial surface epithelial (SE), glandular epithelial (GE) and stromal cells (St) 
(Figure 107). As evidenced by Figure 104 and 105, HIF-1β staining was maximal 
during the proliferative phase of the cycle. There was significantly reduced staining 
of GE, SE and St cells in women with HMB during the proliferative phase when 
compared to normal controls (Figure 105A). There were no significant differences 































































Figure 103. HIF-1α protein in menstrual endometrium from women with 
objectively measured menstrual blood loss. (A) Western blot for HIF-1α and β-
actin in menstrual phase endometrium from women with heavy menstrual bleeding 
(HMB: blood loss >80ml) and normal controls (NMB: blood loss <80ml). (B) 









Figure 104. Immunohistochemical staining for HIF-1β in the human 
endometrium. SE: surface epithelial cells, GE: glandular epithelial cells, St: stromal 
cell compartment, arrow: perivascular cells, scale bar: 50μm. NMB: normal 
menstrual bleeding (<80ml), HMB: heavy menstrual bleeding (>80ml). M: 




Figure 105. Semi-quantitative histoscoring of HIF-1β staining in endometrium 
from women with objectively measured menstrual blood loss. HIF-1β staining 
scores in (A) menstrual endometrium (B) proliferative endometrium and (C) 
secretory phase endometrium from women with HMB (blood loss >80ml) and 

















































































6.3.9 VEGF levels in women with HMB  
As a known downstream target of HIF-1, vascular endothelial growth factor (VEGF) 
levels were examined in the endometrium of women with HMB and NMB.  VEGF 
mRNA levels were significantly decreased in the menstrual endometrium of women 
with HMB versus normal blood loss controls (p<0.05) (Figure 106A). When 
examining VEGF mRNA across the menstrual cycle, there were low levels of 
expression during the proliferative and secretory phases. There was only significant 
up-regulation of VEGF mRNA at menstruation in women with NMB (p<0.001) 
(Figure 106B).  
 
VEGF protein levels were examined using immunohistochemistry. VEGF was 
immunolocalised to the surface epithelium, glandular epithelium, stromal and 
endothelial cells (Figure 107). VEGF immunohistochemical staining was less 
marked in the menstrual endometrium from women with HMB versus NMB (Figure 
107). Menstrual endometrium from women with HMB (n=2) and NMB (n=2) were 
cultured in vitro for 24h. Although numbers were small, supernatants subjected to 
ELISA analysis revealed women with HMB had lower levels of secreted VEGF 
protein than controls (Figure 108).  
 
Expression levels of one of the VEGF receptors, kinase insert domain receptor 
(KDR), were also examined in endometrium from women with HMB/NMB. 
Although there were significant changes in KDR mRNA across the cycle, with 
maximal expression in menstrual phase biopsies, there was no significant difference 





Figure 106. VEGF mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) VEGF mRNA in 
menstrual endometrium from women with normal (<80ml) and heavy (>80ml) 
menstrual blood loss. (B) VEGF mRNA in endometrium from across the menstrual 
cycle in women with heavy and normal loss subjected to two-way ANOVA. M: 
menstrual, P: proliferative, ES: early secretory, MS: mid secretory, LS: late 
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Figure 107. VEGF immunolocalisation in the menstrual endometrium of 
women with heavy and normal menstrual blood loss. (A) menstrual endometrium 
from a woman with normal menstrual bleeding (<80ml). (B) menstrual endometrium 
from a woman with heavy menstrual bleeding (>80ml). GE: glandular epithelial 
cells, SE: surface epithelial cells, St: stromal cell compartment, arrow: perivascular 















Figure 108. VEGF secreted protein levels in culture supernatants of endometrial 
tissue explants from women with heavy (HMB) and normal (NMB) menstrual 

































Figure 109. KDR mRNA in the endometrium of women with objectively 
measured normal and heavy menstrual blood loss. (A) KDR mRNA in menstrual 
endometrium from women with normal (<80ml) and heavy (>80ml) menstrual blood 
loss. (B) KDR mRNA in endometrium from across the menstrual cycle in women 
with heavy and normal loss subjected to two-way ANOVA. M: menstrual, P: 
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6.3.10 Angiogenic potential of endometrial HIF-1α 
An in vitro tube formation assay was utilised to assess the angiogenic potential of 
endometrial HIF-1α. Due to the limitations of human tissue samples, an endometrial 
epithelial cell line was used.  HIF-1α was silenced in these cells using two separate 
ShRNA constructs. Conditioned media from untransfected cells and cells transfected 
with (i) HIF-1α/ShRNA1470, (ii) HIF-1α/ShRNA2192 or (iii) a scrambled sequence 
HIF-1α/ShRNASCR were used to treat HUVECs. There was a significant increase in 
HUVEC branching at 8h with culture supernatant from untransfected endometrial 
epithelial cells cultured in hypoxic versus normoxic conditions (Figure 110). Culture 
supernatant from endometrial cells transfected with a scrambled ShRNA sequence 
before incubation in hypoxia also significantly induced HUVEC branching (p<0.05). 
This increased HUVEC angiogenic response was abolished when HIF-1α was 
silenced in endometrial cells before culture in hypoxic conditions (p<0.05). To assess 
the contribution of VEGF, 300ng/ml of VEGF protein was added to the culture 
supernatant from HIF-1α silenced cells before incubation with HUVEC cells. This 
concentration of VEGF is equivalent to the levels secreted by menstrual endometrial 
biopsies (per mg) from women with NMB (Figure 108). Replacement of VEGF 
partially restored the tube formation ability of hypoxic endometrial cell supernatant, 










Figure 110. Angiogenic potential of endometrial HIF-1α production. Culture 
supernatant from endometrial cells incubated in hypoxia demonstrated increased 
endothelial branching versus normoxic supernatants. This response was lost when 
endometrial cell HIF-1α was silenced prior to hypoxic incubation. Replacement of 
VEGF, at levels equivalent to those in women with normal bleeding, partially 
restored the angiogenic response. UTF: untransfected cells, Hypoxia: 0.5% O2, 
Normoxia: 21% O2, SCR: scrambled ShRNA sequence, 1470/2192: ShRNA against 































































This chapter contributes to existing knowledge of the pathogenesis of HMB. Firstly, 
it reveals the novel findings of an unbiased whole genome array, detailing significant 
differences in the menstrual endometrium of women with HMB and NMB. Secondly, 
results described herein reveal that HIF-1α protein levels are significantly decreased 
in the endometrium of women with HMB when compared to normal controls. In 
addition, expression of the HIF-1 target genes VEGF and CXCR4 follow a similar 
pattern, with significantly lower levels in women with objectively measured HMB 
versus women with NMB. Furthermore, the functional consequences of defective 
HIF-1α protein levels were examined using short-hairpin RNA. These studies 
revealed a significant decrease in endometrial angiogenic potential when HIF-1α 
production was inhibited.  
 
The gene expression profiling study of menstrual endometrium from women with 
NMB and HMB described herein confirms that endometrial tissue is amenable to this 
method of study. Notwithstanding the heterogeneity of the tissue and the 
considerable biological differences that exist between individual women, significant 
differences in endometrial gene expression were detected and validated between the 
two groups of women. These findings concur with other endometrial microarray 
studies, which have also demonstrated endometrial segregation into clusters for stage 
of cycle and for the presence or absence of endometriosis (Ponnampalam et al., 2004, 
Critchley et al., 2006c, Burney et al., 2007).  
 
Unbiased functional analysis of the differently expressed genes in the menstrual 
endometrium of women with NMB and HMB revealed novel processes that may be 
aberrant in women with heavy blood loss. In silico analysis allowed the formation of 
network and sub-network objects. These networks are descriptive of a biological 
function and detail known interactions between genes, reflecting the multi-functional 
activity of some factors. In this way, differences in gene expression between women 
with HMB and NMB were grouped, allowing the complex myriad of differentially 
regulated genes to reflect possible biological dysfunction. 
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The top ranked GeneGo process network was apoptosis. In addition, a number of 
significant sub-networks contained GO processes such as “regulation of cell death” 
and “programmed cell death”. The presence of differentially expressed genes in these 
networks suggests that apoptosis may be aberrant in the menstrual endometrium of 
women with HMB. Electron microscopy studies of the normal human endometrium 
have identified apoptotic bodies in the late secretory and menstrual phases of the 
cycle, with decreasing levels during the early proliferative phase (Hopwood and 
Levison, 1976). B cell lymphoma 2 (bcl-2) is an apoptosis regulator protein and is 
found in the human endometrium (Otsuki et al., 1994). Interestingly, its detection in 
the glandular epithelial cells was limited to the proliferative and early secretory 
phases, with decreased detection in the late secretory and menstrual phase. This 
decreased staining correlated with the appearance of apoptotic cells, suggesting bcl-2 
prevents or limits apoptosis in the human endometrium.  There is recent evidence 
that androgens are also involved in suppression of apoptosis during the proliferative 
phase, to facilitate post-menstrual remodelling of the endometrium (Marshall et al., 
2011). It appears that a balance of proliferation and apoptosis is necessary for normal 
endometrial function throughout the cycle. Considering its key role in endometrial 
physiology, excessive or prolonged apoptosis in the endometrium at menstruation 
may have a significant impact on menstrual bleeding. Interestingly, analysis of 
proliferative endometrium of women with a subjective complaint of HMB revealed 
significantly higher levels of apoptotic bodies than in endometrium from normal 
controls (Stewart et al., 1999). The finding of aberrant expression of several factors 
with a known role in apoptosis in the menstrual endometrium of women with HMB 
provides a novel field of research.  
 
This chapter details validation of the down regulation of SMAD-3 and the up-
regulation of ACTG2 and IDH1 in women with HMB versus normal controls. These 
three genes appear on GeneGo subnetwork 2 (Figure 89), which details gene 
interactions involved in regulation of signalling and cellular processes. ESR1 mRNA 
was not significantly increased in women with HMB in this study. ESR1 negatively 
regulates SMAD3 (red arrow, Figure 89) (Blanchette et al., 2006) and is known to 
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have a binding site in the IDH1 promoter region (Gao et al., 2008). Therefore a role 
in the down regulation of SMAD3 and up-regulation of IDH1 in women with HMB 
cannot be excluded. Furthermore, ACTG2 appears downstream of SMAD3 on this 
gene network (Figure 89) and has also been validated as being differentially 
expressed in women with HMB/NMB. An additional downstream target of SMAD-3 
is ESM-1, as detailed in Figure 93. ESM-1 was also validated as being decreased in 
women with HMB versus controls, consistent with less positive regulation due to 
decreased expression of SMAD-3.  
 
Subnetwork 24 includes CXCR4; the most significantly down regulated gene on the 
microarray study of menstrual endometrium from women with HMB versus NMB 
(Figure 91). This network details gene interactions that are involved in regulation of 
biological processes and apoptosis. Signalling of CXCL12 through CXCR4 in 
trophoblast cell cultures has been shown to stimulate anti-apoptotic pathways and 
increase cell survival (Jaleel et al., 2004, Wu et al., 2004). CXCR4 has recently been 
identified in the human endometrium, with significantly higher mRNA during the 
early proliferative phase (Laird et al., 2011). CXCR4 protein was identified by 
immunohistochemistry in the epithelium and blood vessels, with weaker staining in 
stromal cells. There were no obvious staining patterns across the cycle but this study 
did not include endometrium from the menstrual phase. The promoter region of 
CXCR4 contains the hypoxic response element that binds HIF-1α (Ishikawa et al., 
2009, Pan et al., 2006). HIF-1α does not appear in the differentially regulated gene 
list in women with HMB and NMB, which is unsurprising considering its 
posttranslational regulation. However, P300, a cofactor for HIF-1α that facilitates 
HIF-1 transactivation, features on subnetwork 24. This interacts with a number of 
differentially expressed genes, including CXCR4, SMAD3 and ETS2, a member of a 
family of transcription factors known to be involved in the up-regulation of hypoxia 
induced genes (Aprelikova et al., 2006). 
 
Assessment of the protein levels of all of these Q-RT-PCR validated factors is 
required. In addition, validation of other differentially expressed genes in these 
GeneGo networks is necessary, using Taqman Q-RT-PCR and protein quantification 
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methods. Furthermore, delineation of a functional difference in apoptotic activity in 
the menstrual endometrium of women with HMB and NMB would provide evidence 
for its involvement in the pathophysiology of HMB.  
 
Functional analysis of the differentially expressed genes using globaltest GO 
annotations identified “response to hypoxia” as the 7th ranked process (Table 16). 
There were 72 genes in the differentially expressed list that were functionally related 
to this process (Figure 87). This finding, coupled with the data presented in chapter 
5, suggested that hypoxia-inducible factor may be aberrant in the endometrium of 
women with HMB.  
 
On examination of mRNA, there were no significant differences in HIF-1α or HIF-
1β expression between women with NMB and HMB at any stage of the menstrual 
cycle. These findings are consistent with the well documented evidence for post-
translational regulation of HIF-1α protein (Ivan et al., 2001, Jaakkola et al., 2001). 
The contribution of transcriptional and translational mechanisms to HIF-1 regulation 
remains unclear. There are some reports of hypoxia increasing the transcription of 
HIF-1α (Belaiba et al., 2007) and others that report a significant decrease in HIF-1α 
mRNA in prolonged hypoxic conditions (Uchida et al., 2004). In contrast, the 
dominant mechanism of non-hypoxic regulation of HIF-1 appears to be increased 
transcription or translation by inflammatory mediators or growth hormones (van 
Uden et al., 2008, Frede et al., 2005, Dery et al., 2005). Therefore, even if there is a 
marked difference in oxygen levels between the menstrual endometrium of women 
with NMB and HMB, HIF-1α mRNA may not reflect this. 
 
As the presence of HIF-1α protein appears to be limited to the pre-menstrual and 
menstrual phases of the cycle (Chapter 5, Figure 63)(Critchley et al., 2006b), levels 
of this protein were examined in menstrual phase endometrium from women with 
objectively measured MBL. Densitometric analysis of Western blot data revealed 
significantly lower levels of HIF-1α protein in the endometrium of women with 
HMB versus normal controls. This novel finding provides new insight into the role 
of HIF-1 in endometrial physiology.  
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Previous studies have focused on the role of HIF-1 in the development and 
progression of cancer. These studies have found an association with high levels of 
HIF-1 and poor cancer prognosis (Sivridis et al., 2002, Krishnamachary et al., 2003, 
Baba et al.). Induction of HIF-1 in the hypoxic environment of the tumour is thought 
to aid proliferation and angiogenesis. This exaggerated physiological response is 
associated with disease progression. High levels of HIF-1α have also been observed 
in ectopic endometrial deposits in the myometrial layer of women with adenomyosis, 
when compared to eutopic endometrium in the same subjects (Goteri et al., 2009). 
This increase in HIF-1α was associated with higher levels of VEGF and increased 
microvascular density, leading the authors to propose that increased levels of HIF-1α 
were involved in the pathogenesis of this condition. 
 
Unlike cancer and adenomyosis, where an exaggerated physiological response 
contributes to disease, heavy menstrual bleeding may result from a defective 
response. Much of the knowledge regarding the physiological role of HIF-1 in vivo 
has been generated using knockout animals. Targeted inactivation of HIF-1α or HIF-
1β in the mouse resulted in embryonic lethality due to vascular abnormalities (Iyer et 
al., 1998, Ryan et al., 1998, Maltepe et al., 1997). To overcome lethality and study 
the effects of HIF-1 in specific tissue sites, Cre recombinase-loxP technology has 
been used. These studies have demonstrated that HIF-1α not only mediates tissue 
adaptation to hypoxia but also has a fundamental role in physiological function. 
Utilising conditional HIF-1α knockouts in the mouse, HIF-1α has been shown to be 
necessary for the infiltration and activation of myeloid cells (Cramer et al., 2003). 
The resulting metabolic defect of HIF-1α deficiency is a profound impairment of 
innate immunity. In the gastrointestinal tract, HIF-1α also appears to maintain 
colonic barrier protection during hypoxic and inflammatory insults (Furuta et al., 
2001, Karhausen et al., 2004), suggesting a potential therapeutic role for HIF-1α in 
inflammatory conditions such as colitis. The finding of reduced HIF-1α in the 
menstrual endometrium of women with HMB is therefore consistent with a defective 
physiological response. Endometrial inflammation and tissue destruction leads to 
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menstrual bleeding. Decreased levels of endometrial HIF-1α at this time may 
contribute to excessive tissue damage, defective repair and subsequent HMB. 
 
To further examine the contribution of HIF-1 to endometrial repair, the expression of 
VEGF, a known target of HIF-1, was determined in the menstrual endometrium of 
women with NMB and HMB. VEGF is a potent angiogenic factor that stimulates 
endothelial cell proliferation and migration (Ferrara, 2004). Therefore, it has an 
attractive role in the repair of damaged blood vessels at menstruation. A recent study 
of the decidualised mouse uterus and rhesus macaque endometrium, found that 
VEGF blockade with VEGF Trap completely inhibited neovascularisation and 
reepithelialisation during endometrial repair (Fan et al., 2008). Data presented in this 
chapter clearly demonstrate aberrant endometrial expression of VEGF in women 
with HMB. There were significantly lower levels of VEGF mRNA and protein in the 
menstrual endometrium of women with HMB when compared to normal controls. 
These findings are in agreement with a previous study, which found VEGF mRNA 
and protein were significantly reduced in menstrual effluent from women with HMB 
when compared to normal controls (Malik et al., 2006). The finding of increased 
VEGF receptor expression during the late secretory and menstrual phases of the 
cycle is in agreement with a previous study (Nayak et al., 2000) and suggests it may 
be regulated by progesterone withdrawal. In addition to significantly decreased 
VEGF levels in the menstrual endometrium of women with HMB, another 
downstream target of HIF-1 was also shown to be aberrantly expressed. CXCR4 
mRNA was significantly decreased in the menstrual endometrium of women with 
HMB versus controls, in a pattern similar to that of VEGF and HIF-1. 
  
To examine the functional consequences of decreased endometrial HIF-1, an in vitro 
tube formation assay was performed using conditioned media from endometrial 
epithelial cells. Cells in which HIF-1α had been silenced using ShRNA produced a 
significantly decreased angiogenic response compared to untransfected cells. This 
finding confirms that endometrial HIF-1α has the ability to induce a significant 
angiogenic response. This response is likely to be due to induction of a number of 
angiogenic factors, including VEGF, AM, IL-8 and CTGF (Forsythe et al., 1996, 
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Cormier-Regard et al., 1998, Kim et al., 2006, Higgins et al., 2004). Replacement of 
VEGF in the HIF-1α silenced conditioned media, only partially restored the 
angiogenic response. Therefore, treatments to correct the endometrial defect in 
women with HMB may be most effective when they replace multiple angiogenic 
factors.  
 
Prolyl hydroxylase inhibitors may provide an effective therapeutic intervention for 
women with HMB. They prevent hydroxylation of proline residues on the HIF-1α 
subunit, stabilising HIF-1α in normoxic conditions and thereby increasing 
transcription of target genes. PHD inhibitors have been shown to protect mice and 
rats from kidney ischaemia-reperfusion injury (Hill et al., 2008, Bernhardt et al., 
2006) and have had beneficial effects in the murine model of colitis (Cummins et al., 
2008, Robinson et al., 2008). As the endometrium displays similar features of 
inflammation and vasoconstriction, these treatments may have substantial beneficial 
effects in women with HMB. Moreover, the endometrium is amenable to 
intermittent, local administration of pharmacological treatments, allowing 
minimisation of potential side effects. Monitoring of the efficacy of these treatments 
may be possible with subjective pictorial menstrual charts, as results herein 
demonstrate a good correlation with objective measurements, in agreement with 
previous studies (Wyatt et al., 2001, Wilkens et al., 2008). Examination of the effects 
of compounds which stabilise HIF-1α in animal models of menstruation will further 
elicit their risks and benefits in the treatment of HMB.  
6.4.1 Summary 
The data presented in this chapter detail differences in the human endometrium of 
women with normal and heavy menstrual bleeding at the time of endometrial repair. 
Altered gene expression, lower levels of HIF-1α protein and an aberrant angiogenic 
response at this time may all contribute to the presentation of HMB. Further 
delineation of (i) the physiological processes at menstruation and (ii) aberrations that 
occur in the endometrium of women with HMB may promote significant advances in 










7. General Discussion 
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7.1 Synopsis of Results 
The data presented in this thesis describe the presence and regulation of known 
angiogenic and mitogenic factors in the human endometrium. Interleukin-8 (IL-8), 
vascular endothelial growth factor (VEGF), adrenomedullin (AM), connective tissue 
growth factor (CTGF) and endothelin-1 (ET-1) were all found to be maximally 
expressed during the perimenstrual phase of the human menstrual cycle. The timing 
of this repair factor up-regulation is consistent with previous microscopic 
examination of the human endometrium, which revealed that endometrial repair 
commences on day two of the cycle (Ludwig and Spornitz, 1991). As oestrogen 
levels remain low during menstruation, it was hypothesised that factors involved in 
the initial endometrial repair process were regulated by declining progesterone levels 
following the regression of the corpus luteum.  
 
Progesterone withdrawal is known to increase the levels of COX-2 enzyme in the 
endometrium, which subsequently increases prostaglandin synthesis (Critchley et al., 
1999). In addition, there is evidence for a transient hypoxic episode in the uppermost 
endometrial layer as spiral arterioles constrict following progesterone withdrawal 
(Fan et al., 2008). Therefore, the effects of progesterone withdrawal, prostaglandin 
E2, prostaglandin F2α and hypoxic conditions on endometrial repair factor expression 
were examined. Results from in vitro, ex vivo and in vivo models of the 
perimenstrual phase revealed that progesterone withdrawal and the downstream 
induction of hypoxic conditions and prostaglandin production were all necessary to 
increase IL-8, AM and VEGF mRNA in endometrial tissue.  
 
The mechanisms by which hypoxic conditions and prostaglandins increase these 
endometrial repair factors were then examined. The transcription factor hypoxia-
inducible factor (HIF) had previously been shown to regulate IL-8, AM and VEGF in 
other tissue sites (Kim et al., 2006, Cormier-Regard et al., 1998, Forsythe et al., 
1996) but the endometrial regulation of these factors by HIF had not been examined. 
Therefore, the presence of HIF-1α in the human endometrium was examined in 
tissue from across the menstrual cycle. Western blotting for HIF-1α revealed a 
transient presence of HIF-1α, with stable protein found only during the perimenstrual 
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phase. To examine the contribution of HIF-1α to repair, pharmacological inhibition 
of HIF-1 binding and silencing of HIF-1α using RNA interference was performed in 
endometrial cells. Data from these experiments suggested that two pathways of 
repair factor induction are present in the perimenstrual endometrium; a HIF-1α 
dependent hypoxic pathway and prostaglandin mediated induction that is 
independent of HIF-1α (Figure 111).  
 
NF-κB  is also a transcription factor involved in the up-regulation of a wide variety 
of genes, including IL-8 (Kayisli et al., 2004). NF-κB has been demonstrated in 
human endometrial biopsies during the perimenstrual phase (King et al., 2001). 
Progesterone has inhibitory effects on NF-κB activity, suppressing its activity until 
menstruation is required (Kelly et al., 2001). Therefore, its role in the induction of 
endometrial repair factors downstream of progesterone withdrawal was examined 
using a dominant negative inhibitor of NF-κB. Initial experiments demonstrated that 
this transcription factor may contribute to the normoxic induction of IL-8 by PGE2 
and suggested interactions with HIF-1α could enable synergistic increases in IL-8 
when both hypoxic conditions and PGE2 are present simultaneously (Figure 111).  
 
Finally, to assess the possibility that suboptimal endometrial repair contributes to the 
pathogenesis of heavy menstrual bleeding (HMB), an unbiased whole genome array 
was carried out to compare gene expression in menstrual endometrium from women 
with objectively measured heavy and normal menstrual blood loss. This revealed 259 
differentially expressed genes between the two groups. Differential expression of 
five genes was confirmed by Q-RT-PCR (Figures 92, 93, 94, 96, 97). Functional 
analysis of the differentially expressed gene set determined that the most relevant 
network processes included response to steroid hormone stimulus, regulation of cell 
cycle and cell communication and signalling. Of the 171 genes that were down-
regulated in women with HMB versus normal controls, CXCR4 was the most 
significantly decreased gene. Interestingly, CXCR4 is a known target of HIF-1 
(Ishikawa et al., 2009, Pan et al., 2006). Therefore, the levels of HIF-1α were 
assessed in the menstrual endometrium of four women with HMB and four normal 
controls. Densitometric analysis of Western blotting for HIF-1α demonstrated that 
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women with HMB had significantly less HIF-1α protein than controls. Moreover, 
women with HMB had significantly reduced menstrual CXCR4 and VEGF mRNA 
expression than women with normal loss.  Decreased expression of these known 
target genes of HIF-1 is consistent with Western blot data and suggests the HIF-1 
system may be aberrant in women with HMB. This may be due to a defective 
hypoxic response secondary to inefficient spiral arteriole vasoconstriction (discussed 
in Chapter 1.6.3.1). This hypothesis concurs with previous studies detailing reduced 
levels of the potent vasoconstrictor endothelin-1 and a reduced PGF2α:PGE2 ratio in 
the endometrium of women with HMB versus normal controls (Marsh et al., 1997, 
Smith et al., 1981a). Alternatively, normoxic induction of HIF-1α may be aberrant in 
the endometrium of women with HMB. Although the data herein demonstrate HIF-
1α was not induced by prostaglandins in normoxia, the effects of other inflammatory 
mediators were not examined. Furthermore, the endometrial response to progesterone 
withdrawal remains to be determined in women with heavy and normal loss. Women 
with HMB may have delayed or defective progesterone withdrawal during the 
perimenstrual period, resulting in aberrant endometrial repair. 
 
To determine the functional impact of decreased endometrial HIF-1α protein levels, 
HIF-1α was silenced in endometrial cells with RNA interference. The angiogenic 
potential of the culture supernatant of these HIF-1α depleted cells was then compared 
to that of untransfected endometrial cells. This revealed that decreased endometrial 
HIF-1α levels resulted in a significantly reduced angiogenic response. Therefore, 
reduced endometrial HIF-1α in vivo may delay the repair of blood vessels and result 
in women experiencing prolonged, heavy menstrual bleeding (Figure 112).  
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Figure 111. The two pathway hypothesis of endometrial repair factor 
induction at menstruation. Following progesterone withdrawal in the late secretory 
phase, endometrial cyclooxygenase-2 (COX-2) levels are increased. This results in 
the synthesis of prostaglandins (PG). PGF2α is a potent vasoconstrictor and, in 
collaboration with other factors, causes vasoconstriction of the spiral arterioles. The 
subsequent hypoxic insult stabilises endometrial hypoxia inducible factor-1α (HIF-
1α) to allow increased transcription of endometrial repair factors such as interleukin-
8 (IL-8), vascular endothelial growth factor (VEGF), adrenomedullin (AM) and 
connective tissue growth factor (CTGF). An alternative pathway for repair factor 
induction also exists, where endometrial PGs stimulate HIF-1α independent increases 
in repair factor expression, perhaps via nuclear factor kappa B (NFκB). Results of 
this thesis suggest that there may be some interaction between these two pathways to 







Figure 112. Endometrial changes during the perimenstrual phase and 
aberrations in women with heavy menstrual bleeding (HMB). Following 
progesterone withdrawal in the late secretory phase, there is vasoconstriction of the 
endometrial spiral arterioles. This leads to a transient hypoxic insult in the uppermost 
endometrial zones. Hypoxia inducible factor (HIF)-1α is stabilised in the human 
endometrium, leading to induction of endometrial repair factors, such as vascular 
endothelial growth factor (VEGF) and CXCR4. Women with HMB have decreased 
endometrial HIF-1α protein levels at menstruation and decreased VEGF and CXCR4 
expression. Delayed endometrial repair secondary to these aberrations may 
contribute to their heavy and prolonged menstrual blood loss.  
 
 
 Vasoconstriction Hypoxia 
VEGF, CXCR4 HIF-1 
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7.2 Areas for future study 
 
1. This thesis details the endometrial expression of IL-8, AM, VEGF, CTGF 
and ET-1 across the menstrual cycle. Results demonstrate that these factors 
are selectively increased in the perimenstrual phase. Limited analysis of the 
functional consequence of these changes was assessed with an in vitro 
angiogenesis assay. Further analysis of other aspects of endometrial repair, 
such as cell proliferation, wound healing and apoptosis, would be valuable to 
compare the functional potential of the endometrium at different stages of the 
cycle. Development of in vitro assays to compare culture supernatants of 
proliferative, secretory and menstrual explants with and without antibody 
neutralisation of specific repair factors will further delineate the mechanisms 
of endometrial repair.  
 
2. The study of multiple endometrial biopsies from the same woman at various 
stages of her menstrual cycle would eliminate patient variability and allow 
paired analysis of repair factor expression. Unfortunately ethical approval 
was not obtained for collecting multiple endometrial samples in this study but 
should be considered in future ethical applications.  
 
3. Data displayed in chapter 4 of this thesis demonstrate that PGE2 and PGF2α 
have a significant impact on endometrial repair factors in endometrial cells 
and endometrial tissue explants. The role of PGI was not studied, although a 
contribution to endometrial function has previously been identified (Battersby 
et al., 2004, Smith et al., 2006, Smith et al., 1981b). Examination of the 
impact of PGI on endometrial repair factors is necessary to fully elucidate the 
contribution of prostaglandins to the repair process. 
 
4. This thesis contains the novel findings of (i) selective HIF-1α stabilisation in 
the perimenstrual endometrium and (ii) significantly decreased HIF-1α levels 
in women with heavy versus normal bleeding. Future assessment of 
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endometrial levels of the alternative alpha subunits, HIF-2α and HIF-3α, is 
necessary to delineate the role of HIF in the human endometrium.  
 
5. This work demonstrates that prostaglandins act independently of HIF-1α to 
increase endometrial repair factor expression. However, the contribution of 
HIF-1α to the production of prostaglandins was not assessed. It would be 
interesting to determine the effect of hypoxia and HIF-1α on endometrial 
COX-2 levels. In addition, the contribution of NF-κB to endometrial repair 
factor expression deserves further examination. The effect of inhibition of 
NF-κB on PGE2 induced IL-8 expression was examined but the contribution 
of NF-κB to PGF2α mediated increases was not assessed. Furthermore, the 
interactions between HIF-1α and NF-κB in the human endometrium provide 
an attractive area of future research.  
 
6. The whole genome array study of menstrual endometrium from women with 
heavy and normal bleeding requires further validation with Q-RT-PCR and 
by confirmation of protein levels. In addition, the in silico analysis of the 
differentially expressed gene group would be enhanced with in vitro 
functional studies of menstrual endometrium to confirm differences in 
apoptosis, angiogenesis or proliferation between women with heavy and 
normal menstrual bleeding. 
 
7. Herein, women with HMB were shown to have significantly reduced HIF-1α 
protein levels and defective expression of downstream VEGF and CXCR4 
mRNA. It remains to be determined if this is a result of defective 
vasoconstriction and prevention of a hypoxic stimulus. With advancements in 
magnetic resonance imaging, it may be possible to measure the endometrial 
perfusion of women with objective blood loss measurements during the 
immediate pre-menstrual phase. Furthermore, when the safety profile of 
pimonidazole is determined, this marker of hypoxia could be administered to 
women prior to menstrual endometrial sampling to ascertain any differences 
in expression between women with heavy and normal menstrual blood loss.  
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8. Genetic disorders can result in stabilisation of HIF-1α in normoxic 
conditions. Von Hippel-Lindau disease is a result of a mutation in the Von 
Hippel-Lindau protein, which is involved in targeting HIF-1α for proteosomal 
degradation (Semenza, 2000). Individuals with mutations in prolyl 
hydroxylase domains have also been described (Percy et al., 2006). 
Individuals with these conditions over-express HIF-1α protein. Despite the 
systemic nature of these conditions, determination of the menstrual blood loss 
of women with these disorders may provide interesting insights into the 




The data contained in this thesis support the role of progesterone withdrawal, 
hypoxia and prostaglandins in the regulation of endometrial repair factors at 
menstruation. Delineation of the regulation of repetitive endometrial injury and its 
efficient repair may have important translational implications for other tissue sites. 
The endometrium heals without scarring or loss of function and further research into 
these processes may reveal novel therapeutic targets for conditions such as persistent 
inflammation and problematic scarring.  
 
In addition, this thesis details significant differences in gene expression in the 
menstrual endometrium of women with normal and heavy menstrual bleeding. A 
potential pathway involving reduced menstrual levels of HIF-1α and its downstream 
transcription targets was identified in women with objectively measured HMB, 
consistent with suboptimal repair in these women. Compounds that stabilise HIF-1α 
may help restore efficient endometrial repair. Such treatments could be delivered 
locally during the menstrual phase to limit potential side effects. Continued research 
to introduce an effective medical treatment for women with HMB will allow 
significant improvements in quality of life for many women and lead to widespread 
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